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ABSTRACT 
 
In the last two decades, anti-cancer therapy has grown considerably with the help of both 
natural and synthetic anti-cancer compounds but, the search for new and improved cancer 
treatment remains an ongoing and important issue.  Some anti-cancer compounds such as 
cisplatin are limited by their toxicity in normal tissues and the development of drug resistance.  
Therefore, in order to address drug resistance and side-effects of anti-cancer agents, recent 
research has been focusing on finding novel combinations of anti-cancer agents that have non-
overlapping mechanisms of action.   
 
The first objective of this study was to determine the mechanism of action of Anemone 
nemorosa, Artemisia afra, N-[[3-(4-bromophenyl)-1H-pyrazol-5-yl]-carbamothioyl]-4-chloro-
benzamide (BC-7) and N-benzoyl-N’-(3-(4-bromophenyl)-1H-pyrazol-5-yl)-thiourea (BT-7) 
through cell cycle arrest, phosphatidylserine translocation (PS), caspase activation and 
mitochondrial membrane depolarization.  This study has shown that A. nemorosa, BC-7 and A. 
afra are capable of inducing cell death within three cancer cell lines namely HeLa, MeWo and 
HepG2, at varying degrees.  HeLa cells were the most susceptible to treatment with A. 
nemorosa and BC-7 with IC50 values of 20.33 ± 2.480 µg/ml and 65.58 ± 8.400 µM (28.58 ± 
3.660 µg/ml), respectively.  A. afra was the most active against HepG2 cells with an IC50 value 
of 37.55 µg/ml.  BT-7 was not cytotoxic against any of the cancer cell lines.  The effects on 
HeLa cells and their progression through the cell cycle indicated that cells were arrested in the 
early M phase for all treatments.  The induction of apoptosis was confirmed by an increase in 
PS translocation and activation of caspase 3 and 8 as well as a decrease in the mitochondrial 
membrane potential.  It was deduced that A. nemorosa, A. afra and BC-7 induce caspase-
dependent apoptosis in a mitochondrial dependent manner. 
 
The second objective of this study was to investigate the potential of A. nemorosa, A. afra and 
BC-7 to target various mediators involved in the inflammatory response as an alternative 
method in which cell death may be induced.  Most treatments indicated that a tumour-elicited 
inflammatory response is indeed induced in HeLa cells and that the significant activation of 
nuclear factor kappa B (NF-κB) favoured the production of nitric oxide (NO) over cyclo-
oxygenase 2 (COX-2).  However, treatments with A. nemorosa, BC-7 and A. afra at their IC10 
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showed the potential of inhibiting this response.  ROS levels were increased by most treatments 
and support the idea of ROS-mediated apoptosis. 
 
The third objective was to investigate combination treatments of these extracts and compounds 
for their potential synergistic cytotoxic activity and thus formulating the combinations as potential 
anti-cancer agents.  Thirty combination mixtures were prepared using the IC50 values of each 
extract or compound at ratios of 1:3, 1:2, 1:1, 2:1 and 3:1, respectively.  The cytotoxic/anti-
proliferative activity of each mixture was determined by the bisBenzamide H 33342 
trihydrochloride/propidium iodide (Hoechst 33342/PI) dual staining method on HeLa cervical 
cancer cells.  The combination index (CI) values, at inhibition of 50% of HeLa cell growth, for 
each combination mixture, were determined by means of the Chou and Talalay method.  The 
combined effect can then be indicated as CI < 1, synergism; CI = 1, additive effect or CI > 1, 
antagonism, respectively.  Most combination treatments showed to have an antagonistic effect 
except for cisplatin:BC-7 (1:3, 1:1, 2:1, 3:1) and cisplatin:A. afra (1:3, 1:2, 1:1, 3:1) combinations 
that showed synergism.  The 1:2 ratio of cisplatin:BC-7 and the 2:1 ratio of cisplatin:A. afra were 
additive.   
 
CI values were also calculated at inhibition of 10, 25 and 75% of HeLa cell growth, for each 
combination mixture.  Antagonistic effects were frequently observed at lower effect levels such 
as at 10 and 25% inhibition of growth.  However, this was not seen for the cisplatin:BC-7 
combinations as all the ratios indicated synergism.  Some of these ratios, such as the 1:3 and 
1:2, even led to a greater degree of synergism being obtained, with noticeable antagonistic 
effects seen at 50 and 75% inhibition of growth.    The current finding is that BC-7 and A. afra 
could lower the dose of cisplatin in combination to achieve a similar anti-cancer efficacy 
compared to the higher cisplatin dose when used alone.  The lower dosage in combination 
could result in reduced drug resistance as well as limit the toxicity on normal cells associated 
with cisplatin treatment. 
 
In conclusion, this study shows, for the first time, that A. nemorosa has the potential to induce 
apoptosis and also has some anti- and pro-inflammatory activity in HeLa cancer cells.   This 
study also enhanced the knowledge of the mechanism of apoptosis induction of BC-7, in a more 
detailed manner, as well as investigated its inflammatory effects for the first time.  Results 
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obtained for A. afra correlated nicely to previously reported studies and confirmed that the 
methods used in this study, although different, leads to the same conclusions. 
 
Combination treatments also indicated, for the first time, that BC-7 and A. afra have the ability to 
function in a synergic manner with cisplatin and proves that, although extensive research may 
have been done on a plant or compound, more can be discovered.  This new information can 
lead to identification of new compounds in the plants and the integration of signalling pathways 
that can be targeted for treatment of cancer.       
 
Keywords: A. nemorosa, A. afra, BC-7, cytotoxicity, apoptosis, inflammation, combination 
therapy 
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Chapter 1: Introduction to this Study 
1.1. Cancer 
 
Cancer is a multifactorial disease that is known as one of the top ten leading causes of deaths 
worldwide.  According to the Cancer Association of South Africa (CANSA) and the International 
Agency for Research on Cancer (IARC) Globocan Report, 14 million people are diagnosed with 
cancer each year of which approximately 8.2 million people succumb to the detrimental effects 
of cancer per annum (World Health Organization, 2014).  In 2012, the three most common 
diagnosed cancers worldwide were lung, breast and large bowel.  Of these three, breast cancer 
was the second highest with approximately 1.7 million cases which amounts to 11.9% of the 
total cases diagnosed (World Health Organization, 2014). 
 
In South Africa, one in four South Africans are affected by cancer within his or her lifetime as 
more than 100 000 people are diagnosed with cancer every year.  With a survival rate of 60%, 
one in every eight men and one in every nine women in South Africa are affected every year 
(CANSA, 2014). 
 
The term cancer, first used by Hippocrates (460-370 BC), refers to the uncontrolled and 
abnormal growth of cells with the potential to invade and spread to other parts of the body.  
There are two types of tumours, namely benign and malignant tumours.  Benign tumours are 
non-cancerous and therefore do not spread throughout the body.  Malignant tumours on the 
other hand are cancerous and have the ability to metastasize. Malignant tumours are produced 
by cancer cells acquiring functional capabilities allowing them to survive.  
 
In 2000, Hanahan and Weinberg proposed six distinctive and complementary hallmark 
capabilities of cancer cells that enable their survival (Figure 1.1).  These hallmarks were: 1) 
sustaining proliferative signalling, 2) evading growth suppressors, 3) enabling replicative 
immortality, 4) activating invasion and metastasis, 5) inducing angiogenesis and 6) resisting cell 
death (Hanahan & Weinberg, 2000).  Since then they have continued their work and in 2011 
added four new hallmarks: 1) avoiding immune destruction, 2) tumour-promoting inflammation, 
3) genome instability & mutation and 4) deregulating cellular energetics (Hanahan & Weinberg, 
2011).      
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Figure 1.1: Hallmark capabilities of cancer and how they have been therapeutically 
targeted (Hanahan & Weinberg, 2011). 
 
Anti-cancer therapy has developed considerably over the past few decades with the help of new 
anti-cancer compounds and target specific treatments.  However, most of the latest innovations 
come at great costs as well as an increasing number of patients, especially in poorer countries 
such as South Africa and Romania.  
  
Cancer treatment remains an important topic of research, mainly because: 
 Cancer is a multifactorial disease comprising of a variety of pathophysiological 
mechanisms with intricate pathways. Thus certain anti-cancer agents may be very 
effective against some types of cancer whilst being completely ineffective against other 
types. 
 Resistance to anti-cancer treatment through a complex series of mechanisms. 
 Almost all anti-cancer agents have associated toxic effects, mainly due to the low 
selectivity on cancer cells. 
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Most of the above mentioned problems may be overcome through administration of combination 
therapies rather than monotherapy.  Synergism between the individual components of a 
combination of treatments would reduce the concentrations of each component for efficacy 
(Chou, 2006).  This, in turn, could reduce both the toxic side-effects as well as the chances of 
cancer cells to develop resistance.  An additional advantage of combination therapy is that 
individual components may have different biochemical targets which would make it more 
effective against a greater variety of cancers.  Thus the above mentioned impediments may be 
overcome by synergistic mechanisms of a mixture of anti-cancer agents (Chou, 2010; Foucquier 
& Guedj, 2015). 
1.2. Plants and other clinically used anti-cancer agents 
 
Numerous plant-derived anti-cancer agents have been isolated and identified of which more 
than 60% are clinically used (Cragg & Newman, 2005).  Some of these anti-cancer agents 
include the vinca alkaloids (derived from Catharanthus roseus), etoposide (derived from 
Podophyllum peltatum), camptothecin (derived from Camptotheca acuminata) and paclitaxel 
(derived from Taxus brevifolia).   
 
Cisplatin and etoposide are two of the most commonly used chemotherapeutic drugs, but is 
known to have a number of side-effects.  Cisplatin belongs to a class of platinum-containing 
drugs and is classified as a covalently binding agent.  It is mainly used to treat lung, testicular, 
ovarian, bladder, breast, cervical, stomach and prostate cancers.   Induction of apoptosis is its 
main mode of action as it has the ability to crosslink with the purine bases in DNA, interferes 
with DNA repair mechanisms and causes DNA damage.  The most common side-effects 
associated with cisplatin treatment are anemia, neurotoxicity, nephrotoxicity, and cisplatin 
resistance by some cancers (Byun, et al., 2016).  Etoposide belongs to a class of 
topoisomerase II inhibitors which are known to stabilize a covalent topoisomerase II-DNA 
cleavable complex intermediate subsequently causing double-strand DNA breaks.  It is mainly 
used to treat lung cancer, Kaposi’s sarcoma, Ewing’s sarcoma, testicular cancer, lymphoma, 
non-lymphocytic leukemia and glioblastoma multiforme.  The most common side-effects 
associated with etoposide treatment are hematologic toxicity, gastrointestinal toxicity and 
mutagenesis (Byun, et al., 2016). 
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Recently, flavonoids have shown significant anti-cancer activity through the inhibition of specific 
protein kinases. For example, quercetin inhibits PI3K; apigenin and curcumin inhibit protein 
kinase C and hyperoside inhibits protein kinase ERK (Parsai, 2013; Gutierrez-Venegas, 2014). 
It is, however, known that flavonoids have low solubility, stability and bioavailability and these 
issues need to be addressed to improve their potential as therapeutic agents. Synergistic anti-
cancer therapy with bio-compounds and chemical agents, as based on traditional Chinese 
medicine, is a constantly developing process and is aimed to reduce the chemotherapeutic 
doses, whereas maintaining the pharmacological effect and decreased resistance of tumour 
cells to therapeutic agents (Cragg & Newman, 2005; Wong & Chiu, 2010; Amado, 2011; Xu, 
2011; Choudhury, 2013).  A study has been completed in which the combination of cisplatin and 
triptolide, a component extracted from the traditional Chinese herbal medicine Tripterygium 
wilfordii Hook F, has shown an increase within both caspase 3 and 9 activation along with 
downstream cleavage of PARP in SC-M1 (gastric cancer) cells (Li, et al., 2012).   
1.3. Anemone nemorosa 
 
Anemone is a genus of the Ranunculaceae family with more than 150 species of flowering 
plants that are native to the temperate zones of both the Northern and Southern hemispheres.  
Of the 150 species, more than 50 are used in various traditional medical systems.  In China 
alone, fifty-three species, 9 subspecies and 36 varieties are found in most provinces of which at 
least 38 species/varieties have ethnopharmacological uses (Hao, et al., 2017).   Observed 
pharmacological activities include anti-cancer, anti-microbial, anti-inflammatory, sedative and 
analgesic activities as well as anti-convulsant and anti-histamine effects.   
 
A. nemorosa is botanically characterized as a herbaceous, perennial plant that grows in 
deciduous forests and clearings in West Polesie, a transboundary biosphere reserve in Central 
Europe.  The stem length is between 10 and 25 cm.  Leaves are found on the node of the stem 
(cauline) and the flowers are medium in size ranging from 20 to 30 mm in diameter.  A. 
nemorosa only blossoms in April and May and the flowers consist of six to eight petals and can 
be found in a variety of colours namely white, pale pink and also purple (Lukianchuk, et al., 
2017).   
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Figure 1.2: Anemone nemorosa (http://www.pixnio.com/flora-plants/flowers/anemone-
nemorosa-flower/wood-anemone-anemone-nemorosa-flower)  
 
Various parts of A. nemorosa have been used, traditionally, for the treatment of numerous 
medical conditions such as malignant tumours, headaches, tertian agues, fever, rheumatic gout, 
leprosy, lethargy, eye inflammation, malignant ulcers and as an anti-microbial, anti-fungal, 
diuretic and abortive agent, etc. (Hao, et al., 2017; Lukianchuk, et al., 2017).  Chemical 
constituents identified from A. nemorosa include alkaloids, glycosides, vitamin C, resins, organic 
acids, coumarins and flavonoids.  Protoanemonin is the main active component and is 
described as having anti-microbial, anti-fungal and anti-mutagenic properties.  Protoanemonin is 
converted to Anemonin upon drying of A. nemorosa.  Anemonin is mainly used in the treatment 
of asthma, whooping cough, rachitis and uterine bleeding (Lukianchuk, et al., 2017).  
1.4. Artemisia afra 
 
Artemisia is a genus of the Asteraceae family with more than 500 species of plants of which the 
most well used species in traditional medical systems are A. annua (from which the anti-malarial 
drug Artemisinin was isolated), A. cina (from which the anti-helminthic drug Santonin was 
isolated) and A. austriaca (reduces morphine withdrawal symptoms).  
 
Artemisia afra is characterized as a highly aromatic perennial shrub that is found widely 
distributed across Africa (Liu, et al., 2009).  The stem length ranges up to 2 meters and the 
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leaves have a characteristic dark green colour on the adaxial surface and a light green colour 
on the abaxial surface.  A. afra blossoms from January until June and the flowers are yellow in 
colour (van Wyk, et al., 1997).   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Artemisia afra (http://pza.sanbi.org/artemisia-afra)   
 
A. afra has been, traditionally, used for the treatment of asthma, malaria, diabetes, influenza, 
fever, headaches, loss of appetite, rheumatism, colic croup, convulsions, etc.  Chemically, A. 
afra consists of approximately 132 volatile secondary metabolites of which most of them are 
monoterpenes and sesquiterpenes.  Non-volatile secondary metabolites isolated from A. afra 
include sesquiterpene lactones, taurine, triterpenes, coumarins, organic acids, glycosides and 
flavonoids (Liu, et al., 2009).       
1.5. Pyrazole derivatives 
 
Pyrazole is an organic compound consisting of a five membered ring of three carbon atoms and 
two nitrogen atoms (Figure 1.4).  This compound underwent Phase I evaluation in the 1960’s as 
an anti-cancer agent.  However, it was too toxic for human consumption even at doses of 0.15 
mmol/kg/day and this led to the synthesis of 1-carboxamidopyrazole and 1-
thiocarbamoylpyrazole.  These pyrazole derivatives failed the clinical evaluation even though 
they showed significant anti-cancer potential during animal experimentation (Nitulescu, et al., 
2010).        
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In recently published articles by Nitulescu, et al. (2015) as well as Strocchi, et al. (2012), it was 
shown that newly synthesized pyrazole derivatives have the ability to counteract the evasion 
tactics of cancer cells on pro- and anti-apoptotic components.  The research done by Strocchi, 
et al. (2012) has also demonstrated how Akt is affected in cancer cells by means of treatment 
with pyrazole derivatives. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Structure of pyrazole 
(https://commons.m.wikimedia.org/wiki/File:Pyrazole_2D_numbered.svg)  
 
The Akt pathway plays a central role in the regulation of cellular processes including apoptosis 
(Nitulescu, et al., 2015).  It is known, that the hyper-activation of Akt influences numerous 
downstream targets which then are capable of mediating multiple pathways which favour 
tumourigenesis (Boukes, 2010).  Research has shown that almost all known oncogenic growth 
factors and cytokines are capable of activating the Akt pathway.  Along with this, cancer cells 
have shown to contain numerous mutations or amplifications of certain major elements in the 
Akt pathway (Vara, et al., 2004; Hers, et al., 2011).  The activation of Akt in cancer cells can be 
due to numerous factors such as the overexpression of tyrosine kinase receptors and their 
ligands. The GTP binding protein Ras, has been found to be mutated within 20% of human 
tumours which prevents the hydrolysis of GTP.  Thus, Ras is in its active GTP-bound state 
allowing for it to bind to the p110 subunit of PI3K which increases its translocation to the plasma 
membrane (Hers, et al., 2011). 
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There are three reasons as to why the PI3K-Akt pathway and its components present a 
promising target for cancer therapy: 1) inhibition of tumour-suppressor like proteins such as 
FOXO, Bad and GSK3 which negatively regulates cell survival, proliferation and growth thus 
blocking this pathway may sensitize cancer cells towards apoptosis, 2) this pathway consists of 
many kinases which are ideal for small molecule inhibitors, 3) this pathway is found within 
numerous types of tumours (Luo, et al., 2003). 
1.5.1. N-[[3-(4-bromophenyl)-1H-pyrazol-5-yl]-carbamothioyl]-4-
chloro-benzamide 
 
N-[[3-(4-bromophenyl)-1H-pyrazol-5-yl]-carbamothioyl]-4-chloro-benzamide (BC-7) is a synthetic 
pyrazole derivative (Figure 1.5) with the following chemistry according to Infrared (IR) and 
Nuclear Magnetic Resonance (NMR) spectroscopy (Nitulescu, et al., 2015):  
 
mp: melting point, ppm: parts per million, s: singlet, d: doublet, J: J-coupling, Hz: Hertz, ArH: 
aromatic hydrogens, Pyrz: pyrazole moiety 
 
Yield 70%, mp 234–235°C. IR (cm-1): 3165 (N-H), 3027 (N-H), 1667 (C=O), 1539 (C-N).  1H 
NMR (DMSO-d6, ppm): 13.30 (s, 1H, NH), 12.86 (s, 1H, -CS-NH-), 11.80 (s, 1H, -CO-NH-), 8.00 
(d, J = 8.5 Hz, 2H, ArH), 7.72 (d, J= 8.5 Hz, 2H, ArH), 7.67 (d, J = 8.5 Hz, 2H, ArH), 7.61 (d, J= 
8.5 Hz, 2H, ArH), 7.50 (s, 1H, Pyrz).  13C NMR (DMSO-d6, ppm): 177.16 (C=S), 167.79 (C=O), 
147.79 (Pyrz), 138.13 (Pyrz), 134.71, 132.08, 130.78, 130.22, 130.19, 128.56, 127.17, 121.57, 
96.05 (Pyrz). Calcd. for C17H12BrClN4OS: C, 46.86; H, 2.78; N, 12.86; S, 7.36; Found: C, 46.79; 
H, 2.83; N, 12.92; S, 7.33%. 
 
Briefly, 1H NMR spectra presented two broad singlets for the thiourea group at 12.86 and 11.80 
ppm and one broad singlet for the pyrazole NH at 13.30 ppm.  Aromatic hydrogens were found 
in the range of 8.00 – 7.30 ppm.  Using, 13C NMR, the thiourea carbons (C=S) and (C=O) were 
found in the ranges of 177.4 – 177.0 ppm and 168.7 – 167.7 ppm, respectively.  The pyrazole 
moiety was found between the range of 147.8 and 96.05 ppm. 
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Figure 1.5: Structure of N-[[3-(4-bromophenyl)-1H-pyrazol-5-yl]-carbamothioyl]-4-chloro-
benzamide (Nitulescu, et al., 2015). 
 
BC-7 has only been evaluated, once before, for its biological activity against HT29 (human 
colorectal adenocarcinoma) and THP1 (acute monocytic leukemia) cells and indicated a 
significant increase in G2/M phase arrest.  This was supported by the increased expression of 
cyclin A and B.  It was also found to induce apoptosis as witnessed by phosphatidylserine 
translocation and increased gene expression of casp3, Bcl-2 and Mcl-1 (Nitulescu, et al., 2015).    
1.5.2. N-benzoyl-N’-(3-(4-bromophenyl)-1H-pyrazol-5-yl)-thiourea 
 
N-benzoyl-N’-(3-(4-bromophenyl)-1H-pyrazol-5-yl)-thiourea (BT-7) is a synthetic pyrazole 
thiourea derivative (Figure 1.6) with the following chemistry according to IR and NMR 
spectroscopy (Nitulescu, et al., 2010):  
 
Yield 73%, mp 223-224°C. IR (cm-1): 1665 (C=O). 1H NMR (DMSO-d6, ppm): 13.37 (s, 1H, NH), 
13.17 (s, 1H, -CS-NH-), 11.65 (s, 1H, -CO-NH-), 7.99 (dd, J = 7.2 Hz, J = 1.5 Hz, 2H, ArH), 
7.73-7.67 (m, 4H, ArH), 7.67 (tt, J = 7.3 Hz, J = 1.4 Hz, 1H, ArH), 7.54 (bt, 2H, ArH), 7.52 (s, 1H, 
PyrzH). 13C NMR (DMSO-d6, ppm): 177.07 (C=S), 168.75 (C=O), 147.79 (Pyrz), 140.77, 133.27, 
132.10, 128.79, 128.49, 128.20, 128.13, 127.16, 121.58, 96.08 (Pyrz). Calcd. for C17H13BrN4OS: 
C, 50.88; H, 3.27; N, 13.96; S, 7.99; Found: C, 51.03; H, 3.28; N, 13.88; S, 8.11%. 
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Briefly, 1H NMR spectra presented two broad singlets for the thiourea group at 13.17 and 11.65 
ppm and one broad singlet for the pyrazole NH at 13.37 ppm.  Aromatic hydrogens were found 
in the range of 7.99 – 7.38 ppm.  Using, 13C NMR, the acyl thiourea carbons (C=S) and (C=O) 
were found in the ranges of 180.1 – 170.0 ppm and 168.8 – 168.0 ppm, respectively.  The 
pyrazole moiety was found between the range of 147.79 and 96.08 ppm. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Structure of N-benzoyl-N’-(3-(4-bromophenyl)-1H-pyrazol-5-yl)-thiourea 
(Nitulescu, et al., 2010). 
 
BT-7 has only been evaluated for its cytotoxic ability as part of a set of pyrazole based small 
molecules and was found to have logGI50 values of below -4 molar (< 0.1 mM) for 43 of the 60 
cancer cell lines used (Nitulescu, et al., 2010).   
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Chapter 2: Research Rationale, Aims and Objectives 
2.1. Aims 
 
The incidence of cancer is increasing globally and the search for novel, effective and affordable 
treatments is ongoing.  If one or more formulations can be developed with synergistic anti-
cancer activity, the number of cancer survivors worldwide may be increased.  This can be 
ascribed to the following benefits of combination therapy: 1) different mechanisms of action, 2) 
reduced dose of treatment, 3) reduced toxicity on normal/host cells and 4) reduced resistance of 
cancer cells towards treatment (Chou, 2010). 
 
This study was a continuation of a collaboration between researchers from the Nelson Mandela 
University Port Elizabeth, South Africa and the ‘Carol Davila’ University of Medicine and 
Pharmacy, Bucharest, Romania.  The two teams have had the opportunity to meet in person in 
Bucharest, Romania during December 2016 and in Port Elizabeth, South Africa in July 2017.   
This was due to the approval of the NRF Joint Call for Thematic Cooperation Proposal between 
the Romanian and South African teams, applied for in May 2014 (reference 
RJCT14050666847).  
 
Preliminary work, revealed great potential of Romanian plant extracts (work done by Dr. Luanne 
Venables on behalf of the SA team: Olaru, et al.; 2015) and pyrazole compounds (work done by 
the Romanian team: Nitulescu, et al., 2010 and Nitulescu, et al., 2015) as 
cytotoxic/antiproliferative agents. The pyrazole compounds act through inhibition of cyclin 
dependent kinases and mitogen activated kinase, all of which regulate cell proliferation.  Based 
on the above, this project set out to continue and expand ongoing studies in both participating 
countries with the following elements of originality: 1) development of anti-cancer 
phytocomplexes by the exploitation of plants and compounds insufficiently studied so far and 2) 
combining of plant extracts and synthetic compounds in optimal ratios, in order to achieve a 
biomaterial with a wide anti-cancer spectrum on the basis of a multi-targeted mechanism of 
action. 
 
The expertise of the two teams was highly complementary and non-overlapping: The Romanian 
team was responsible for preparation of A. nemorosa extract and pyrazole derivatives as well as 
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combination (biomaterial) preparation and toxicity studies on invertebrate models. The South 
African team was responsible for all cell based work, including screening of extracts, 
compounds and combinations against cancer and normal cell lines as well as investigations of 
biochemical mode of action. 
2.2. Objectives 
 
The main objective of this study was to: 
 Investigate combinations of A. nemorosa, A. afra, BC-7, BT-7 and cisplatin for their 
synergistic cytotoxic activity 
 after the:  
 Determination of their cytotoxic effects against normal cell lines: Vero and MRHF  
 Determination of their cytotoxic effects against cancer cell lines: HeLa, MeWo and 
HepG2 
 Characterization of their mechanism(s) of action 
 Determination of their anti-inflammatory activity in cancer cells rather than macrophages 
2.3. Overview of chapters 
 
This project has been divided into 3 experimental chapters, Chapters 4 – 6.  In each 
experimental chapter, a literature review is followed by materials and methods used to meet the 
objectives of each chapter.  Results and discussions are presented in separate sections of each 
chapter.   
 
Chapter 3 – Provides a detailed description of the principles of the methods used in this study 
and any other background information relating to the methods. 
 
Chapter 4 – Focuses on the determination of the cytotoxic effects and the characterization of 
the mechanism of action of A. nemorosa, A. afra, BC-7 and BT-7. 
 
Chapter 5 – Focuses on the anti-inflammatory effects of A. nemorosa, A. afra and BC-7 in HeLa 
cervical cancer cells.   
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Chapter 6 – Focuses on the effects of A. nemorosa, A. afra and BC-7 in combination with each 
other and with cisplatin, respectively. 
 
Chapter 7 – Highlights the findings of this study and suggestions and recommendations are 
made for future work. 
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Chapter 3: Methods: Principles and Background 
 
This chapter provides a description of all the principles and other background information 
relating to the methods used in this study. Detailed methods and materials information are 
described in the relevant chapters. 
3.1. Preparation of extracts and compounds 
 
Cisplatin was used as a positive control, in all assays, unless otherwise indicated.  It was 
purchased from Sigma-Aldrich (PHR1624-200mg).  A stock of 5 mM was made in 0.9% NaCl 
and kept at 4°C and was replaced approximately every 57-60 days due to stability issues.  
 
Ethanolic extracts of A. afra were prepared by Dr. Luanne Venables (co-supervisor to this 
project) by submerging dried, ground leaves in 80% ethanol after which they were incubated in 
the dark at room temperature overnight.  The liquid was then filtered through 11 µm Whatman 
filter paper and evaporated using nitrogen gas in a round bottomed flask at 45°C.  Remaining 
samples were then frozen in deionized water, overnight at -80°C.  Powdered extracts were 
obtained by freeze drying.  For all experiments the plant extract was reconstituted in DMSO at a 
final concentration of 100 mg/ml and stored at -20°C until use. 
 
An aqueous extract of the flowers of A. nemorosa was prepared, by Prof. Octavian Tudorel 
Olaru at the ‘Carol Davila’ University of Medicine and Pharmacy, Bucharest, Romania by 
grinding approximately 10 g (mesh 14) and then extracting with 3 x 100 ml water under reflux.  
This was followed by concentration through rotary evaporation (RVO 004; Ignos, Prague, Czech 
Republic) and lyophilization at -55°C (CoolSafe ScanVac 55; LaboGene, Lynge, Denmark).  For 
all experiments the plant extract was reconstituted in DMSO at a final concentration of 100 
mg/ml and stored at -20°C until use.  
 
BC-7 and BT-7 were synthesized by Prof. George Mihai Nitulescu at the ‘Carol Davila’ 
University of Medicine and Pharmacy, Bucharest, Romania.  Details of the chemistry can be 
found in sections 1.5.1 and 1.5.2. 
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3.2. Cell lines and Cell culture 
 
Cancer cells accumulate multiple mutations in genes that regulate the cell cycle. Certain 
mutations occur more frequently than others and the sensitivity of cancer cells to anti-cancer 
treatment is influenced by the specific mutations in that cancer. Three cancer cell lines were 
selected on the basis of their status in terms of some of the most common mutations found in 
human cancers, namely p53, PTEN, B-Raf and caspase 3. A variety of mutations were included 
as the mutations may affect the sensitivities of the cell lines to cisplatin, A. afra, A. nemorosa, 
BC-7 and BT-7 and may provide direction in the elucidation of the mechanism of action. The 
final list of cancer cell lines that were used were as follows: HeLa (cervical carcinoma; p53 
wildtype), HepG2 (hepatoblastoma; low expression levels of PTEN) and MeWo (skin melanoma; 
p53 mutant). 
 
Vero (African Green Monkey kidney) and MRHF (human foreskin fibroblast) cells were used to 
evaluate the cytotoxicity on normal cells. 
 
Cells were maintained in 10 cm culture dishes in complete DMEM low glucose (Vero, MRHF 
and MeWo), EMEM (HepG2) or RPMI (HeLa) supplemented with 10% foetal bovine serum 
(FBS) (Biowest) and incubated at 37°C in a humidified incubator with 5% CO2.  Additional 
supplementation, in the form of MEM Non-Essential Amino Acids at 1X the stock concentration 
(HyClone), was required for HepG2 cells. 
3.3. Cytotoxicity 
 
The screening for cytotoxicity against cancer and normal cell lines is based on their proliferation 
in the presence or absence of extracts or compounds.  There are two main reasons for using a 
normal cell line: 1) to indicate whether or not an extract or compound could be detrimental to 
normal cells in an in vivo experiment and 2) to determine whether an extract or compound is 
selective towards a cancer cell line or not.  The first reason is debatable as well-known 
chemotherapeutic agents, such as cisplatin, which are commercially used, exhibit great toxicity 
towards normal cell lines in most research studies.  Cytotoxicity screening can be used to 
determine whether a cytotoxic effect is cytocidal (cells are killed) or cytostatic (cell growth and 
division is inhibited). 
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The 3,4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay is one of the most 
commonly used assays to assess cell death.  It is a sensitive and quantitative colourimetric 
assay that measures the viability of cells but can also be used to measure proliferation and 
metabolic activation of cells.  The principle of this method is largely based on the capacity of 
mitochondrial dehydrogenase enzymes to reduce the yellow water-soluble substrate into a dark 
bluish-purple insoluble formazan product.  Other cellular dehydrogenases may also be able to 
reduce MTT.  After solubilization of the formazan product using dimethylsulfoxide (DMSO), the 
amount produced can be measured spectrophotometrically at 540 nm. Therefore, the amount of 
formazan produced is proportional to the number of viable cells (Vega-Avila & Pugsley, 2011). 
 
There are two major limitations to the use of the MTT assay: 1) false positive results may be 
obtained if a cell’s metabolism is altered and 2) it does not discriminate between cytostasis 
(inhibition of cell proliferation) and cytotoxicity (cell death).  These limitations are mainly due to 
the fact that chemicals such as ascorbic acid, or sulfhydryl-containing compounds including 
reduced glutathione, coenzyme A, and dithiothreitol, can reduce tetrazolium salts non-
enzymatically and lead to increased absorbance values.  Likewise, culture medium at elevated 
pH or extended exposure of reagents such as MTT to direct light also may cause an 
accelerated spontaneous reduction of tetrazolium salts and result in increased background 
absorbance values (Riss, et al., 2013). 
 
Interference can be confirmed by assays such as the Ferric Reducing Antioxidant Potential 
(FRAP) assay in which samples with a high FRAP value, those with potentially great antioxidant 
capabilities, would interfere with the reduction of MTT.  Furthermore, control wells can be made 
containing only test samples and culture medium containing MTT.  Increased absorbance 
values would then indicate possible interference.  Additional assays can be used to overcome 
this problem of interference such as the lactate dehydrogenase (LDH) release assay and 
staining procedures such as the bisBenzamide H 33342 trihydrochloride/propidium iodide 
(Hoechst 33342/PI) dual staining method (Riss, et al., 2013).  The latter was used in this study. 
 
Hoechst 33342 binds to the minor grooves of double-stranded DNA with enhanced fluorescence 
being obtained when bound to A-T rich sequences.  Hoechst 33342 is excited at a wavelength 
of 350 nm and emits a blue fluorescence at 461 nm.  Due to the fact that Hoechst 33342 is 
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membrane permeant and stains all nucleic acids, it is used to generate a total cell count of the 
population (Chazotte, 2011).  PI intercalates between DNA base pairs with little or no sequence 
preference and is excited at 536 nm and emits a red fluorescence at 623 nm.  The permeability 
of PI is dependent on the integrity of the cell membrane and correct functioning of efflux pumps.  
Therefore, dead cells stain more easily and thus the non-viable population can be determined.  
The Hoechst 33342/PI dual staining method distinguishes between three population groups 
namely live, apoptotic and dead cells. This is because live cells would have a less intense blue 
fluorescent signal than that of apoptotic cells.  Dead cells on the other hand would have a less 
intense blue fluorescent signal but a much more pronounced red fluorescent signal (Ciancio, et 
al., 1998). 
3.4. Cell Cycle analysis 
 
The goal of the cell cycle is to produce two accurate copies of the parent cell, known as the 
daughter cells.  The cell cycle consists of 4 phases namely gap 1 (G1), synthesis (S), gap 2 
(G2) and mitosis (M).  The G1 phase is typically the longest and is the phase in which the cells 
that are formed by cytokinesis are able to grow back to their optimal size before they had 
undergone mitosis.  A restriction point is found within this phase where cells can either delay 
their progress or enter the G0 phase.  This happens in response to a negative stimulus such as 
a poor nutrient supply or an anti-proliferative stimulus.  However, this restriction point block can 
be overcome when appropriate positive stimuli are received and cells can then commit 
themselves to a new cycle of DNA replication and division (Pollard & Earnshaw, 2008).  Since 
eukaryotic chromosomes are so large, their replication has to be initiated at different sites 
known as origins of replication.  Replication of the DNA of proliferating cells occurs in the S 
phase of the cell cycle and only does so once.  This is due to the fact that the pre-replication 
complex is dismantled and can only be re-assembled when the next G1 phase is reached. The 
G2 phase is a relatively short period in which key enzymes are accumulated and their activities 
triggered to allow the cells to enter the mitotic phase.  In parallel, the chromatin and 
cytoskeleton are also prepared for the structural changes that will occur during mitosis.  During 
the M phase cell division occurs in the form of mitosis where two daughter cells are formed.  
Mitosis usually consists of five discrete stages namely prophase, pro-metaphase, metaphase, 
anaphase and telophase (Pollard & Earnshaw, 2008). 
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Every second, millions of cells in the human body are dividing and replacing their predecessors.  
This process can therefore not happen at random and, as mentioned in section 4.1.6., 
checkpoints are scattered throughout the cell cycle to prevent the cell cycle from spinning out of 
control.  However, when the cell cycle is disturbed, in normal cells, it leads to abnormal growth 
and division.  These cells are then known as neoplasms and these can be further classified into 
benign and malignant neoplasms.  Cancer is a form of a malignant neoplasm in which the cells 
grow and divide abnormally (Starr, et al., 2009).  Therefore, the induction of cell cycle arrest in 
cancer cells by exposure to extracts and compounds may give insight into how this abnormal 
growth and division may be stopped. 
 
Cell cycle arrest was determined by staining with NucRedTM Live 647(NucRed) from Molecular 
Probes by Life Technologies with modifications. NucRed is a bright, far-red, cell-permeant 
nuclear stain for live or fixed cells.  When bound to DNA, it is excited at 638 nm and emits at a 
maximum wavelength of 686 nm.  The intensity of the dye is directly proportional to the amount 
of DNA in a cell and therefore mitotic cells would stain the brightest.   An example of staining 
can be seen in Figure 3.9 (section 3.12.2).  
3.5. Micronuclei formation assay 
 
Micronuclei refer to small nuclei that are formed whenever a chromosome or a fragment of a 
chromosome is not incorporated into one of the daughter nuclei during cell division.  It is usually 
a sign of genotoxic events and chromosomal instability.  It is therefore believed that the 
formation of micronuclei is associated with M phase arrest and more specifically mitotic 
catastrophe (McGee, 2015).  NucRed, as mentioned in section 3.4, was used for staining of 
nuclei.  An example of staining can be seen in Figure 3.10 (section 3.12.2).   
3.6. Phosphatidylserine translocation 
 
Changes in the cellular membrane are characteristic of apoptosis thus such modifications can 
be used to identify and distinguish apoptotic cells from the rest of the population.  During 
apoptosis the membrane phospholipid phosphatidylserine (PS) is translocated from the inner to 
the outer leaflet of the plasma membrane (Figure 3.1).  Annexin V, is a 35-36 kDa calcium-
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dependent phospholipid-binding protein that is capable of binding to PS with high affinity.  
Annexin V may also be conjugated to fluorochromes such as fluorescein isothiocyanate (FITC) 
for the detection of apoptosis via flow cytometry or fluorescence microscopy and would still 
retain its high affinity for PS.  FITC is excited at a wavelength of 482 nm and emits a bright 
green fluorescence at 536 nm.  During late necrosis, the membrane integrity becomes 
compromised and Annexin V may enter the cell and bind to PS in the inner leaflet.   Therefore, 
staining of cells with Annexin V is commonly used in conjunction with PI.  Non-apoptotic or 
healthy cells would stain negative for both Annexin V and PI whereas cells undergoing early 
apoptosis would be positive for Annexin V but negative for PI.  Late apoptotic and -necrotic cells 
stain positive for both Annexin V and PI whereas early necrotic cells only stain positive for PI 
(Hingorani, et al., 2011).   
 
 
Figure 3.1: PS translocation and detection by Annexin V-FITC/PI (BioLegend, 2018). 
3.7. Mitochondrial membrane potential analysis 
 
Cells that are metabolically active generate a mitochondrial membrane potential (MMP) of 
approximately -150 to -180 mV during oxidative phosphorylation (Perry et al., 2011).  The onset 
of the intrinsic mode of apoptosis is believed to be indicated by the loss of mitochondrial 
membrane potential and the subsequent release of pro-apoptotic proteins.  The mitochondrial 
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membrane potential was measured by using a lipophilic cationic dye, tetramethylrhodamine 
ethyl ester (TMRE), which reversibly accumulates in the mitochondrial matrix in a voltage 
dependent manner and emits a bright yellow fluorescence at 575 nm after being excited at 549 
nm.  During apoptosis the ability of TMRE to accumulate inside the mitochondria is hampered 
(Figure 3.2) and the dye becomes evenly distributed throughout the cytosol.  This leads to an 
overall drop in the fluorescence intensity which can then be quantified by fluorescence 
microscopy (Krohn, et al., 1999). 
 
 
 
 
 
 
Figure 3.2: Mitochondrial staining with TMRE (G-Biosciences, 2016). 
3.8. Autophagy induction 
 
Autophagy, Latin for “self-eating”, is a highly regulated process involving the formation of 
autophagosomes which fuse with lysosomes for the degradation of damaged proteins, 
organelles and invading organisms.  Together with apoptosis and necrosis, it was originally 
deemed as a mode of cell death.  However, it is now known that autophagy promotes cell 
survival and rarely cell death (Bildirici, et al., 2012).  LysoTracker™ Deep Red (LysoTracker 
Red) is an acidotrophic fluorophore that is linked to a weak base only partially protonated at 
neutral pH.  Thus, LysoTracker Red can freely permeate live cells and indicate the presence of 
late autophagic vesicles and autophagy activation.  LysoTracker Red is excited at a wavelength 
of 647 nm and emits a bright orange-red fluorescence at 668 nm.  Examples of positive staining 
can be seen in Figure 4.17 (section 4.3.8). 
3.9. Nitric Oxide production 
 
Nitric oxide (NO) has anti- and pro-apoptotic functions of which the latter includes the loss of 
mitochondrial membrane potential, increase in cytochrome c (cyt-c) release, induction of p53 
expression and the activation of caspase 3 through the activation of the MAPK pathway.   
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Measurement of NO was done using DAF-FM diacetate staining.  DAF-FM diacetate is a cell-
permeant dye which is capable of passively diffusing across cellular membranes and becomes 
de-acetylated by intracellular esterases to DAF-FM (Figure 3.3).  DAF-FM is a weakly 
fluorescent intermediate and upon reacting with NO forms a benzotriazole derivative that emits 
a green fluorescence at 515 nm upon excitation at 495 nm. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: The DAF-FM diacetate reaction used for the quantification of NO (adapted 
from Molecular Probes, 2001). 
3.10. Reactive Oxygen Species production 
 
The levels of reactive oxygen species (ROS) in cells, under normal physiological conditions, are 
controlled by the balance between anti-oxidants and free radicals.  Excessive production of 
reactive oxygen species can induce lipid peroxidation, depletion of sulfhydryl groups, altered 
signal transduction pathways, altered calcium homeostasis and DNA damage, which could lead 
to the induction of apoptosis (Florea & Busselberg, 2011).  CellRoxTM Orange reagent (CellRox 
Orange) is a cell-permeant dye that indicates the presence of ROS, through oxidation, and 
emits a bright orange fluorescence at 565 nm after excitation at 545 nm.  Examples of positive 
staining can be seen in Figure 5.5 (section 5.3.4). 
 
 
Esterase NO 
DAF-FM 
diacetate 
DAF-FM Benzotriazole 
derivative 
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3.11. Immunofluorescence staining 
 
Immunofluorescence staining is based on the principle that antibodies bind to antigens and can 
be achieved in a direct or indirect manner (Figure 3.4).  In the direct manner of detection, a 
primary antibody is conjugated to a fluorophore whereas the indirect manner involves the use of 
a secondary antibody that is conjugated to a fluorophore.  The direct detection method is less 
time-consuming and allows for multiplexing.  However, the indirect method offers higher 
sensitivity due to signal amplification.  Therefore, selecting the appropriate primary to secondary 
pairs and fluorophore conjugates is a critical part of the experimental design.  The indirect 
method of immunofluorescence staining was mostly used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Direct and Indirect methods of immunofluorescence staining (Cell Signaling 
Technology, 2017). 
 
3.11.1. Histone H3 phosphorylation 
 
Phosphorylation of histone H3 at Ser10 is believed to be a marker for cells progressing from G2 
to M phase in the cell cycle (van Hooser, et al., 1998).  Phosphorylation of histone H3 begins in 
late G2 and peaks during metaphase of mitosis.  De-phosphorylation occurs during anaphase 
and ends in early telophase, therefore the phosphorylation of histone H3 has further been 
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implicated as being essential for the passage of cells from metaphase to anaphase.  Cells with 
no phosphorylation of histone H3 indicate perturbed condensation and abnormal segregation, 
further supporting the idea that it plays a role during the transition from metaphase to anaphase 
(Hans & Dimitrov, 2001).   
 
The phosphorylation of histone H3 was studied by means of immunofluorescence using the 
phospho-Histone H3 (Ser10) Rabbit monoclonal antibody (mAb) from Cell Signaling Technology 
which detects endogenous levels of histone H3 when phosphorylated at Ser10.  However, these 
levels of phosphorylated histone H3 cannot be detected when Lys9 is acetylated or methylated. 
3.11.2. Caspase 8 and 3 analysis 
 
Increased expression and activation of caspases is a hallmark parameter of the initiation and 
execution of apoptosis.  Initiator caspases, such as caspase 8, are responsible for the activation 
of executioner caspases such as caspase 3.   Caspase 8 is activated when apoptosis is induced 
by CD95 and tumour necrosis factor receptor 1 (TNFR1).  This activation leads to the release of 
both the p18 and p10 active fragments.  Caspase 8 activation was measured using the cleaved 
caspase 8 (Asp391) Rabbit mAb from Cell Signaling Technology as it detects the p18 subunit 
alone as well as cleavage products containing the pro-domain with the p18 subunit. 
 
Caspase 3 is activated by proteolytic processing of its inactive zymogen into activated p17 and 
p12 fragments.  The cleavage of caspase 3 is dependent on the presence of an aspartic residue 
at the P1 position.  It is mainly responsible for the proteolytic cleavage of many key proteins 
during apoptosis.  An example of such a protein would be the nuclear enzyme poly (ADP-
ribose) polymerase (PARP).  The activation of caspase 3 was measured using the cleaved 
caspase 3 (Asp175) Rabbit mAb (Cell Signaling Technology) which only detects the 
endogenous levels of the protein when cleaved at Asp175.   
 
Total caspase 8 and 3 protein levels (activated + inactivated) were also measured using Anti-
CASP8 Rabbit polyclonal and Anti-CASP3 Rabbit monoclonal antibodies from Sigma-Aldrich, 
respectively. 
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3.11.3. Nuclear Factor kappa B analysis 
 
The constitutive activation of nuclear factor kappa B (NF-κB) in cancer cells leads to the up-
regulation of anti-apoptotic genes which aids in drug resistance.  Therefore, inhibitors of NF-κB 
would most likely induce apoptosis (Hoesel & Schmid, 2013).  Phospho-NF-kappaB p65 
(Ser536) Rabbit mAb (Cell Signaling Technology) was used for immunofluorescent detection of 
activated NF-κB as it does not cross react with the p50 subunit or any other related proteins. 
3.11.4. Cyclo-oxygenase 2 analysis 
 
The overexpression of cyclo-oxygenase 2 (COX-2) leads to the increased production of 
prostaglandin E2 (PGE2) which in turn increases the levels of anti-apoptotic proteins such as 
Bcl-2 and decreases the levels of pro-apoptotic proteins such as Bax (Colotta, et al., 2009).  
Therefore, induction of apoptosis can be determined through the inhibition of COX-2.  Total 
endogenous levels of COX-2 were measured using a FITC conjugated COX-2 Rabbit mAb from 
Cell Signaling Technology. 
3.12. ImageXpress Micro XLS Widefield High-Content Analysis System 
(Molecular Devices®) 
 
The ImageXpress Micro XLS is an automated 
microscope, with a 4.66 megapixel scientific sCMOS 
camera with a large field-of-view, capable of fluorescent, 
transmitted light and phase-contrast imaging for high 
content analysis of fixed- or live-cell assays, tissues and 
small organisms.   
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3.12.1. Image acquisition 
 
All images were acquired using the plate acquisition setup for a 96 well plate (Figure 3.5) using 
a spatial distribution of 9 sites per well (3 by 3) and a magnification of 10 times (10x).  
Acquisition of images was dependent on the exposure time for each dye measured in 
milliseconds (ms) and varied for each experiment depending on staining intensity.   
 
A combination of five filter sets was used for acquisition depending on the assay and the 
relevant dye and/or conjugate used (Table 3.1). 
 
Table 3.1: Filter sets used for each fluorescent dye and conjugate. 
Filter Set 
Excitation/Emission 
wavelengths (nm) 
Fluorescent dyes and conjugates 
DAPI 377/447 Hoechst 33342 
FITC 482/536 Annexin V-FITC, Alexa Fluor 488, DAF-FM diacetate 
TRITC 543/593 TMRE, CellRox Orange 
Texas Red 562/624 PI, LysoTracker Red 
Cy5 628/692 NucRed Live 647, Alexa Fluor 647 
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Figure 3.5: Acquisition setup for a 96-well plate.  
3.12.2. Image analysis 
 
Analysis of acquired images was performed using the applicable modules of the MetaXpress® 
version 6.1 High-Content Image Acquisition & Analysis Software (Figure 3.6).  The Multi 
Wavelength Cell Scoring module was used for all experiments except cell cycle analysis and the 
micronuclei formation assay.  A number of different multi-parameter measurements can be 
obtained such as cell counts, nuclei mean area, percentage of positively or negatively stained 
cells as well as nuclear and cytoplasmic average and integrated intensities.  All of these 
parameters are based on segmentation parameters defined for each wavelength (Figure 3.7).  
These segmentation parameters are based on measurements such as the approximate 
minimum and maximum widths, the intensity above local background and the minimum stained 
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area of the cellular component of interest (i.e. caspases, acidic organelles, reactive oxygen 
species, etc.).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Analysis modules of the MetaXpress® version 6.1 software. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Multi Wavelength Cell Scoring analysis module.  
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Images acquired for cell cycle analysis were analysed using the Cell Cycle module (Figure 3.8).  
Using this module, it could be determined in which phase of the cell cycle the cells were 
arrested.  This is based on the approximate minimum and maximum width and intensity above 
local background measurements (expressed as integrated intensities).  Mitotic classification can 
be based on mitotic-specific staining with antibodies such as phosphorylated histone H3 or DNA 
average intensity.  The latter was used in this study.  Additionally, apoptotic-specific staining can 
be done in order to classify cells as undergoing apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Cell Cycle analysis module. 
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Histograms, dot plots and masks are generated (Figure 3.9) based on the measurements 
required by the Cell Cycle module.  The masks generated using this module are segmentation 
overlays with representative colours corresponding to each phase of the cell cycle.  Histograms 
are single parameter plots that display the number of cells detected as a function of their 
intensity.  Dot plots on the other hand are dual parameter plots (average vs integrated intensity) 
in which each cell, is represented as a single dot.  This allows for the identification and 
quantification of individual sub-populations in a heterogeneous sample.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Masks, histograms and dot plots generated from Cell Cycle analysis module. 
 
Images acquired for the micronucleus assay were analysed using the Micronuclei module 
(Figure 3.10).  The same measurements are required as mentioned for the Multi Wavelength 
Cell Scoring and Cell Cycle modules with the addition of the minimum and maximum distances 
between main nuclei and micronuclei as well as the maximum distance between nuclei in poly-
Control Cisplatin 
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nucleated cells.  Segmentation overlays are generated with representative colours 
corresponding to the ploidy of each cell (Figure 3.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Micronuclei analysis module and segmentation overlays generated. 
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Chapter 4: In vitro Anti-Cancer Activity and Mechanism(s) of Action  
4.1. Introduction 
4.1.1. Cell death 
 
Normal physiological processes are maintained through a homeostatic balance between two 
very critical parts of the normal development and maturation cycle namely cell proliferation and 
cell death.   Any alterations to this homeostatic balance can lead to diseases such as AIDS, 
diabetes, neurodegenerative diseases and cancer.  Cell death can be classified according to the 
criteria in Table 4.1. 
 
Table 4.1: Criteria involved in the classification of cell death (Kroemer, et al., 2009). 
Morphological  Apoptotic, Necrotic, Autophagic or associated with mitosis 
Enzymological With and without the involvement of nucleases or of distinct classes of 
proteases, such as caspases, calpains, cathepsins and transglutaminases 
Functional Programmed or accidental, physiological or pathological 
Immunological Immunogenic or non-immunogenic 
 
4.1.2. Apoptosis  
 
Apoptosis is a cellular suicide mechanism that is regulated by a family of cysteine proteases 
otherwise known as caspases (Kerr, et al., 1972).  Apoptosis is characterized by: 1) reduction in 
MMP, 2) intracellular acidification, 3) cell shrinkage, 4) DNA fragmentation and condensation, 5) 
production of ROS, 6) externalization of PS and 7) selective proteolysis of a subset of cellular 
proteins (Cryns & Yuan, 1999).  Apoptosis is sub-classified into two non-exclusive types of 
death pathways namely the extrinsic (receptor-mediated) and intrinsic (mitochondria-mediated) 
pathway (Indran, et al., 2011). Cancer cells have the ability to resist apoptotic insults by means 
of various mechanisms including: the overexpression of anti-apoptotic proteins, reduced 
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expression of death receptors and their ligands, defects or mutations in tumour suppressor 
proteins such as p53 and the reduced expression of caspases (Figure 4.1).  Therefore, a 
thorough understanding of these mechanisms is imperative to unravel the secret to designing 
more effective and target selective therapeutic strategies (Wong, 2011). 
 
 
Figure 4.1: Mechanisms by which cancer cells evade apoptosis (Wong, 2011). 
 
4.1.2.1. Extrinsic (receptor-mediated) pathway 
 
This pathway requires the effective engagement of death receptors from the tumor necrosis 
factor superfamily; such as TNF, CD95 (Fas) and TNF-related apoptosis inducing ligand 
(TRAIL); with their respective ligands (Figure 4.2).  The engagement of death receptors with 
their ligands is achieved through the extracellular domain.  These death receptors also have a 
characteristic intracellular cytoplasmic domain, famously known as the death domain, which is 
responsible for the transmission of death signals from the surface of the cell to the intracellular 
signalling pathways (Fulda & Debatin, 2006).  The activation of CD95 or TNF receptors leads to 
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receptor clustering and intracellular recruitment of proteins, such as the adaptor protein Fas-
associated death domain (FADD), into what is known as the death-inducing signalling complex 
(DISC) (Elmore, 2007).  This signalling complex subsequently activates the initiator caspase, 
procaspase 8, which triggers the execution phase of apoptosis through the activation of the 
downstream effector caspases, caspase 3, 6 and/or 7 (Figure 4.2).  Activation of caspases can 
also reinforce the death signal via the induction of mitochondrial damage by facilitating the 
release of death amplifying proteins from the mitochondrial inter-membranous space (Cryns & 
Yuan, 1999; Simstein, et al., 2003; Fulda & Debatin, 2006; Elmore, 2007; Indran, et al., 2011).  
4.1.2.2. Intrinsic (mitochondria-mediated) pathway 
 
This pathway can be activated by numerous receptor-independent stimuli such as radiation, free 
radicals, viral infections, and serum/growth factor starvation (Figure 4.2).  It was initially 
demonstrated that these signals invariably lead to the opening of the mitochondrial permeability 
transition pore (MPTP) subsequently resulting in a change within the permeability of the inner 
mitochondrial membrane (Indran, et al., 2011).  Changes in permeability results in a loss of: 1) 
MMP, 2) the release of pro-apoptotic proteins and 3) the arrest of the bio-energetic function of 
the organelle (Elmore, 2007).  The pro-apoptotic proteins can be classified into two categories 
of which the first comprises of those that activate the caspase dependent pathway.  These 
include cyt-c and second mitochondria-derived activator of caspases (Smac/DIABLO).  Cyt-c 
induces apoptosis proteinase activating factor-1 (Apaf-1) oligomerization, which leads to the 
activation of caspase 9.  Subsequently, a complex, known as the apoptosome, is formed 
resulting in the activation of executioner caspases 3 and 7.  These executioner caspases are 
ultimately responsible for nuclear fragmentation.  Smac/DIABLO deactivates inhibitor of 
apoptosis proteins (IAP’s) which prevents them from arresting the apoptotic process (Figure 
4.2). The second category of pro-apoptotic proteins includes apoptosis inducing factor (AIF) and 
endonuclease G (Endo G) both of which act in a caspase-independent manner.  The release of 
these proteins is a late event in apoptosis which only occurs once cells are committed to death.  
Once AIF is released it translocates to the nucleus where it promotes DNA fragmentation 
(Blanc, et al., 2000; Del Bello, et al., 2004; Elmore, 2007; Indran, et al., 2011). 
4.1.2.3. The Bcl-2 family of proteins 
 
Apoptotic events are highly regulated by the Bcl-2 family of proteins and their functions differ 
based on the number of Bcl-2 homology (BH) domains they have.  The anti-apoptotic proteins 
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Bcl-2, Bcl-XL and Mcl-1 contain all four domains (BH1-4), whereas the pro-apoptotic proteins 
Bax and Bak only contain the first 3 domains (BH1-3) (Adams & Cory, 1998; Simstein, et al., 
2003).  The anti-apoptotic proteins also contain a hydrophobic carboxy terminal domain that 
enables them to dock onto the outer mitochondrial membrane (Figure 4.2), the nucleus and 
endoplasmic reticulum (ER).  Bcl-2 and Bcl-XL protect the membrane integrity of cells by 
interacting with mitochondrial proteins such as adenine nucleotide translocase (ANT) or the 
voltage dependent anion channel (VDAC) which prevents the formation of mitochondrial pores 
and the release of apoptogenic factors such as cyt-c (Brenner, et al., 2000).  Overexpression of 
Bcl-2 is associated with a slight increase in steady state intracellular superoxide production that 
results in the increased consumption of mitochondrial oxygen and the increased activity of the 
rate limiting enzyme, cytochrome c oxidase.  However, research has shown that Bcl-2 
overexpressing cells can be sensitized towards apoptosis through the inhibition of nicotinamide 
adenine dinucleotide phosphate (NADPH) production thus implicating a pro-oxidant activity of 
Bcl-2 in its anti-apoptotic function (Indran, et al., 2011).   
 
As mentioned, Bax is a pro-apoptotic protein and it resides within the cytosol under 
physiological conditions.  When apoptosis is triggered, Bax is translocated to the mitochondria 
where it is inserted into the outer mitochondrial membrane through interaction with the 
translocase of the outer mitochondrial membrane (TOM) complex.  This TOM complex is 
responsible for the translocation of nuclear-encoded proteins through the outer membrane 
(Cartron, et al., 2008).  Once inserted, Bax can homodimerize or heterodimerize with other pro-
apoptotic members such as Bak and truncated Bid (t-Bid) leading to the formation of pores 
within the mitochondrial membrane increasing its permeability and subsequently resulting in the 
release of cyt-c (Vyssokikh, et al., 2002).  Bax has also been shown to interact with ANT and/or 
VDAC to induce mitochondrial membrane permeabilization.  Bak can also homodimerize and 
result in pore formation when it is freed from its inhibited state with VDAC.  A third group of Bcl-
2 family proteins also exist and include the BH3 domain only proteins namely Bim, Bad, Bmf, 
Noxa and Puma.  These proteins, when upregulated by the activation of the tumour suppressor 
gene p53, act as neutralizers of Bcl-2 and Bcl-XL by sequestering them and thus blocking their 
anti-apoptotic action (Fulda & Debatin, 2006).  
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4.1.2.4. The tumour suppressor p53 
 
p53 plays a vital role within cell cycle regulation in response to DNA damage (section 4.1.6.1.) 
however, if the damage to the DNA is irreversible apoptosis will be triggered.  p53 can 
alternatively be activated by oncogenes such as MYC, RasV12 and E2F-1 via the activation of 
an Alternative Reading Frame (ARF) which sequesters Mdm2.  Apoptosis can be regulated by 
p53 in both a transcription dependent and independent manner of which, in the former, it 
activates the expression of apoptotic proteins such as Puma, Bax and Bid.  These proteins are 
mainly involved in the intrinsic pathway but can also upregulate CD95 and DR5 receptors in the 
extrinsic pathway.  p53 has also been shown to suppress the expression of some anti-apoptotic 
proteins such as Survivin (Indran, et al., 2011).  In the transcription-independent pathway, 
fractions of p53 localizes to the mitochondria where it interacts with Bcl-2 and Bcl-XL 
antagonizing their anti-apoptotic function.  This results in the release of Bax and Bid which are 
then able to elicit their downstream effects.  p53 can also interact with Bak leading to its release 
from Mcl-1.  Cytosolic p53 can also induce the activation of Bax through the transcription-
independent manner leading to the release of cyt-c (Speidel, 2009). 
4.1.2.5. Inhibitors of apoptotic proteins 
 
The fate of the cell is thus very tightly regulated by the interactions between the pro- and anti-
apoptotic proteins.  In cancer, these proteins are modulated to favour survival by either crippling 
the pro-apoptotic pathway or enhancing the anti-apoptotic pathway.  To date, there are eight 
mammalian IAP’s namely: 1) neuronal apoptosis inhibitory protein (NAIP), 2) cellular IAP1 and 
3) IAP2 (cIAP1 and cIAP2), 4) X-linked IAP (XIAP), 5) Survivin, 6) Testis-specific IAP (Ts-IAP), 
7) BIR-containing ubiquitin conjugating enzyme (BRUCE) and 8) Livin.  IAP’s are characterized 
by their 70-80 amino acid baculoviral IAP repeat (BIR) domains which are important for binding 
and inhibiting caspases (Cryns & Yuan, 1999).  XIAP has been the best described out of all the 
IAP’s and has been found to antagonize the apoptotic cascade by degradation of caspases.  In 
addition to this, it has also been found to activate the pro-survival transcription factor (NF-κB) 
through nuclear localization.  As mentioned, IAP’s are regulated by Smac/DIABLO which 
normally resides in the mitochondria (Figure 4.2) and upon receiving an apoptotic signal is 
proteolytically cleaved and released into the cytosol via the Bax/Bak channel or Bid-induced 
permeabilization of the outer mitochondrial membrane (Fadeel & Orrenius, 2005). 
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Figure 4.2: Overview of the extrinsic and intrinsic pathways of apoptosis (Indran, et al., 
2011). 
4.1.3. Necrosis 
 
Necrosis has for long been thought to be an accidental, pathologically related type of cell death.  
However, over the past decade, data has been provided that suggests that necrosis may be a 
normal physiological and regulated event.  Morphologically, necrosis is characterized by: 1) cell 
swelling and 2) the rapid disruption of the plasma membrane (Proskuryakov, et al., 2003). 
 
Numerous stimuli lead to the initiation of necrotic cell death through a series of strictly regulated 
signalling events.  Death receptor ligands normally activate apoptotic rather than necrotic cell 
death if caspase activation is not hampered.  In Fas- and TRAIL-R-induced necrosis the adaptor 
protein, FADD, plays an essential role whereas TNF receptor type 1 associated death domain 
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(TRADD) seems to be more crucial for TNF-induced necrosis (vanden Berghe, et al., 2014).  
Programmed necrosis (necroptosis) refers to receptor interacting protein-1 (RIP1) dependent 
death receptor-mediated necrosis (Kung, et al., 2011).  Studies have identified a RIP3 kinase 
which regulates RIP1-dependent necrosis and treatment with TNF has revealed the formation of 
a pro-necrotic complex of RIP1-RIP3 in which the kinase activity of both was crucial for stable 
complex formation and subsequent induction of necrosis.  The anti-apoptotic and/or pro-necrotic 
properties of these two kinases are known to be suppressed by caspase 8 during death 
receptor-mediated apoptosis (Duprez, et al., 2009).   
 
The triggering of pathogen recognition receptors (PRR’s) such as transmembrane toll-like 
receptors (TLR’s), the cytosolic NOD-like receptors (NLR)’s and the RIG-I-Like receptors 
(RLR’s) have also been shown to trigger necrosis (vanden Berghe, et al., 2014).  This is 
achieved by the recognition of pathogen-associated molecular patterns (PAMP’s) such as 
lipopolysaccharide (LPS), flagellin and double-stranded RNA which are found in both bacteria 
and viruses.  Recognition of these PAMP’s by TLR3 and TLR4 induces activation of the innate 
immunity and/or cell death.  TLR4 is mainly expressed in macrophages and monocytes and is 
critical for the recognition of LPS (vanden Berghe, et al., 2014).   
 
When DNA is damaged, PARP-1 is responsible for the repair process, however, when damage 
is extensive PARP-1 is hyper-activated leading to the depletion of nicotinamide adenine 
dinucleotide (NAD+) through hydrolysis of NAD+ into nicotinamide and poly(ADP-ribose) (PAR).  
This leads to the depletion of adenosine triphosphate (ATP) thus causing irreversible energy 
failure and ultimately necrotic cell death.  The activation of RIP1 and TNF receptor associated 
factor 2 (TRAF2) is required for PARP-1 mediated necrotic cell death but, it is not yet known 
how these molecules sense activation of PARP-1 (Proskuryakov, et al., 2003) 
 
Once, necrotic cell death is induced there are many mediators that play a key role within the 
execution phase of this type of cell death.  These mediators include ROS, calcium, calpains, 
cathepsins, phospholipases and ceramide.   
 
Excessive DNA damage is a result of oxidative stress leading to the hyper-activation of PARP-1 
which then induces necrotic cell death.  Lipid peroxidation is another major effect of oxidative 
stress as this leads to the destabilization of the plasma membrane and intracellular membranes 
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of various organelles.  This causes Ca2+ leakage that leads to the activation of calpains whose 
main function is to cleave the Na+/Ca2+ antiporter, resulting in a sustained Ca2+ overload.  In the 
mitochondria, this overload causes the opening of MPTP’s, depolarization of the inner 
membrane, uncoupling of oxidative phosphorylation, matrix swelling and outer membrane 
rupture which ultimately leads to ATP depletion (Proskuryakov, et al., 2003; Duprez, et al., 
2009; Kung, et al., 2011; vanden Berghe, et al., 2014). 
4.1.4. Autophagy 
 
Autophagy is a catabolic process that is regulated by the mammalian target of rapamycin 
(mTOR) kinase.  Autophagy is characterized by its homeostatic role in the autophagosomic-
lysosomal degradation of: 1) bulk cytoplasmic contents, 2) abnormal protein aggregates and 3) 
excess or damaged organelles. This role mainly reflects on its pro-survival function, but several 
studies have suggested a role in cell death as monitored by the accumulation of LC3-II in cells 
in which apoptotic signalling has been perturbed (Duprez, et al., 2009).   
 
The classical pathway of autophagic signalling involves the inhibition of mTOR in response to 
either starvation or treatment with rapamycin (Figure 4.3).  The inhibition of mTOR leads to the 
activation of the ULK-Atg13-FIP200 complex which is responsible for the induction of the 
autophagosome formation (Guan, et al., 2013).  The synthesis of autophagic vacuoles require 
vesicle nucleation which is initiated by the assembly of the PI3KC3 (Vps-34)-complex containing 
Beclin-1 (Atg6).  The Beclin-1 serves as a binding site for positive regulators such as PI3KC3 
(Vps34), UVRAG, Bif-1 and Ambra-1.  Interestingly, anti-apoptotic family members of Bcl-2, 
represses autophagy by binding to Beclin-1 (Mizushima & Komatsu, 2011).  However, during 
starvation Bcl-2 becomes phosphorylated and thus is released from Beclin-1 leading to the 
stimulation of autophagy.  Activation of the PI3KC3 (Vps)-34-complex results in the production 
of PI3P, which along with other Atg proteins mediate vesicle membrane elongation.  Two 
ubiquitin-like conjugation systems are implicated in elongation, the first of which involves the 
formation of an Atg12-Atg5-Atg16(L) multimer complex responsible for vesicle curvature (Yang, 
et al., 2011).  During the second conjugation step LC3 (Atg8) is lipidated by binding to 
phosphatidylethanolamine (PE) and specifically binds to the autophagic membranes.  Hence it 
is generally used as an autophagic marker.  The autophagosome then fuses with a lysosome 
where the autophagic content is released into the lysosomal lumen for degradation by 
hydrolases (Duprez, et al., 2009). 
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Figure 4.3: Autophagy pathway (Yang, et al., 2011).  
 
4.1.5. The Cell Cycle 
 
The cell cycle can be defined as a series of consecutive events that ultimately leads to the 
duplication and division of a cell.  The goal of the cell cycle is to produce two accurate copies of 
the parent cell known as the daughter cells.  The cycle itself consists of an integration of both a 
continuous growth cycle and a discontinuous division or chromosome cycle.  This means that 
there is a continuous increase in the mass of cells and a discontinuous replication and 
partitioning of the genome into the respective daughter cells (Pollard & Earnshaw, 2008). 
 
Four main phases constitute the cell cycle namely the G1-, S-, G2- and M phase.  Cells may 
enter a fifth phase, known as the G0 phase, when they differentiate to carry out specialized 
functions and no longer divide.  These cells are therefore not dormant and often are found to be 
actively engaged in protein synthesis and secretion.  The G0 phase is however not permanent 
and cells can be recruited to re-enter the cell cycle (Krauss, 2008). 
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4.1.6. Cell Cycle regulation 
 
The cell cycle is a highly regulated process and various checkpoints exist that control the 
transitions between the four phases.  These checkpoints are biochemical circuits capable of 
detecting external and internal problems and when doing so send inhibitory signals to the cell 
cycle system leading to cell cycle arrest (Lodish, et al., 2000). 
4.1.6.1. G1/S checkpoint 
 
The regulation of the G1 phase occurs through two tumour suppressor proteins namely p53 and 
pRb (retinoblastoma protein).  p53 has shown to play a critical role in intrinsic tumour 
suppression via two mechanisms namely cell cycle arrest and induction of apoptosis.  Activation 
of p53 normally occurs due to DNA damage, oncogene activation and telomere erosion.   DNA 
damage, due to exposure to radiation or drugs, signals the activation of ataxia telangiectasia 
mutated (ATM) or ATM and Rad3-related (ATR) cellular checkpoint kinases.  Activation of these 
kinases leads to the phosphorylation of p53 (Figure 4.4: 4a), disrupting its interaction with 
MDM2 which normally sequesters p53.  The cell is then held at this checkpoint until the damage 
is repaired (Indran, et al., 2011).  Furthermore, the phosphorylation of p53 can lead to the 
activation of cyclin dependent kinase inhibitors (CKI’s) such as INK4, p21, p27 and p57.  These 
CKI’s can inhibit the cyclin-CDK complexes or CDK4/6 specifically (mainly done by INK4).  By 
inhibiting the complexes or CDK’s the CKI’s inhibit the phosphorylation of pRb allowing it to bind 
to the early gene 2 factor (E2F), leading to G1 arrest.  Alternatively, the transcription of Cdc25A 
(Figure 4.4: 4b) is required for the activation of CDK4/6. Therefore the phosphorylation of this 
phosphatase at a critical convergence point by Chk1/2 leads to it being ubiquitinated and 
targeted for degradation (Cell Signaling Technology, 2017). 
4.1.6.2. G2/M checkpoint 
 
The main function of this checkpoint is to prevent the entry of cells with genomic DNA damage 
into mitosis.  There are two parallel cascades that ultimately serve to inactivate the CyclinB1-
CDK1 complex subsequently blocking entry into the M-phase.  The first cascade occurs quite 
rapidly where Chk1 phosphorylates Cdc25C (Figure 4.4: 1) preventing it from activating CDK1, 
leading to G2 arrest.  The slower second parallel cascade involves the phosphorylation of p53 
(Figure 4.4: 4d) by means of activating CKI’s (such as p21) which inactivate the CyclinB1-CDK1 
complex (Cell Signaling Technology, 2017). 
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Figure 4.4: Cell cycle checkpoints (adapted from Lodish, et al., 2000). 
4.1.6.3. Mitotic catastrophe 
 
Mitotic catastrophe or cell death in mitosis occurs as a consequence of failure to complete 
mitosis.  Mitotic catastrophe is generally characterized by the formation of micro-nucleated cells 
due to abnormal chromosome segregation.  After a transient cell cycle arrest, cells enter into 
mitosis but fail to separate leading to catastrophic cell division.  It can also be caused by the 
over-duplication of centromeres as well as the consequent entry into mitosis with multiple 
spindle poles.  Mitotic cell death is prevented by the G2 checkpoint, however when it is aborted 
mitotic catastrophe occurs (Fragkos & Beard, 2011).   
 
With reference to figure 4.4 it can be seen that mitotic catastrophe is brought on by the 
activation of APC-Cdc20 which is inhibited by Mad2 and other proteins and thus poly-
ubiquitination of securin cannot occur and thus entry into anaphase is blocked (spindle 
assembly checkpoint 2).  The prevention of the release of Cdc14 phosphatase from the nucleoli 
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within the chromosome segregation checkpoint (3) inhibits the activation of Cdh1 and thus poly-
ubiquitination of B-type cyclins cannot occur and therefore telophase cannot occur (Lodish, et 
al., 2000).   
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4.2. Materials and Methods 
4.2.1. Reagents 
 
All cell lines mentioned below were purchased from Highveld Biological, South Africa (Vero and 
HepG2), Cellonex, South Africa (HeLa) or Japanese Collection of Research Bioresources Cell 
Bank (MeWo and MRHF).  RPMI 1640, EMEM, DMEM low glucose cell culture medium, MEM 
NEAA and FBS was purchased from GE Healthcare Life Sciences (Logan, Utah, USA).  
Trypsin-EDTA, Dulbecco’s phosphate buffered saline (DPBS) with Ca2+ and Mg2+ and DPBS 
without Ca2+ and Mg2+ were purchased from Lonza (Wakersville, MD, USA).  Trypan blue, 
bisBenzamide H 33342 trihydrochloride (Hoechst 33342), cisplatin, penicillin/streptomycin, 
bovine serum albumin fraction V (BSA), Anti-CASP8 polyclonal and Anti-CASP3 monoclonal 
antibodies were purchased from Sigma-Aldrich (St. Louis, MO, USA).  NucRedTM Live 647, 
LysoTracker™ Deep Red and tetramethylrhodamine ethyl ester were purchased from Molecular 
Probes® - Life Technologies - Thermo Fisher Scientific (Logan, Utah, USA).  Annexin V-FITC/PI 
kit was purchased from MACS Miltenyi Biotec (Germany).  Cleaved caspase 3 (Asp 175) 
(D3E9) Rabbit mAb, Cleaved caspase 8 (Asp 391) (18C8) Rabbit mAb, Anti-rabbit IgG (H+L), 
F(ab’)2 fragment (Alexa fluor® 647 conjugate), Anti-rabbit IgG (H+L), F(ab’)2 fragment (Alexa 
fluor® 488 conjugate) and Phospho-Histone H3 (Ser10) (D2C8) mAb were purchased from Cell 
Signaling Technology (Massachusetts, USA). 
4.2.2. Cytotoxicity 
 
Cells were seeded in 96-well plates at densities of 5000 cells/well (HeLa, Vero and MRHF) and 
10000 cells/well (MeWo and HepG2) using 100 µl aliquots and left overnight to attach. For 
treatment, an additional 100 µl of the treatments at varying concentrations of extracts (0.1 – 300 
µg/ml and compounds (0.1 – 200 µM) were added. Treated cells were incubated at 37°C in a 
humidified 5% CO2 incubator for 48 hours. Treatment medium was removed and replaced with 
100 µl phosphate buffered saline (DPBS with Ca2+ and Mg2+) containing Hoechst 33342 at a 
final concentration of 5 µg/ml.  PI was added at a final concentration of 10 µg/ml using 10 µl per 
well of a 110 µg/ml stock just before image acquisition. 
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4.2.3. Cell Cycle analysis and Micronuclei formation assay 
 
HeLa cells were seeded in 96-well plates at a density of 5000 cells/well using 100 µl aliquots 
and left overnight to attach. The cells were treated with the IC10, IC25, IC50 and IC75 
concentrations of cisplatin, A. nemorosa, BC-7 and A. afra, respectively. Treated cells were 
incubated at 37°C in a humidified 5% CO2 incubator for 24 and 48 hours. Treatment medium 
was removed and cells were fixed using 4% formaldehyde for 15 minutes at room temperature 
prior to the addition of 100 µl NucRed stain (50 µl NucRed in 10ml DPBS with Ca2+ and Mg2+, 
according to manufacturer’s instructions).  Cells were incubated for 15 minutes at room 
temperature prior to imaging. 
4.2.4. Histone H3 phosphorylation 
 
HeLa cells were seeded and treated as described for cell cycle analysis (section 4.2.3).  
Staining was performed as described for cell cycle analysis, after which cells were 
permeabilized using 80% ice cold methanol at minus 20°C for 10 minutes.  Phospho-Histone H3 
(Ser10) (D2C8) XP® Rabbit mAb (Cell Signaling Technology) was used to detect the presence 
of phosphorylated Histone H3.  After permeabilization the cells were blocked using DPBS with 
Ca2+ and Mg2+ containing 0.5% BSA and thereafter incubated with the primary antibody (1:250) 
for 1 hour at 37°C. Cells were washed and incubated with a conjugated secondary antibody 
(1:1000), anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) for 30 minutes 
at 37°C in the dark. After staining with the secondary antibody, the cells were washed twice to 
eliminate unbound antibody and imaged. 
4.2.5. Phosphatidylserine translocation 
 
The Annexin V-FITC/PI kit from MACS Miltenyi Biotec was used with modifications.  HeLa cells 
were seeded and treated as described for cell cycle analysis (section 4.2.3).  After 24 and 48 
hours, cells were stained by removing treatment medium and adding 50 μl aliquots of a mixture 
of Annexin V-FITC at a final concentration of 1X the stock (50 μl) and Hoechst 33342 at a final 
concentration of 2 µg/ml (1 μl of 10 mg/ml stock) in 5 ml DPBS with Ca2+ and Mg2+ containing 
250 μl of Binding Buffer (20X).  Cells were incubated in the dark for 15 minutes at room 
temperature.  PI at a final concentration of 1 µg/ml (50 μl per well of 2 μg/ml working stock) was 
added to the Annexin/Hoechst 33342 stain just before image acquisition. 
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4.2.6. Mitochondrial membrane potential analysis 
 
HeLa cells were seeded and treated as described for cell cycle analysis (section 4.2.3).  Cells 
were stained by removing treatment medium and adding 100 µl aliquots of a mixture of TMRE at 
a final concentration of 0.25 µM (50 µl of 0.05 mM stock) and Hoechst 33342 at a final 
concentration of 2 µg/ml (2 µl of 10 mg/ml stock) in 10 ml DPBS with Ca2+ and Mg2+.  Cells were 
incubated in the dark for 30 minutes at 37°C prior to imaging. 
4.2.7. Cleaved caspase 8 and 3 analysis 
 
HeLa cells were seeded and treated as described for cell cycle analysis (section 4.2.3).  Cells 
were treated for 24 and 48 hours, after which they were fixed and permeabilized as described 
for histone H3 phosphorylation.  Cleaved caspase 8 (Asp 391) and cleaved caspase 3 (Asp 
175) (D3E9) rabbit monoclonal antibodies (Cell Signaling Technology) were used to detect the 
presence of activated caspase 8 and caspase 3, respectively.  After permeabilization the cells 
were blocked using DPBS with Ca2+ and Mg2+ containing 0.5% BSA and thereafter incubated 
with the antibodies separately (1:100 for caspase 8 and 1:200 for caspase 3) for 1 hour at 37°C. 
Cells were washed and incubated with a conjugated secondary antibody (1:500), anti-rabbit IgG 
(H+L), F(ab')2 Fragment (Alexa Fluor® 647 Conjugate) for 30 minutes at 37°C in the dark. After 
staining with the secondary antibody, the cells were washed twice to eliminate unbound 
antibody and Hoechst 33342 was used as a counterstain, at a final concentration of 2 µg/ml, 
prior to imaging. 
4.2.8. Total caspase 8 and 3 analysis 
 
HeLa cells were seeded and treated as described for cell cycle analysis (section 4.2.3).  Cells 
were treated for 24 and 48 hours, after which they were fixed, permeabilized and blocked as 
described in section 4.2.7.  Caspase 8 and caspase 3 rabbit monoclonal antibodies (Sigma-
Aldrich) were used to determine the presence of total (both the pro- and active forms) caspase 8 
and caspase 3, respectively.  Cells were washed and incubated with a conjugated secondary 
antibody (1:500), anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 647 Conjugate) for 30 
minutes at 37°C in the dark. After staining with the secondary antibody, the cells were washed 
twice to eliminate unbound antibody and Hoechst 33342 was used as a counterstain, as 
described in section 4.2.7, prior to imaging. 
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4.2.9. Autophagy induction 
 
HeLa cells were seeded and treated as described for cell cycle analysis (section 4.2.3).  Cells 
were stained by removing treatment medium and adding 100 μl aliquots of a mixture of 50 nM 
LysoTracker Red (0.5 μl of a 1 mM stock) and Hoechst 33342 at a final concentration of 2 µg/ml 
(2 μl of 10 mg/ml) in 10 ml DPBS with Ca2+ and Mg2+.  Cells were incubated in the dark for 30 
minutes at 37°C prior to imaging.  Chloroquine (100 µM) was included as a positive control for 
acidic vesicle production. 
4.2.10. Statistical analysis 
 
At least three experiments were completed for each cell line in which three different transfer 
numbers were used.  Statistical analysis was performed by means of the two-tailed Student t-
test for two samples assuming equal variance.  Error bars represent the standard deviation of 
the mean (SD, n=3).  IC50 values were calculated from 6-point log-dose response curves using 
GraphPad Prism version 5.01.  IC10, IC25 and IC75 values were calculated using the GraphPad 
QuickCalcs: Compute ECanything from EC50 calculator available at 
http://www.graphpad.com/quickcalcs/Ecanything1/ 
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4.3. Results 
 
The aim of this chapter was to determine the mechanism of cell death induced by three 
compounds (cisplatin, BC-7, BT-7) and two plant extracts (A. afra and A. nemorosa) using 
HeLa, MeWo and HepG2 cancer cells.  This was achieved by analyzing biochemical features 
involved in cell cycle regulation and apoptosis, namely cell cycle arrest, Histone H3 
phosphorylation, micronuclei formation, PS translocation, mitochondrial membrane 
depolarization and caspase activation.  The two normal cell lines, Vero and MRHF, were used 
to determine selectivity indices for compounds and extracts. 
 
4.3.1. Cytotoxicity and IC50 determination: 
 
HeLa, MeWo, HepG2, Vero and MRHF cells were treated with various concentrations of 
compounds and extracts to determine their cytotoxic abilities and IC50 values were determined 
for each cell line, where applicable.  Figures 4.5 and 4.6 are dose-response curves resulting 
from treatment of Vero and MRHF cells, respectively.  Cisplatin was the most toxic against Vero 
and MRHF cells with IC50 values of 5.921 ± 0.810 µM (1.776 ± 0.243 µg/ml) and 6.490 ± 1.782 
µM (1.947 ± 0.535 µg/ml), respectively.  When comparing the two plant extracts, A. nemorosa 
was the most cytotoxic, yielding IC50 values of 33.50 ± 6.485 µg/ml and 19.92 ± 7.590 µg/ml on 
Vero and MRHF cells, respectively, whereas, A. afra yielded 141.2 ± 8.200 µg/ml and 67.20 ± 
6.210 µg/ml, respectively.  The IC50 values for BC-7 on Vero and MRHF cells were 169.5 ± 
27.45 µM (73.86 ± 11.96 µg/ml) and 111.4 µM ± 9.300 µM (48.54 ± 4.052 µg/ml), respectively.  
IC50 values for BT-7 could not be determined as it was greater than 200 µM (80.23 µg/ml), 
which was outside the concentration range tested.  It was also noted that BT-7 precipitated out 
of solution at concentrations higher than 80 µM (32.10 µg/ml). 
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Figure 4.5: Cytotoxic effects of compounds and extracts on Vero cells after 48 hours of 
exposure.  Cell viability was determined using the Hoechst 33342/PI staining method.  Error 
bars indicate SD of three individual experiments, each performed in quadruplicate (n=3). 
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Figure 4.6: Cytotoxic effects of compounds and extracts on MRHF cells after 48 hours of 
exposure.  Cell viability was determined using the Hoechst 33342/PI staining method.  Error 
bars indicate SD of three individual experiments, each performed in quadruplicate (n=3). 
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Figures 4.7, 4.8 and 4.9 are dose-response curves resulting from treatment of the three cancer 
cell lines with compounds and extracts.  Cisplatin was once again the most effective on HeLa 
cells yielding an IC50 value of 1.675 ± 0.301 µM (0.503 ± 0.090 µg/ml) followed by 20.33 ± 2.480 
µg/ml for A. nemorosa, 65.58 ± 8.400 µM (28.58 ± 3.660 µg/ml) for BC-7, 70.87 ± 4.320 µg/ml 
for A. afra and greater than 200 µM for BT-7.  All extracts and compounds indicated a decrease 
in activity against MeWo cells compared to the results obtained for HeLa cells (Figure 4.8).  
Cisplatin and A. afra were the most effective with IC50 values of 9.300 ± 1.527 µM (2.79 ± 0.458 
µg/ml) and 113.2 ± 9.850 µg/ml, respectively.  A. nemorosa yielded an IC50 value greater than 
200 µg/ml, but a half maximal response concentration (EC50) of 41.47 ± 8.075 µg/ml could be 
calculated.    Results obtained for the HepG2 cells (Figure 4.9) also indicated a slight decrease 
in activity for all extracts and compounds compared to HeLa cells except for A. afra with an IC50 
of 37.55 ± 4.770 µg/ml.  Cisplatin and A. nemorosa yielded IC50 values of 3.525 ± 1.521 µM 
(1.058 ± 0.456 µg/ml) and 27.66 ± 12.27 µg/ml, respectively.  Both BC-7 and BT-7 yielded IC50 
values greater than 200 µM for MeWo and HepG2 cells. 
 
-3 -2 -1 0 1 2 3
20
40
60
80
100
Cisplatin (1.675 M)
A. afra (70.87 g/ml)
A. nemorosa (20.33 g/ml)
BC-7 (65.58 M)
log[Extract or Compound], g/ml or M
C
e
ll
 D
e
a
th
 (
%
)
 
Figure 4.7: Cytotoxic effects of compounds and extracts on HeLa cancer cells after 48 
hours of exposure.  Cell viability was determined using the Hoechst 33342/PI staining method.   
Error bars indicate SD of three individual experiments, each performed in quadruplicate (n=3). 
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Figure 4.8: Cytotoxic effects of compounds and extracts on MeWo cancer cells after 48 
hours of exposure.  Cell viability was determined using the Hoechst 33342/PI staining method.  
Error bars indicate SD of three individual experiments, each performed in quadruplicate (n=3). 
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Figure 4.9: Cytotoxic effects of compounds and extracts on HepG2 cancer cells after 48 
hours of exposure.  Cell viability was determined using the Hoechst 33342/PI staining method.  
Error bars indicate SD of three individual experiments, each performed in quadruplicate (n=3). 
 
The IC10, IC25 and IC75 values were determined (Table 4.2) and together with the IC50 values 
were used for all the subsequent experiments.  BT-7 was excluded from any further 
experiments due to it not showing any activity against any of the cancer cell lines. 
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Table 4.2: Summary of IC10, IC25, IC50 and IC75 values for each cell line as determined from 
dose response curves for each respective treatment. 
 
Cisplatin (µM) IC10 IC25 IC50 IC75 
Vero 0.496 ± 0.068 1.714 ± 0.235 5.921 ± 0.810 20.45 ± 2.798 
MRHF 0.166 ± 0.046 1.037 ± 0.285 6.490 ± 1.782 40.60 ± 11.15 
HeLa 0.069 ± 0.012 0.342 ± 0.060 1.675 ± 0.301 8.194 ± 1.499 
MeWo 0.795 ± 0.131 2.719 ± 0.446 9.300 ± 1.527 31.81 ± 5.223 
HepG2 0.123 ± 0.053 0.659 ± 0.284 3.525 ± 1.521 18.86 ± 8.137 
 
A. nemorosa (µg/ml) IC10 IC25 IC50 IC75 
Vero 6.035 ± 1.168 14.22 ± 2.753 33.50 ± 6.485 78.92 ± 15.28 
MRHF 0.253 ± 0.096 2.244 ± 0.855 19.92 ± 7.590 176.9 ± 67.39 
HeLa 4.093 ± 0.785 9.120 ± 1.395 20.33 ± 2.480 45.31 ± 4.408 
MeWo - - >200 - 
HepG2 0.809 ± 0.359 4.732 ± 2.099 27.66 ± 12.27 161.7 ± 71.73 
 
A. afra (µg/ml) IC10 IC25 IC50 IC75 
Vero 17.80 ± 3.035 50.14 ± 4.989 141.2 ± 8.200 397.7 ± 13.48 
MRHF 24.88 ± 0.783 40.89 ± 2.205 67.20 ± 6.210 110.4 ± 17.49 
HeLa 22.30 ± 1.709 39.75 ± 2.717 70.87 ± 4.320 126.4 ± 6.869 
MeWo 18.06 ± 1.571 45.21 ± 3.934 113.2 ± 9.850 283.4 ± 24.66 
HepG2 6.301 ± 0.800 15.38 ± 1.954 37.55 ± 4.770 91.66 ± 11.64 
 
BC-7 (µM) IC10 IC25 IC50 IC75 
Vero 40.69 ± 6.590 83.05 ± 13.45 169.5 ± 27.45 345.9 ± 56.02 
MRHF 53.09 ± 4.432 76.91 ± 6.420 111.4 ± 9.300 161.4 ± 13.47 
HeLa 18.50 ± 3.520 34.83 ± 5.437 65.58 ± 8.400 123.5 ± 12.98 
MeWo - - >200 - 
HepG2 - - >200 - 
 
BT-7 (µM) IC10 IC25 IC50 IC75 
Vero - - >200 - 
MRHF - - >200 - 
HeLa - - >200 - 
MeWo - - >200 - 
HepG2 - - >200 - 
(-) Not determined 
 
The selectivity index (SI) of each of the compounds and extracts for the cancer cells were 
calculated relative to the normal cells by dividing the IC50 value of the normal cells by that of the 
cancer cells (Table 4.3).  An SI value of less than 2 indicates general toxicity.  When comparing 
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HeLa cell toxicity to that of Vero cell toxicity, cisplatin and BC-7 indicated SI values of 3.53 and 
2.58, respectively.  A. afra indicated greater selectivity towards HepG2 cells relative to Vero 
cells.  Compared to MRHF cells, only cisplatin indicated any significant selectivity.  
 
Table 4.3: SI values of compounds and extracts for cancer cells relative to normal cells.   
Relative to Vero HeLa MeWo HepG2 
Cisplatin 3.53 0.64 1.68 
A. nemorosa 1.65 0.17 1.21 
BC-7 2.58 <0.85 <0.85 
A. afra 1.99 1.25 3.76 
 
Relative to MRHF HeLa MeWo HepG2 
Cisplatin 3.87 0.70 1.84 
A. nemorosa 0.98 0.10 0.72 
BC-7 1.70 <0.56 <0.56 
A. afra 0.95 0.59 1.79 
 
Greater selectivity towards HeLa cells compared to MeWo and HepG2 cells were seen for 
treatments with cisplatin and BC-7 (Table 4.4).  A. nemorosa also indicated greater selectivity 
towards HeLa cells compared to MeWo cells.  Interestingly, these SI values (except that of 
cisplatin for HeLa cells compared to HepG2 cells) were greater than compared to normal cells.   
 
Table 4.4: SI values of compounds and extracts for HeLa cells compared to MeWo and 
HepG2 cells. 
Treatment MeWo HepG2 
Cisplatin 5.55 2.10 
A. nemorosa 9.93 1.36 
BC-7 >3.05 >3.05 
A. afra 1.60 0.53 
 
HeLa cells were used for all subsequent assays due to the greater selectivity of all the 
compounds and extracts towards HeLa cells compared to that of MeWo and HepG2 cells. 
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4.3.2. Cell Cycle analysis: 
 
DNA cell cycle analysis was performed to determine arrest of cells in a certain phase of the cell 
cycle.  HeLa cells were exposed to all the compounds and extracts at their respective IC10, IC25, 
IC50 and IC75 values for 24 and 48 hours.  Cisplatin arrested cells in the G2 phase whereas with 
all the other treatments arrest occurred in the early M phase after 24 hours (Figure 4.10).  The 
same was seen after 48 hours for treatment with cisplatin but early M phase arrest for the other 
treatments was not as pronounced (Figure 4.11).  
 
Figure 4.10: Cell Cycle Analysis of HeLa cells after 24 hour treatments.  Cell cycle analysis 
was determined by the NucRed staining method.  Control treatment refers to untreated control. 
Results displayed as percentage of cells detected in each phase.  Error bars indicate SD of 
three individual experiments, each performed in quadruplicate (n=3).  Significance was 
determined using the two-tailed Student t-test: *p<0.05 and #p<0.005 compared to untreated 
control. 
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After 48 hours of treatment with BC-7 and A. afra, there was a noticeable increase in the 
number of cells arrested in the G2 and S phase, respectively, compared to 24 hours (Figure 
4.10).  
 
Figure 4.11: Cell Cycle Analysis of HeLa cells after 48 hour treatments.  Cell cycle analysis 
was determined by the NucRed staining method.  Control treatment refers to untreated control. 
Results displayed as percentage of cells detected in each phase Error bars indicate SD of three 
individual experiments, each performed in quadruplicate (n=3).  Significance was determined 
using the two-tailed Student t-test: *p<0.05 and #p<0.005 compared to untreated control. 
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4.3.3. Histone H3 phosphorylation: 
 
Phosphorylation of Histone H3 at Ser10 is believed to be a marker for cells entering into mitosis 
and was therefore looked at to confirm the results of the cell cycle analysis in section 4.3.2.  
Immunofluorescence staining with phospho-Histone H3 (Ser10) antibody was done after 24 and 
48 hours of treatment.  Cisplatin and A. afra treatments indicated a dose dependent decrease in 
positive staining for phosphorylated histone H3 after 24 hours.  However, the same trend was 
not seen after 48 hours as the IC50 treatment of cisplatin indicated a significant increase.  A 
significant dose dependent increase was also seen for A. afra treatments.  A. nemorosa, at its 
IC75, showed significant increases in the amount of positive staining for phosphorylated histone 
H3 after both 24 and 48 hours.  Treatment with BC-7 after 24 hours, but not 48 hours, indicated 
significant increases in positive staining.  It was also evident that there was a general decrease 
in positive staining for phosphorylated histone H3 after 48 hours which could support the low 
percentage of cells in the early M phase of the cell cycle analysis after 48 hours.  
 
Table 4.5: Changes in phosphorylated Histone H3 levels in HeLa cells after 24 and 48 
hours of treatment.  
 Treatment Cells stained positive for phospho-Histone H3 (%) 
   IC10 IC25 IC50 IC75 
24H 
Control 12.28 ± 1.88     
Cisplatin  13.01 ± 1.35 11.95 ± 0.76 7.90 ± 0.52* 6.04 ± 1.16* 
A. nemorosa  11.54 ± 0.93 11.17 ± 0.49 11.50 ± 0.47 41.31 ± 6.23** 
BC-7  16.57 ± 0.58* 16.71 ± 0.61* 17.40 ± 0.77* 15.42 ± 0.47* 
A. afra  13.55 ± 1.06 13.14 ± 0.89 11.14 ± 0.30 9.41 ± 0.16 
       
48H 
Control 5.35 ± 0.52     
Cisplatin  5.32 ± 0.99 5.83 ± 1.23 8.70 ± 1.42* 4.55 ± 1.47 
A. nemorosa  5.20 ± 0.68 6.45 ± 0.77 7.01 ± 0.69* 11.70 ± 1.77** 
BC-7  5.83 ± 0.44 5.74 ± 0.23 5.39 ± 0.28 5.89 ± 0.24 
A. afra  6.52 ± 0.10* 6.88 ± 0.17* 8.49 ± 0.86* 10.01 ± 1.77* 
       
Control treatment refers to untreated control. Significance was determined using the two-tailed 
Student t-test: *p<0.05 and **p<0.005 compared to untreated control. 
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4.3.4. Micronuclei formation assay: 
 
The onset of mitotic catastrophe through treatment with cisplatin, A. nemorosa, BC-7 and A. 
afra was evaluated by the measurement of micronuclei formation (Figure 4.12).  Treatments 
with BC-7 and A. afra after 24 and 48 hours led to significant dose dependent increases in 
micronuclei formation with that of A. afra being the greatest compared to all other treatments.  
A. nemorosa indicated a greater effect on micronuclei formation after 24 hours except for 
treatment with its IC75.  Cisplatin on the other hand showed no effect on micronuclei formation 
after 24 hours and a significant dose dependent effect after 48 hours.  
 
Figure 4.12: Assessment of micronuclei formation in HeLa cells after 24 and 48 hours.  
The NucRed staining method was used.  Control treatment refers to untreated control. Results 
displayed as percentage micronucleated cells Error bars indicate SD of three individual 
experiments, each performed in quadruplicate (n=3).  Significance was determined using the 
two-tailed Student t-test: *p<0.05 and #p<0.005 compared to untreated control. 
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4.3.5. Phosphatidylserine translocation: 
 
PS translocation is considered an early feature of apoptosis due to the loss of membrane 
asymmetry upon induction of apoptosis.  The presence of PS was determined using the 
Annexin V-FITC/ PI assay after 24 and 48 hours.  Significant dose dependent increases were 
seen for all treatments after 24 hours of exposure, A. afra being the most significant, compared 
to untreated control (Figure 4.13).  
 
Figure 4.13: Analysis of PS translocation in HeLa cells after 24 hours of treatment. The 
Annexin V-FITC/ PI dual staining method was used.  Control treatment refers to untreated 
control. Results displayed as percentage positively stained cells.  Error bars indicate SD of three 
individual experiments, each performed in quadruplicate (n=3).  Significance was determined 
using the two-tailed Student t-test: *p<0.05 and #p<0.005 compared to untreated control.  
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Significant increases were seen for all treatments, except for cisplatin, in a dose dependent 
manner after 48 hours (Figure 4.14) with the greatest increase in the number of apoptotic cells 
recorded for the IC75 treatment of A. nemorosa.  BC-7 indicated the greatest increases in both 
the number of necrotic and late apoptotic/ necrotic cells. 
 
Figure 4.14: Analysis of PS translocation in HeLa cells after 48 hours of treatment. The 
Annexin V-FITC/ PI dual staining method was used.  Control treatment refers to untreated 
control. Results displayed as percentage positively stained cells.  Error bars indicate SD of three 
individual experiments, each performed in quadruplicate (n=3).  Significance was determined 
using the two-tailed Student t-test: *p<0.05 and #p<0.005 compared to untreated control.  
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4.3.6. Mitochondrial membrane depolarization: 
 
Mitochondrial membrane depolarization is a marker for the onset of the intrinsic mode of 
apoptosis and the subsequent release of cyt-c.  All treatments indicated a dose dependent loss 
in MMP after 24 and 48 hours (Table 4.6).  The most significant loss was seen after 48 hours, 
except for treatment with A. afra which indicated a gain in MMP compared to 24 hour treatment.  
Treatment with A. afra and A. nemorosa yielded the greatest loss in MMP after 24 and 48 hours, 
respectively.  Cisplatin treatment was the least effective of all treatments. 
 
Table 4.6: Changes in MMP in HeLa cells after 24 and 48 hours of treatment. 
 Treatment Mean Cytoplasmic Integrated Intensity (% of control) 
   IC10 IC25 IC50 IC75 
24H 
Control 100 ± 9.49     
Cisplatin  72.17 ± 6.75* 81.95 ± 5.54* 80.65 ± 6.28* 77.33 ± 2.98* 
A. nemorosa  72.65 ± 8.37* 89.23 ± 1.67 73.78 ± 1.33* 58.61 ± 2.58** 
BC-7  94.85 ± 1.74 92.28 ± 1.83 90.74 ± 2.30 77.60 ± 2.05* 
A. afra  90.63 ± 1.88 73.42 ± 4.53* 53.94 ± 5.60** 33.03 ± 4.74** 
       
48H 
Control 100 ± 3.29     
Cisplatin  86.62 ± 2.04** 88.00 ± 1.04** 76.30 ± 1.85** 62.87 ± 0.04** 
A. nemorosa  89.30 ± 0.50* 90.00 ± 0.72* 53.46 ± 1.08** 25.67 ± 0.90** 
BC-7  64.55 ± 1.72** 63.83 ± 3.45** 61.63 ± 0.06** 42.39 ± 3.33** 
A. afra  97.82 ± 3.39 94.80 ± 0.03 87.12 ± 0.87** 56.68 ± 0.46** 
       
Control treatment refers to untreated control. Significance was determined using the two-tailed 
Student t-test: *p<0.05 and **p<0.005 compared to untreated control. 
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4.3.7. Caspase 8 and 3 protein levels and activation: 
 
Caspase 8 and 3 are the two main caspases involved in the initiation and execution of 
apoptosis.  The total protein levels (activated + inactivated) along with the activated levels, 
alone, of caspase 8 and 3 were determined after 24 and 48 hours by immunofluorescence 
staining with antibodies against total and activated/cleaved caspase 8 and 3.  The total levels of 
caspase 8 and 3 are dependent on expression and degradation.  Therefore, an increase in the 
total levels could be indicative of, the inhibition of degradation or up-regulation of expression. 
Likewise, a decrease in the total levels could be indicative of, increased degradation or inhibition 
of expression. An increase in the mean cell integrated intensity values, when compared to the 
untreated control, correlates to an increase in the total and active caspase 8 and 3.  
4.3.7.1. Caspase 8 
 
A. afra treatments indicated the greatest increase in cleaved caspase 8 levels (Table 4.7) of all 
treatments followed by cisplatin and then BC-7.  A. nemorosa treatment had the lowest levels of 
cleaved caspase 8 with the most significant increase seen for the IC75 treatment after 48 hours. 
 
Table 4.7: Changes in cleaved caspase 8 levels in HeLa cells after 24 and 48 hours of 
treatment.  
 Treatment Cleaved Caspase 8 Mean Cell Integrated Intensity (% of control) 
   IC10 IC25 IC50 IC75 
24H 
Control 100 ± 1.15     
Cisplatin  99.14 ± 1.23 105.9 ± 2.66* 116.3 ± 0.21** 124.7 ± 2.24** 
A. nemorosa  104.7 ± 4.47 110.9 ± 12.6 101.6 ± 4.98 116.5 ± 17.5 
BC-7  108.1 ± 8.25 111.6 ± 6.46* 113.4 ± 10.8 114.0 ± 9.81 
A. afra  169.3 ± 18.5** 213.2 ± 33.7** 273.3 ± 12.8** 400.2 ± 19.7** 
       
48H 
Control 100 ± 1.82     
Cisplatin  102.9 ± 1.46 108.2 ± 2.77* 151.8 ± 8.08** 167.2 ± 7.37** 
A. nemorosa  102.7 ± 0.14 102.7 ± 3.13 107.9 ± 3.90* 112.8 ± 3.06** 
BC-7  113.3 ± 1.77** 118.2 ± 6.32** 117.0 ± 3.00** 119.3 ± 0.96** 
A. afra  144.0 ± 26.5* 162.5 ± 25.6* 228.5 ± 54.0* 285.3 ± 45.4** 
       
Control treatment refers to untreated control. Significance was determined using the two-tailed 
Student t-test: *p<0.05 and **p<0.005 compared to untreated control. 
 
All treatments indicated a significant dose dependent increase in total caspase 8 levels after 24 
and 48 hours (Table 4.8).   
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Table 4.8: Changes in total caspase 8 levels in HeLa cells after 24 and 48 hours of 
treatment.   
 Treatment Total Caspase 8 Mean Cell Integrated Intensity (% of control) 
   IC10 IC25 IC50 IC75 
24H 
Control 100 ± 3.11     
Cisplatin  112.1 ± 5.76* 112.1 ± 2.82** 125.3 ± 3.57** 126.0 ± 5.26** 
A. nemorosa  100.7 ± 2.38 103.9 ± 2.12 111.8 ± 1.84** 141.3 ± 2.18** 
BC-7  107.2 ± 1.23* 115.9 ± 2.77** 121.0 ± 3.35** 119.4 ± 5.72** 
A. afra  107.4 ± 3.88* 115.3 ± 5.88** 125.9 ± 7.79** 135.6 ± 4.80** 
       
48H 
Control 100 ± 3.05     
Cisplatin  113.3 ± 0.93** 116.8 ± 7.06** 178.2 ± 6.67** 192.8 ± 14.0** 
A. nemorosa  119.7 ± 1.49** 122.5 ± 4.99** 133.2 ± 4.96** 199.6 ± 8.55** 
BC-7  123.7 ± 8.54** 154.3 ± 8.05** 163.1 ± 11.2** 176.4 ± 19.6** 
A. afra  112.9 ± 5.22* 116.3 ± 2.48** 145.8 ± 1.22** 208.0 ± 19.5** 
       
Control treatment refers to untreated control. Significance was determined using the two-tailed 
Student t-test: *p<0.05 and **p<0.005 compared to untreated control. 
 
The relative levels of cleaved towards total caspase 8 levels (Figure 4.15) revealed that there 
was significantly more caspase 8 activation for treatment with A. afra, in a dose dependent 
manner, as opposed to all other treatments which showed that there was less.  This result for A. 
afra is even more significant if one considers the very large increase in total caspase 8 
illustrated in Table 4.8.   
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Figure 4.15: Relative levels of cleaved caspase 8 to total caspase 8 in HeLa cells after 24 
and 48 hours of treatment.  Immunofluorescence staining with cleaved caspase 8 and total 
caspase 8 antibodies was done.  Control treatment refers to untreated control. Results 
displayed as a ratio of the mean cell integrated intensity of cleaved caspase 8 relative to that of 
total caspase 8 and expressed as a percentage of the untreated control.  Error bars indicate SD 
of three individual experiments, each performed in quadruplicate (n=3).  Significance was 
determined using the two-tailed Student t-test: *p<0.05 and #p<0.005 compared to untreated 
control. 
 
4.3.7.2. Caspase 3 
 
All treatments caused a significant dose dependent increase in cleaved caspase 3 levels after 
48 hours (Table 4.9).  Once again, treatment with A. afra yielded the greatest increases followed 
by cisplatin and BC-7.  A. nemorosa treatment indicated the lowest levels compared to other 
treatments except at its IC75 where it was higher than for BC-7. 
# * # # * * * 
0
50
100
150
200
250
300
350
IC10 IC25 IC50 IC75
Control Cisplatin
C
le
av
e
d
 C
as
p
as
e
 8
/C
as
p
as
e
 8
  
(%
 o
f 
co
n
tr
o
l)
 
24H 48H
* # # # 
# 
0
50
100
150
200
250
300
350
IC10 IC25 IC50 IC75
Control A. nemorosa
C
le
av
e
d
 C
as
p
as
e
 8
/C
as
p
as
e
 8
 
(%
 o
f 
co
n
tr
o
l)
 
24H 48H
# # # # 
0
50
100
150
200
250
300
350
IC10 IC25 IC50 IC75
Control BC-7
C
le
av
e
d
 C
as
p
as
e
 8
/C
as
p
as
e
 8
  
(%
 o
f 
co
n
tr
o
l)
 
24H 48H
# 
# # 
# 
* * 
0
50
100
150
200
250
300
350
IC10 IC25 IC50 IC75
Control A. afra
C
le
av
e
d
 C
as
p
as
e
 8
/C
as
p
as
e
 8
 
(%
 o
f 
co
n
tr
o
l)
 
24H 48H
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
63 
Table 4.9: Changes in cleaved caspase 3 levels in HeLa cells after 24 and 48 hours of 
treatment.  
 Treatment Cleaved Caspase 3 Mean Cell Integrated Intensity (% of control) 
   IC10 IC25 IC50 IC75 
24H 
Control 100 ± 4.86     
Cisplatin  103.5 ± 5.20 110.6 ± 5.94 123.2 ± 5.28* 129.1 ± 6.23** 
A. nemorosa  101.5 ± 4.65 102.8 ± 5.28 103.4 ± 5.64 106.1 ± 4.95 
BC-7  103.4 ± 5.43 104.8 ± 5.02 103.7 ± 4.75 110.4 ± 5.72 
A. afra  155.8 ± 5.96** 170.5 ± 1.54** 175.6 ± 1.30** 217.2 ± 9.31** 
       
48H 
Control 100 ± 1.17     
Cisplatin  105.1 ± 1.94* 111.2 ± 3.29* 155.7 ± 7.82** 174.0 ± 8.58** 
A. nemorosa  100.2 ± 2.46 104.4 ± 0.19** 108.4 ± 2.65** 126.7 ± 4.31** 
BC-7  107.7 ± 1.83** 115.7 ± 1.62** 116.4 ± 2.94** 117.6 ± 0.45** 
A. afra  157.9 ± 11.7** 172.7 ± 4.08** 216.3 ± 15.4** 460.8 ± 32.3** 
       
Control treatment refers to untreated control. Significance was determined using the two-tailed 
Student t-test: *p<0.05 and **p<0.005 compared to untreated control. 
 
The same observation can be made for the changes in total caspase 3 levels (Table 4.10) as 
was made for the changes in the total caspase 8 levels. 
 
Table 4.10: Changes in total caspase 3 levels in HeLa cells after 24 and 48 hours of 
treatment. 
 Treatment Total Caspase 3 Mean Cell Integrated Intensity (% of control) 
   IC10 IC25 IC50 IC75 
24H 
Control 100 ± 4.71     
Cisplatin  109.5 ± 3.78* 119.1 ± 6.61** 128.7 ± 6.62** 140.6 ± 3.59** 
A. nemorosa  103.2 ± 7.91 108.1 ± 4.74 122.9 ± 4.66** 167.6 ± 4.51** 
BC-7  116.5 ± 9.45* 125.3 ± 7.08** 137.5 ± 7.27** 140.4 ± 10.3** 
A. afra  114.2 ± 5.88* 121.1 ± 1.82** 143.4 ± 7.16** 156.1 ± 4.07** 
       
48H 
Control 100 ± 4.07     
Cisplatin  122.8 ± 4.18** 130.3 ± 5.09** 189.0 ± 10.2** 198.5 ± 12.4** 
A. nemorosa  119.7 ± 6.62** 128.8 ± 3.88** 149.7 ± 5.11** 275.6 ± 29.1** 
BC-7  141.2 ± 10.8** 169.1 ± 5.67** 209.2 ± 18.1** 199.9 ± 17.2** 
A. afra  111.0 ± 8.87 131.4 ± 6.71** 153.4 ± 13.4** 241.2 ± 19.2** 
       
Control treatment refers to untreated control. Significance was determined using the two-tailed 
Student t-test: *p<0.05 and **p<0.005 compared to untreated control. 
 
The same observation was made for relative cleaved caspase 3 levels towards total caspase 3 
levels (Figure 4.16) as was made for cleaved caspase 8 towards total caspase 8. 
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Figure 4.16: Relative levels of cleaved caspase 3 to total caspase 3 in HeLa cells after 24 
and 48 hours of treatment.  Immunofluorescence staining with cleaved caspase 3 and total 
caspase 3 antibodies was done.  Control treatment refers to untreated control. Results 
displayed as a ratio of the mean cell integrated intensity of cleaved caspase 3 relative to that of 
total caspase 3 and expressed as a percentage of the untreated control.  Error bars indicate SD 
of three individual experiments, each performed in quadruplicate (n=3).  Significance was 
determined using the two-tailed Student t-test: *p<0.05 and #p<0.005 compared to untreated 
control. 
 
 
 
 
 
 
 
# # # * 
0
50
100
150
200
250
IC10 IC25 IC50 IC75
Control Cisplatin
C
le
av
e
d
 C
as
p
as
e
 3
/C
as
p
as
e
 3
 
(%
 o
f 
co
n
tr
o
l)
 
24H 48H
* 
# 
# # # 
# 
0
50
100
150
200
250
IC10 IC25 IC50 IC75
Control A. nemorosa
C
le
av
e
d
 C
as
p
as
e
 3
/C
as
p
as
e
 3
 
(%
 o
f 
co
n
tr
o
l)
 
24H 48H
* * # # # # 
# # 
0
50
100
150
200
250
IC10 IC25 IC50 IC75
Control BC-7
C
le
av
e
d
 C
as
p
as
e
 3
/C
as
p
as
e
 3
 
(%
 o
f 
co
n
tr
o
l)
 
24H 48H
# # 
# 
# # # # 
# 
0
50
100
150
200
250
IC10 IC25 IC50 IC75
Control A. afra
C
le
av
e
d
 C
as
p
as
e
 3
/C
as
p
as
e
 3
 
(%
 o
f 
co
n
tr
o
l)
 
24H 48H
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
65 
4.3.8. Autophagy induction 
 
The induction of autophagy was assessed to identify whether the plant extracts and compounds 
had the potential to promote cell death in a non-apoptotic manner.  Chloroquine served as a 
positive control and significantly (p<0.005) increased the amount of acidic organelles after 24 
and 48 hours of treatment (data not shown).  Positive staining with LysoTracker Red for 
treatment with chloroquine was evident in micrographs during acquisition (Figure 4.17). 
 
 
Figure 4.17: Micrographs (10x magnification) indicating positive staining for acidic 
organelles in HeLa cells after 48 hours of treatment compared to control.  Control 
treatment refers to untreated control. Cells were stained with LysoTracker Red and Hoechst 
33342.  Nuclei: Blue; acidic organelles: Orange.   
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Cisplatin and BC-7 treatments led to significant increases in the mean cytoplasmic integrated 
intensity correlating to an increase in the amount of acidic organelles (Figure 4.18).  All 
treatments with A. nemorosa yielded a significant decrease in the amount of acidic organelles, 
except for treatment with its IC75 after 24 hours.  A. afra treatment yielded a dose dependent 
decrease in the amount of acidic organelles after 24 hours whereas a significant increase was 
seen after 48 hours.      
 
Figure 4.18: Changes in the levels of acidic organelles in HeLa cells after 24 and 48 hours 
of treatment.  The LysoTracker Red staining method was used.  Control treatment refers to 
untreated control. Results displayed as mean cytoplasmic integrated intensity and expressed as 
a percentage of the untreated control Error bars indicate SD of three individual experiments, 
each performed in quadruplicate (n=3).  Significance was determined using the two-tailed 
Student t-test: *p<0.05 and #p<0.005 compared to untreated control. 
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4.4. Discussion 
 
To date there has been no evidence of the use of a crude extract of A. nemorosa for the 
treatment of cancer.  Studies involving A. nemorosa mainly consist of anti-microbial activity 
against known hospital and fish pathogens such as E. coli and Vibrio anguillarum, respectively 
(Hearst, et al., 2010; Turker, et al., 2015).  However, a review by Lukianchuk, et al. (2017) 
details the historical use of A. nemorosa by scientists and doctors including Culpepper, 
Motherby, Meyerick, Porcher and Clapp between 1720 and 1850.  This herb was also included 
into numerous Pharmacopoeias from as early as 1804.   
 
The isolation of numerous phytochemical compounds from other species of the Anemone genus 
has also provided sufficient reasons as to why A. nemorosa could be used for cancer treatment.  
Raddeanin A is a pentacyclic triterpenoid saponin, isolated from A. raddeana, and induces 
apoptosis in multiple cell lines by means of increased Bax expression, reduced Bcl-2 and 
Survivin expression and the activation of caspase -3, -8 and -9 in gastric cancer cells (Hao, et 
al., 2017).  Whilst isolated triterpenoid saponins from A. flaccida, hedera saponin StI4a, hedera 
saponin St-J, anhuienoside E, hedera saponin B and flaccidoside II, have shown to induce 
apoptosis in HeLa cervical cancer cells (Han, et al., 2013).  
 
The review by Lukianchuk, et al. (2017) also mentions the isolation of the main active 
substance, protoanemonin, from A. nemorosa and that it is converted to anemonin upon drying 
of the herb.  Interestingly, the studies on anemonin indicated anti-apoptotic properties. 
 
Nitulescu, et al. (2015) (collaborators of this study) has shown, for the first time, that their 
synthesized pyrazole derivative (BC-7) as mentioned in section 1.5.1, was cytotoxic (IC50 of 
40.34 µg/ml) to HT29 and THP1 cells.  Nitulescu, et al. (2015) also, briefly, looked into the 
mechanism of induced cytotoxicity and cell death through cell cycle analysis, PS translocation 
and expression of apoptotic genes in HT29 cells.   The current study made use of a different cell 
line namely HeLa cells and focused on additional parameters to enhance the knowledge of the 
mechanism of action of BC-7. 
 
An extensive study on the ethanolic extract of A. afra was done by Spies, et al. (2013) (co-
supervisor of this study) and has detailed its mechanism of action, specifically on HeLa cervical 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
68 
cancer cells.  However, the methods used in this current study differed significantly from those 
by Spies, et al. (2013) and because this project was aimed at combination therapy (discussed in 
chapter 6) it was included as an internal control as well as for consistency.   
 
Dose-response assays (Figures 4.7 – 4.9) were performed by means of the Hoechst 33342/PI 
dual staining method and results indicated that A. nemorosa inhibits proliferation of HeLa and 
HepG2, but not MeWo, cells in a dose dependent manner.  BC-7 was only effective against 
HeLa cells and A. afra was more effective against HepG2 cells with the lowest effect seen for 
MeWo cells.  Cisplatin served as the positive control and also showed to be more toxic against 
HeLa cells compared to HepG2 and MeWo cells with the lowest activity against the latter. 
 
It is widely accepted that for a crude extract to be considered promising for systemic application, 
the IC50 should be less than 100 µg/ml in vitro (Schink, et al., 2015).  However, according to the 
National Cancer Institute (NCI) the IC50 of a crude extract should be less than 30 µg/ml.  The 
IC50 values for A. nemorosa, BC-7 and A. afra were determined to be 20.33 ± 2.480 µg/ml, 
65.58 ± 8.400 µM (28.58 ± 3.660 µg/ml) and 70.87 ± 4.320 µg/ml, respectively.  The IC50 value 
obtained for A. afra was 2.2 times higher than the reported MTT-based value of 31.88 ± 1.09 
µg/ml against HeLa cells (Spies, et al., 2013).  The discrepancy between the IC50 values could 
be explained using the principles of the MTT and Hoechst 33342/PI methods.  The MTT assay, 
as mentioned in section 3.3, can yield false positive results if the cell’s metabolism is altered.  
Hence, it could be said that treatment of HeLa cells by Spies, et al. (2013) with A. afra may have 
altered the metabolism of the cell which may have hampered the reduction of the MTT.  This 
could have led to a greater toxicity being observed at lower doses.  The Hoechst 33342/PI 
method is not affected by cellular metabolism.  The value obtained for BC-7 was 1.4 times lower 
than that reported on HT29 and THP1 cells (Nitulescu, et al., 2015).  This can simply be 
explained as a difference in cell lines used.   
 
Due to the observed cytotoxicity of the extracts and BC-7, they were tested against Vero and 
MRHF cells (Figures 4.5 & 4.6) which model the low proliferation rate of normal cells.  The IC50 
value of 141.2 µg/ml obtained for A. afra against Vero cells closely correlated to the previously 
reported value of 113 ± 2.05 µg/ml by Mativandlela, et al. (2008) but differed from the value of 
>250 µg/ml reported by Spies, et al. (2013).  Once again, the difference in values obtained may 
be related to the principles of the methods used, as mentioned above.  It should also be noted 
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that Spies, et al. (2013) used a confluent monolayer of Vero cells whereas in this study the cells 
were not confluent.  The lower IC50 on proliferating cells therefore points towards a cell cycle 
dependent mechanism of action.  There have been no previous reports on the cytotoxicity of 
BC-7 and A. nemorosa on either Vero or MRHF cells as well as A. afra on the latter. 
 
As mentioned in section 3.2, cancer cells accumulate multiple mutations in genes that may 
affect their sensitivity towards anti-cancer treatments.  HeLa cells are characterized as p53 
wildtype cells whereas MeWo cells are a p53 mutant cell line and HepG2 cells are known to 
express low levels of PTEN.  The role of p53 in the regulation of apoptosis is detailed in section 
4.1.2.4.  These mutations may explain why HeLa cells were more susceptible to treatments as 
supported by the greater SI values (Table 4.4), compared to MeWo and HepG2 cells.  However, 
these are merely examples of well-known mutations within these cell lines and it should be 
noted that many more exist.  
 
One of the basic characteristics of cancer cells is their ability to proliferate uncontrollably.  
Therefore, DNA cell cycle analysis remains an important aspect in the search for new and 
improved chemotherapeutic agents.  Uncontrollable proliferation can be ascribed to the 
alteration of the various cell cycle checkpoints (Pietenpol & Stewart, 2002).  Extracts and 
compounds, such as A. nemorosa, A. afra and BC-7 with cytotoxic activity may counteract these 
alterations by activating cell cycle arrest through damage to the mitotic spindle or by affecting 
the signalling pathways that regulate proliferation (Koczurkiewicz, et al., 2015).  A. nemorosa, A. 
afra and BC-7 were shown to dose dependently arrest HeLa cells in the early M phase of the 
cell cycle after 24 and 48 hours of exposure whereas cisplatin arrested cells in the G2 phase 
(Figure 4.10 & 4.11).  The studies by Nitulescu, et al. (2015) and Spies, et al. (2013) support the 
M phase arrest for BC-7 and A. afra with reported G2/M arrest values of 80.28% in HT29 cells 
and 55.25 ± 2.47% in HeLa cells, respectively.  These previous studies made use of flow 
cytometry for cell cycle analysis: a method that cannot distinguish between cells in G2 and M 
phase without additional phase specific markers.  The image-based method employed in the 
current study overcame this limitation and confirmed early M phase arrest for A. afra and BC-7. 
 
The exact mechanism leading to arrest in the early M and G2 phase, respectively, cannot be 
deduced from the NucRed staining and more than one possibility exists.  There are two parallel 
cascades that ultimately serve to inactivate the CyclinB1-CDK1 complex subsequently blocking 
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entry into mitosis.  The first cascade occurs quite rapidly where Chk1 phosphorylates Cdc25C 
preventing it from activating CDK1, leading to G2 arrest.  The slower second parallel cascade 
involves the phosphorylation of p53 by means of activating CKI’s (such as p21) which inactivate 
the CyclinB1-CDK1 complex.  Mitotic arrest is mainly due to the disruption of the formation of 
the mitotic spindle resulting in mitotic catastrophe (Busino, et al., 2004). 
 
Early M phase arrest was confirmed through staining with phospho-Histone H3 (ser10) antibody 
as the phosphorylation of histone H3 is believed to be a marker for cells entering into mitosis 
(van Hooser, et al., 1998).  Treatment with A. nemorosa, A. afra and BC-7 did not convincingly 
increase the levels of phosphorylated histone H3 after 24 and 48 hours when compared to the 
control (Table 4.5).  Spies, et al. (2013) also indicated that treatment with A. afra after 24 hours 
yielded a very small, yet significant increase in phosphorylated histone H3 from 2.2% in the 
control to 6.3%.  However, treatment with A. afra at 12 and 18 hours yielded greater increases 
to 10.8% and 12.2% respectively, compared to the control (Spies, et al., 2013).  This could 
therefore suggest that shorter incubation periods would be ideal for detection of histone H3 
phosphorylation for all treatments. 
 
Cisplatin treatment indicated a dose dependent decrease in phosphorylated histone H3 which 
supports the G2 phase arrest obtained during cell cycle analysis.  Treatment with staurosporine 
has also showed to inhibit histone H3 phosphorylation leading to G2 phase arrest (van Hooser, 
et al., 1998).  Studies done by Hans and Dimitrov (2001) showed that during cell division, the 
phosphorylation of histone H3 is initiated at different phases.  However, metaphase 
chromosomes have been found to always be the most heavily phosphorylated.  It was also 
shown that upon mitotic arrest, the treatment of cells with a hypotonic solution led to strong de-
phosphorylation but this seems to be a reversible process as incubation in an isotonic solution 
restored chromosomes to their phosphorylated state.  This thus suggests a possible role for 
histone H3 in the passage of cells from metaphase to anaphase (Hans & Dimitrov, 2001).  If 
treatment with A. nemorosa, A. afra and BC-7 were to act in a similar manner to the hypotonic 
solution, HeLa cells would then be mitotically arrested in metaphase which is relatively early in 
the process of mitosis supporting the early M phase arrest obtained for the cell cycle analysis.  It 
is also noted that a mutant strain of Tetrahymena thermophila, with non-phosphorylable histone 
H3, exhibits perturbed chromosome condensation and abnormal segregation (Hans & Dimitrov, 
2001) which would lead to the onset of mitotic catastrophe.   
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Mitotic catastrophe is a regulated process that uses anti-proliferative measures such as 
apoptosis, necrosis and senescence during defective or failed mitosis in order to prevent 
proliferation of cells.  Mitotic catastrophe is characterized by the formation of giant 
multinucleated cells and also micronucleated cells, the former is due to clusters of 
missegregated uncondensed chromosomes, whereas the latter is as a result of lagging 
chromosomes or chromosome fragments, during anaphase, which are not incorporated into the 
daughter nuclei during telophase (McGee, 2015).  Although mitotic catastrophe makes use of 
the anti-proliferative measures mentioned above, it does not always lead to cell death in mitosis.  
Defective mitotic cells can exit mitosis through a process known as slippage and then undergo 
cell death in either the G1 phase of the subsequent cell cycle or they can undergo senescence 
(Hagenbuchner, et al., 2017).  This slippage could also explain why the early M phase arrest 
after 48 hours (Figure 4.11) was not as evident for treatment with A. nemorosa, A. afra and BC-
7 during cell cycle analysis.   
 
Cell death through mitotic catastrophe can manifest in a caspase-dependent or -independent 
manner.  The caspase-dependent manner involves the release of cyt-c following mitochondrial 
membrane depolarization and oligomerization of Bax/Bak.  Caspase-independent cell death on 
the other hand can occur through a sudden Ca2+ overload, oxidative stress and Mitochondrial 
Permeability Transition facilitated by the Permeability Transition Pore Complex (PTPC) which 
acts as a bridge between the inner and outer mitochondrial membranes (McGee, 2015).  All 
treatments indicated a significant increase in the formation of micro-nucleated cells which 
suggests the possible onset of mitotic catastrophe (Figure 4.12).  Taken together with the cell 
cycle analysis results, it could be said that cisplatin does not induce mitotic catastrophe as cells 
were arrested in the G2 phase.  However, research has shown that, upon treatment with 
genotoxic agents such as cisplatin, some cancer cells can overcome a G2 phase arrest and 
enter mitosis.  This is a process known as G2/M checkpoint adaptation (Kalsbeek & Golsteyn, 
2017).  It was also found that, G2/M checkpoint adaptation led to the formation of micronuclei.  
Cells containing micronuclei were also found to be capable of surviving several cycles and the 
chromosomes enclosed in the micronuclei are able to reunite with the main nucleus.  This could 
possibly explain why treatment with A. nemorosa led to fewer micronuclei being observed after 
48 hours. A study completed by Lewis & Golsteyn (2016) confirmed that, upon treatment of 
glioblastoma cells with cisplatin, G2/M checkpoint adaptation occurred and was followed by an 
increase in the formation of micronuclei.  This could possibly explain why there was an 
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indication of micronuclei formation after 48 hours of treatment with cisplatin, but not 24 hours.  
However, there was no significant increase in the percentage of cells arrested in mitosis after 48 
hours.  Thus, suggesting that the formation of micronuclei may occur elsewhere.  Interestingly, it 
has been found that micronuclei can also be formed during interphase.  This is said to occur 
due to a process known as nuclear blebbing in which extrachromosomal pieces of the main 
nucleus are transported to the nuclear envelope, forming a bud which when separated forms a 
micronucleus (Kalsbeek & Golsteyn, 2017).   Therefore, cisplatin could induce micronuclei 
formation in a different manner compared to A. nemorosa, BC-7 and A. afra.  
 
PS translocation is believed to be an early feature of apoptosis due to the loss of membrane 
asymmetry upon induction of apoptosis.  It was therefore thought that 24 hours was ideal for 
detection of this phenomenon as treatment was set at the respective IC values determined after 
48 hours of incubation.  Results obtained supported this idea as greater significant increases in 
the percentage of apoptotic cells (Annexin V pos; PI neg), for all treatments, were seen after 24 
hours (Figure 4.13) than 48 hours (Figure 4.14), compared to the control.  The results obtained 
for A. afra (3.93 ± 0.71%, 5.73 ± 0.83%, 1.80 ± 0.46) and BC-7 (3.65 ± 0.41%, 3.15 ± 0.63%, 
1.34 ± 0.16) differed from those obtained by Spies, et al. (2013) and Nitulescu, et al. (2015), 
respectively.  Values obtained by Spies, et al. (2013) were 40.5% apoptotic, 4.6% late apoptotic 
and 0.6% necrotic whereas those obtained by Nitulescu, et al. (2015) were 5.69% apoptotic, 
1.16% late apoptotic and 8.43% necrotic.  When compared to the results obtained by Nitulescu, 
et al. (2015) it could be said that greater increases, for BC-7 treatment, were seen due to the 
difference in cell lines used.  However, the same does not hold true for the difference in results 
for A. afra as HeLa cells were used in both studies and the concentration used in this study was 
2.2 times higher than that used by Spies, et al. (2013).   The discrepancy could however be 
explained by comparing the detection methods used which in this case was flow cytometry 
(Spies, et al., 2013) compared to fluorescence microscopy (present study). 
 
The use of flow cytometry involves a process known as fluorescence compensation.  This 
involves the knowledge of the excitation and emission spectra of fluorochromes used.  Some 
fluorochromes have emission spectra that overlap and thus the fluorescence of more than one 
fluorochrome may be observed in the selected bandpass filters used for detection (Roederer, 
2001).  Hence, fluorescence compensation is required in order to correct for this overlap to 
ensure that the fluorescence obtained is that of the fluorochrome of interest.  However, 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
73 
compensation does not take into account dye-dye or dye-cell interactions which may alter the 
fluorescence spectrum of a given dye (Roederer, 2001).  Fluorescence microscopy on the other 
hand typically does not apply compensation as filter cubes are utilized, depending on colour, 
that narrow the excitation and emission wavelengths for each fluorochrome.  
 
The use of PI is important to show that the integrity of the cell membrane is still maintained.  
The membrane integrity of late apoptotic cells generally remains intact until cells are engulfed 
by macrophages in vivo (van Engeland, et al., 1998, Aubry, et al., 1999).  However, phagocytes 
are absent in in vitro studies and late apoptotic cells become leaky and can stain positive for 
both Annexin V and PI.  This is also referred to as secondary necrosis.  This can explain the 
significant increases seen in the percentage of late apoptotic/ necrotic cells observed for all 
treatments.  It can however not be determined whether these cells are actually apoptotic or 
necrotic, respectively. 
 
Disruption of the mitochondrial membrane potential and the activation of the caspase proteolytic 
cascade are perhaps the main features of apoptosis induction.  This is mainly because these 
features play an overwhelming role in the two main pathways in which apoptosis can be 
induced, as described in sections 4.1.2.1 and 4.1.2.2.   
 
Caspases are proteases that contain a cysteine in their active site which cleave in the C-
terminal region of aspartate residues and are synthesized as inactive zymogens.  Initiator and 
effector caspases are two groups of caspases involved in cell death.  Initiator caspases contain 
long pro-domains and form aggregates in response to scaffolding co-factors leading to their 
auto-activation (Pollard & Earnshaw, 2008).  In contrast, effector caspases are not capable of 
auto-activation but become activated through cleavage by initiator caspases.  Caspase 8 is an 
initiator caspase whose activation is promoted by CD95 (Fas/APO-1) and tumor necrosis factor 
receptor 1 (TNFR1).  The active fragments, p18 and p10, of caspase 8 are released during its 
activation.  The activated caspase 8 cleaves and activates effector caspase -1, -3, -6 and -7.  
Caspase 3 is ultimately responsible for the morphological changes, such as DNA fragmentation 
and cell shrinkage associated with apoptosis (Cohen, 1997).   
 
The activation of both caspase 8 and caspase 3 without the depolarization of the mitochondrial 
membrane potential would therefore suggest that the extrinsic pathway plays a role in the 
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execution of apoptosis.  Similarly, the activation of caspase 3 but not caspase 8, preceded by 
mitochondrial membrane depolarization would suggest a role of the intrinsic pathway in the 
execution of apoptosis (Kurokawa & Kornbluth, 2009).    
 
Treatment with A. nemorosa, A. afra and BC-7 for 24 and 48 hours indicated significant dose 
dependent decreases in the mean cytoplasmic integrated intensity of TMRE (Table 4.6) and 
therefore suggests the involvement of the mitochondria in the onset of apoptosis. 
 
Increases in the mean cell integrated intensities of both caspase 8 and 3 after 24 and 48 hours, 
respectively, was evident in a dose dependent manner for all treatments to varying degrees 
(Tables 4.7 & 4.9).  Treatment with A. nemorosa indicated greater increases in caspase 3 
activation than caspase 8 with hardly any significant increases in the activation of the latter.  
This coupled with the decrease in mitochondrial membrane potential suggests the involvement 
of the intrinsic pathway rather than extrinsic pathway.  Significant increases in caspase 8 and 3 
activation were seen for treatment with A. afra after 24 and 48 hours indicating the involvement 
of both the intrinsic and extrinsic pathway.  Greater levels of active caspase 8 were seen after 
24 hours as compared to 48 hours indicating that caspase 8 is activated early, as would be 
expected considering its role as an initiator caspase.  The same observations were made by 
Spies, et al. (2013) upon treatment of HeLa cells with A. afra.  Treatment with BC-7 indicated 
significant increases in caspase 8 and 3 activation after 48 hours but not 24 hours and could 
suggest the involvement of both the extrinsic and intrinsic pathway in the execution of 
apoptosis.  However, it seems that activation of the caspase cascade is slower compared to 
other treatments.  This is also supported by the results obtained for the mitochondrial 
membrane potential, as there was a significant decrease after 48 hours but not 24 hours.   
 
The total levels of caspase 8 and 3 were determined due to the exceptionally high levels of 
activated caspase 8 and 3 upon treatment with A. afra.  This was to determine whether or not A. 
afra may increase the levels of the enzymes through increased expression and/or decreased 
degradation of caspase 8 and 3 or whether treatment simply just leads to more activation of 
caspase already present in the cell.  Treatment with A. afra did indeed indicate a significant 
dose-dependent increase in the total caspase 8 and 3 levels (Tables 4.8 & 4.10).  However, 
these increases were not substantially greater than those seen for all other treatments as they 
all indicated more or less the same significant dose dependent increases compared to the 
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control.  Therefore, it could be said that there is no increase in the overall expression of caspase 
8 and 3 by A. afra as compared to all other treatments. The relative levels of cleaved towards 
total caspase 8 and 3 levels (Figure 4.15 & 4.16) indicated that, of the total levels, there was 
significantly more cleaved caspase for treatment with A. afra, in a dose dependent manner, as 
opposed to all other treatments.  Thus it could be concluded that of the total caspase 8 and 3, 
present in the cell, A. afra activates more than compared to all other treatments. 
 
Apoptosis, mitotic catastrophe, autophagy and regulated necrosis constitute the four major 
forms of programmed cell death.  Cell death is hardly ever due to single pathway activation but 
rather the result of cross-talk between multiple pathways of which most of the key players 
participate in more than one signalling cascade.  Autophagy is often observed to occur before 
apoptosis induction, essentially inhibiting it, and is deemed to be a rescue mechanism in which 
a cell adapts to stress (Hagenbuchner, et al., 2017).  This could explain why treatment with 
cisplatin and BC-7 indicated an increase in the mean cytoplasmic integrated intensity for 
LysoTracker Red after 24 and 48 hours as well as A. afra after 48 hours (Figure 4.19).  This 
could also explain the increase in mitochondrial membrane potential by A. afra after 48 hours 
(Table 4.6).  However, when the induction of apoptosis is exacerbated it can lead to the 
cleavage of autophagy-related genes such as ATG3, BECN1 or AMBRA1 which in turn leads to 
the inhibition of autophagy (Hagenbuchner, et al., 2017).  Therefore, the negative or decreased 
staining observed for treatment with A. nemorosa after 24 and 48 hours as well as A. afra after 
24 hours (Figure 4.19) may be attributed to the absence of autophagy, possibly through 
inhibition, or it may favour apoptosis induction by tipping the cell survival to cell death balance 
(Boukes & van de Venter, 2016).  Furthermore, the fact that A. afra seems to induce autophagy 
at lower concentration but less so at higher concentration, again illustrates the dual role of 
autophagy in cell survival/cell death.   
 
Taken together, our results demonstrate that the crude aqueous and ethanolic extracts of A. 
nemorosa and A. afra, respectively, as well as the synthetic compound, BC-7, may have anti-
cancer potential.  This study has shown that upon treatment of HeLa cells apoptosis was 
induced.  The mechanism of induction of apoptosis is accompanied by early M phase cell cycle 
arrest, induction of mitotic catastrophe, mitochondrial membrane depolarization and caspase 
activation. 
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Chapter 5: Inflammation and Cancer 
5.1.  Introduction 
 
Inflammation can be described as a normal physiological process of innate immunity in 
response to tissue damage caused by microbial infection, chemical irritation, cellular 
disturbances or wounding (Lu, et al., 2006).  Innate immunity consists of cellular and 
biochemical defense mechanisms that exist before infection.   The innate immune response is 
rapid and reacts in the same manner to repeated infections (Abbas, et al., 2012).  Neutrophils, 
one of the main components of innate immunity, are regulated by the production of mediators by 
macrophages and are the first cells to migrate toward the inflammatory sites.  As inflammation 
progresses, a vast number of growth factors, cytokines and chemokines stimulate the activation 
and migration of other inflammatory cells, leukocytes and lymphocytes (Nathan, 2002).       
 
The link between cancer and inflammation was first proposed by the German physician Rudolf 
Virchow in 1863 after he observed leukocyte infiltrates within tumours.  This observation was 
initially thought to be indicative of an anti-tumour immune response.  However, it is now well 
established that leukocyte infiltrates can exert both tumour-suppressive and tumour-promoting 
effects (Elinav, et al., 2013).  Inflammatory pathways have been shown to be up-regulated in 
many cancer cells (sections 5.1.1 – 5.1.4) and therefore, targeting inflammation could also 
affect cancer cells directly and not only via the immune system.  The observations made by 
Virchow have gained both mechanistic and epidemiological support and the role of inflammation 
and immunity has since been proposed as the seventh hallmark of cancer (section 1.1) 
(Trinchieri, 2012). 
 
Inflammatory processes remain an important part of the immune response but modulation and 
counteraction of these processes may provide an alternative to protection against diseases 
such as cancer.  Chemoprevention has been proposed to occur due to modulation of certain 
cellular inflammatory components such as: 1) the generation of reactive species with oxidant 
generating enzymes such as iNOS, 2) various cytokines, 3) COX-2 and 4) NF-κB that play an 
essential role within the carcinogenesis process.  These may ultimately provide molecular 
targets that will aid in the prevention, early detection and treatment of inflammation-associated 
cancers (Tan, et al., 2011).   
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
77 
5.1.1. Nuclear Factor kappa B 
 
The NF-κB family of transcription factors is one of the most well-known and widely investigated 
families of transcription factors in inflammation and the innate and adaptive immune responses 
(Hoesel & Schmid, 2013).  It also remains the most vital component of the link between 
inflammation and cancer.  During an inflammatory response, NF-κB is stimulated by pro-
inflammatory cytokines, ROS, microbial infections or tumour promoters through phosphorylation 
of inhibitor of kappa B (IκB).  Once stimulated, NF-κB mediates the transcription of various 
target genes such as iNOS and COX-2 which are responsible for the formation of NO and 
PGE2, respectively (Figure 5.1).  Ultimately, these products interfere with cellular processes that 
may result in the development and progression of cancer (Tan, et al., 2011).  NF-κB is 
constitutively expressed in most types of cancers and causes the activation of anti-apoptotic 
factors such as cellular inhibitors of apoptosis and cell cycle progression factors such as cyclins.  
Thus, coupled with its role in inflammation, NF-κB is a promising target.  One inhibiting agent of 
NF-κB, bortezomib, is already being used to treat patients with multiple myeloma and relapsed 
mantle-cell lymphoma (Crusz & Balkwill, 2015).    
5.1.2. Cyclo-oxygenase 2 
 
The production of prostaglandins by COX-2 plays a central role within tumourigenesis and 
ultimately leads to the inhibition of apoptosis and the subsequent enhancement of cell migration 
and promotion of neo-angiogenesis (Figure 5.1) in both cancer and stromal cells (Regulski, et 
al., 2016).  Numerous cancer types such as breast, prostate, pancreas, skin, lung, bladder and 
head and neck have increased levels of COX-2.  Thus, inhibitors of COX-2 are now being 
investigated for their possible anti-cancer abilities (Sobolewski, et al., 2010).  Peter Rothwell 
and collaborators conducted one of the most extensive epidemiological studies in 2012, 
whereby they explored the effects of daily aspirin use on cancer development by means of 
COX-2 inhibition.  A reduced risk of colorectal, gastric, biliary and breast cancer, following the 
daily use of aspirin, has been reported.  However, the long-term use of aspirin can have 
substantial adverse effects such as major bleeding (Grivennikov, et al., 2010; Algra & Rothwell, 
2012; Crusz & Balkwill, 2015).   
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5.1.3. Nitric Oxide 
 
NO is a key signalling molecule within normal processes such as vasodilation, 
neurotransmission and host defense.  However, at high concentration, NO is capable of 
producing pro-neoplastic functions depending on factors such as cell type, redox status and the 
inflammatory microenvironment.  NO mainly functions through interaction with p53 and in 
normal processes, is able to activate the p53 tumour suppressive pathway.  Alternatively, at 
high concentrations and in inflammatory conditions it is able to induce oncogenic mutations in 
the p53 gene (Tan, et al., 2011).  NO has also been shown to influence the cellular apoptotic 
threshold by inhibiting caspases through S-nitrosylation (formation of thiol adducts) of their 
catalytic cysteine residue (Fulda, et al., 2010).  This would incapacitate their proteolytic activity 
however activity can be restored by addition of dithiothreitol (DTT) (Cryns & Yuan, 1999). 
 
 
 
Figure 5.1: Overview of signalling pathways involved in inflammation-induced cancer 
(Tan, et al., 2011). 
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5.1.4. Reactive Oxygen Species 
 
The production of ROS plays a key role in the progression of numerous inflammatory diseases.  
It is mainly produced as byproducts of cellular metabolism through the electron transport chain 
and cytochrome P450 (Mittal, et al., 2014).  NADPH oxidases, present in phagocytes and 
endothelial cells, are also a source of ROS.  ROS is known to have a dual function as both a 
cell survival and cell death mediator.  At low levels, it exerts its cell survival effect through the 
activation of NF-κB which in turn, as mentioned in section 5.1.1, can lead to the subsequent 
production of NO and COX-2.  The activation of NF-κB together with activating protein-1 (AP-1) 
is mediated through the transient activation of JNK (Figure 5.2) and leads to the production of 
anti-apoptotic proteins such as cIAP2, Bcl-xL, FLICE inhibitory protein (FLIP) and manganese 
superoxide dismutase (MnSOD) (Circu & Aw, 2010).   
 
At high levels, ROS can mediate caspase-dependent apoptosis preceded by mitochondrial 
membrane depolarization through the sustained activation of JNK (Mittal, et al., 2014).  ROS are 
known to interact with mitochondrial permeability transition complex proteins such as VDAC and 
ANT leading to a significant impact on mitochondrial anion fluxes.  The release of cyt-c not only 
leads to the activation of caspase 3 but also to further ROS increases due to a disrupted 
electron transport chain (Circu & Aw, 2010).  
 
The overexpression of human telomerase reverse transcriptase (hTERT) in cancer cells has 
been shown to alleviate cellular ROS levels by means of altering mitochondrial activity and 
stimulating cellular antioxidant defense.  High levels of ROS have also been deemed 
detrimental to cells as the exposure of cells to a slight pro-oxidant state has been shown to 
render caspases ineffective through oxidation of their catalytic cysteine residues.  Therefore, 
ROS plays a dual role within the modulation of the cellular environment with regards to 
apoptosis (Indran, et al., 2011).   
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Figure 5.2: Overview of ROS-mediated cell survival and cell death (Mittal, et al., 2014). 
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5.2. Materials and Methods 
 
5.2.1. Reagents 
 
Reagents, in addition to those mentioned in section 4.2.1, such as DAF-FM diacetate and 
CellRoxTM Orange reagent were purchased from Molecular Probes® - Life Technologies - 
Thermo Fisher Scientific (Logan, Utah, USA).  COX-2 (D5H5) XP® Rabbit mAb (Alexa Fluor® 
488 conjugate) and Phospho-NF-κB p65 (Ser536) Rabbit mAb were purchased from Cell 
Signaling Technology (Massachusetts, USA). 
5.2.2. Nuclear Factor kappa B inhibition 
 
HeLa cells were seeded in 96-well plates at a density of 5000 cells/well using 100 µl aliquots 
and left overnight to attach. The cells were treated with the IC10, IC25, IC50 and IC75 
concentrations of cisplatin, A. nemorosa, BC-7 and A. afra (section 4.3.1).  Cells were incubated 
at 37°C in a humidified 5% CO2 incubator for 24 and 48 hours after which they were prepared 
and stained as described in section 4.2.8 using Phospho-NF-κB p65 (Ser536) Rabbit mAb 
(1:800) for 1 hour at 37°C.  Cells were washed and incubated with a conjugated secondary 
antibody (1:1000), anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) for 30 
minutes at 37°C in the dark.  After staining with the secondary antibody, the cells were washed 
twice to eliminate unbound antibody and Hoechst 33342 (2 µg/ml) was used as a counterstain 
prior to imaging.  Curcumin (10 µM) and mangiferin (50 µM) were included as positive controls 
for NF-κB inhibition. 
5.2.3. Cyclo-oxygenase 2 inhibition 
 
HeLa cells were seeded and treated as described for NF-κB inhibition.  Cells were incubated for 
24 and 48 hours, after which they were fixed and permeabilized as described in section 5.2.2. 
After permeabilization the cells were blocked using DPBS with Ca2+ and Mg2+ containing 0.5% 
BSA and thereafter incubated with COX-2 (D5H5) XP® Rabbit mAb (Alexa Fluor® 488 
conjugate) (1:800) for 1 hour at 37°C.  After staining, the cells were washed twice to eliminate 
unbound antibody and Hoechst 33342 (2 µg/ml) was used as a counterstain prior to image 
acquisition.  Curcumin (10 µM) and mangiferin (50 µM) were included as positive controls for 
COX-2 inhibition. 
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5.2.4. Nitric Oxide production 
 
HeLa cells were seeded and treated as described for COX-2 inhibition.  Cells were incubated at 
37°C in a humidified 5% CO2 incubator for 24 and 48 hours.  Following treatment, the medium 
was removed and replaced with 50 µl aliquots of 10 µM DAF-FM diacetate (20 µl of 2.5 mM 
stock) in 5 ml DPBS with Ca2+ and Mg2+.  Cells were incubated for 1 hour at 37°C.  Cells were 
washed twice with DPBS containing Ca2+ and Mg2+. Hoechst 33342 was used as a counterstain 
at a final concentration of 2 µg/ml and incubated for 30 minutes at 37°C prior to acquisition. 
5.2.5. Reactive Oxygen Species production 
 
HeLa cells were seeded and treated as described for NO production.  Cells were stained by 
removing treatment medium and adding 100 μl aliquots of a mixture of 2.5 µM CellRox Orange 
(20 μl of 2.5 mM stock) and Hoechst 33342 at a final concentration of 2 µg/ml (2 μl of 10 mg/ml 
stock) in 10 ml DPBS with Ca2+ and Mg2+.  Cells were incubated in the dark for 30 minutes at 
37°C prior to image acquisition. 
5.2.6. Statistical analysis 
 
At least three experiments were completed in which three different transfer numbers were used.  
Statistical analysis was performed by means of the two tailed Student t-test for two samples 
assuming equal variance.  Error bars represent the standard deviation of the mean (SD, n=3). 
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5.3. Results  
 
The aim of this chapter was to determine the anti-inflammatory activity of BC-7, A. afra and A. 
nemorosa in HeLa cervical cancer cells as an alternative target in which cell death may be 
induced. 
5.3.1. Nuclear Factor kappa B inhibition 
 
The nuclear translocation of phospho-p65 NF-κB was assessed to evaluate the inflammatory 
status of HeLa cancer cells in response to treatments (Figure 5.3).  Curcumin and mangiferin 
were used as positive controls for inhibition (discussed in section 5.4).  Treatment with 
mangiferin induced an 18.1% decrease in NF-κB translocation after 48 hours as compared to 
the untreated control.  Curcumin on the other hand indicated a significant increase in NF-κB 
translocation after 24 hours of treatment and a slight non-significant decrease after 48 hours.  A. 
nemorosa and A. afra, at their IC10 treatments, showed a small, but significant decrease in NF-
κB translocation by 3.2% and 4.5%, respectively after 48 hours.  Likewise, the IC10 treatment of 
BC-7 also indicated a slight significant decrease by 3.8% after 24 hours.   All other treatments 
mostly indicated significant increases in NF-κB translocation. 
5.3.2. Cyclo-oxygenase 2 inhibition 
 
The ability of HeLa cancer cells to express COX-2 was determined (Figure 5.4) and all 
treatments showed to have no effect when compared to the untreated control, except for 
cisplatin after 24 hours at its IC75 which showed a slight significant decrease by 2.4%.  
Curcumin and mangiferin were once again used as positive controls for inhibition.  Mangiferin 
showed no effect and curcumin increased COX-2 expression by 4.9% after 24 hours, relative to 
the untreated control. 
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24H 48H Figure 5.3: NF-κB analysis in HeLa cells after 
24 and 48 hours of treatment.  
Immunofluorescence staining with phospho-p65 
NF-κB was done.  Control treatment refers to 
untreated control. Results displayed as mean 
nuclear integrated intensity and expressed as a 
percentage of the untreated control.  Curcumin 
and Mangiferin served as positive controls for 
inhibition.  Error bars indicate SD of three 
individual experiments, each performed in 
quadruplicate (n=3). Significance was 
determined using the two-tailed Student t-test: 
*p<0.05 and #p<0.005 compared to untreated 
control.  
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24H 48H Figure 5.4: COX-2 analysis in HeLa cells after 
24 and 48 hours of treatment.  
Immunofluorescence staining with COX-2 
antibody was done.  Control treatment refers to 
untreated control. Results displayed as mean 
cell average intensity and expressed as a 
percentage of the untreated control.  Curcumin 
and Mangiferin served as positive controls for 
inhibition.  Error bars indicate SD of three 
individual experiments, each performed in 
quadruplicate (n=3). Significance was 
determined using the two-tailed Student t-test: 
*p<0.05 and #p<0.005 compared to untreated 
control. 
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5.3.3. Nitric Oxide production 
 
NO production in HeLa cells were measured using DAF-FM diacetate.  Curcumin and 
mangiferin served as the positive controls for inhibition of NO production.  Treatment with 
curcumin led to a significant increase in the levels of NO after 24 hours and a non-significant 
increase after 48 hours, compared to the untreated control.  Mangiferin indicated significant 
decreases in NO levels after both 24 (11.48%) and 48 (16.81%) hours.  Most of the treatments 
with cisplatin showed to significantly decrease levels of NO, except for the IC50 and IC75 
treatments which showed significant increases after 24 hours, compared to the untreated 
control.  Treatment with A. nemorosa led to a decrease in NO production, for all treatments, 
except for the IC25 and IC50 after 24 hours and the IC75 after 48 hours.   Significant decreases 
were seen with the IC10 treatments of A. afra after 24 and 48 hours, whereas all other 
treatments indicated significant increases.  Likewise, treatment with BC-7 also showed 
significant increases in NO production with the only significant decreases being observed for its 
IC10 and IC25 treatments after 24 hours. 
 
Table 5.1: Changes in levels of NO in HeLa cells after 24 and 48 hours of treatment. 
 Treatment Nitric Oxide Mean Cell Average Intensity (% of control) 
   IC10 IC25 IC50 IC75 
24H 
Control 100 ± 0.74     
Curcumin 127.9 ± 4.45**     
Mangiferin 88.52 ± 3.43**     
Cisplatin  91.77 ± 6.03* 97.79 ± 9.29 101.8 ± 13.45 104.4 ± 3.31* 
A. nemorosa  96.32 ± 2.40* 110.9 ± 7.19* 122.9 ± 3.24** 95.99 ± 3.27 
BC-7  89.84 ± 3.64** 92.77 ± 4.58* 108.1 ± 3.47** 113.2 ± 3.99** 
A. afra  88.52 ± 3.43** 104.4 ± 1.76** 110.3 ± 0.76** 73.03 ± 7.57** 
       
48H 
Control 100 ± 7.99     
Curcumin 109.2 ± 6.28     
Mangiferin 83.19 ± 6.28*     
Cisplatin  88.09 ± 4.74* 87.19 ± 2.69* 87.44 ± 3.82* 99.37 ± 4.11 
A. nemorosa  92.92 ± 1.73 91.54 ± 1.70 98.80 ± 0.78 125.4 ± 10.1* 
BC-7  102.2 ± 4.29 114.9 ± 4.43* 105.7 ± 1.91 112.4 ± 3.05* 
A. afra  90.67 ± 4.49* 90.04 ± 5.58 107.8 ± 4.71 145.9 ± 5.33** 
       
Control treatment refers to untreated control. Significance was determined using the two-tailed 
Student t-test: *p<0.05 and **p<0.005 compared to untreated control. 
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5.3.4. Reactive Oxygen Species production 
 
The production of ROS was determined to assess its role in the induction of cell survival or cell 
death in HeLa cancer cells.  Cisplatin was used as the positive control as it has been reported to 
promote the production of ROS.  Positive staining with CellRox Orange was evident in the 
micrographs during acquisition for all treatments to varying degrees (Figure 5.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Micrographs (10x magnification) indicating positive staining for ROS in HeLa 
cells after 24 hours of treatment compared to control.  Control treatment refers to untreated 
control. Cells were stained with CellRox Orange and Hoechst 33342.  Nuclei: Blue; ROS: 
Yellow.   
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All treatments with A. afra and BC-7 indicated significant increases in the amount of ROS after 
both 24 and 48 hours in a dose dependent manner (Figure 5.6). Likewise, most of the cisplatin 
and A. nemorosa treatments also increased ROS.  Significant decreases in ROS, compared to 
the untreated control, was seen for the IC10 (9.9%), IC25 (6.2%) and IC50 (6%) treatments of A. 
nemorosa after 48 hours as well as the IC10 (13.6%) and IC25 (5.1%) of cisplatin.  The IC10 of 
cisplatin after 24 hours also indicated a significant 10.9% decrease in ROS, compared to the 
untreated control. 
 
Figure 5.6: Changes in the levels of ROS in HeLa cells after 24 and 48 hours of treatment.  
The CellRox Orange staining method was used.  Control treatment refers to untreated control.  
Results displayed as mean cell integrated intensity and expressed as a percentage of the 
untreated control.  Error bars indicate SD of three individual experiments, each performed in 
quadruplicate (n=3).  Significance was determined using the two-tailed Student t-test: *p<0.05 
and #p<0.005 compared to untreated control. 
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5.4. Discussion 
 
Chronic inflammation is characterized by the up-regulation of pro-inflammatory mediators such 
as NF-κB, ROS, iNOS and cytokines that are associated with cellular proliferation, disruption of 
DNA repair pathways, inhibition of apoptosis, increased DNA synthesis and the promotion of 
angiogenesis.  All of these processes lead to the initiation and progression of cancer (Rayburn, 
et al., 2009).  Following the observations made by Rudolf Virchow in 1863, as mentioned in 
section 5.1, research was mainly focused at addressing the link between pre-existing 
inflammation and subsequent tumour development.  However, more recent research is directed 
at understanding tumour-elicited inflammation following tumour development (Shalapour & 
Karin, 2015).  Thus, this chapter was aimed at the inhibition of tumour-elicited pro-inflammatory 
mediators which could provide key insights as to how inflammation can be a target for cancer 
treatment.   Activation of NF-κB and COX-2 has been correlated to the progression and 
carcinogenesis of cervical cancer (Zeng, et al., 2014) and therefore HeLa cells were used for 
this study. 
 
Curcumin is a lipophilic polyphenol compound that is the active ingredient in turmeric and 
although it is nearly insoluble in water it is quite stable in the acidic pH of the stomach.  It has 
been shown that curcumin is a highly pleiotropic molecule that is capable of interacting with 
several molecular targets involved in inflammation (Jurenka, 2009).  Numerous clinical trials, 
investigating the use of curcumin in cancer (pancreatic, rectal, colon, multiple myeloma and 
osteosarcoma) have been completed at universities and centers such as Johns Hopkins and the 
MD Anderson Cancer Center. Modulation of the inflammatory response by curcumin is mainly 
due to the down-regulation of COX-2, lipoxygenase and iNOS activities.  The inhibition of COX-
2 and iNOS is likely due to the suppression of NF-κB activation and is thought to occur through 
the blocking of the phosphorylation of IκB.  Curcumin can also be used to inhibit the production 
of cytokines such as tumour necrosis factor-alpha, monocyte chemoattractant protein, migration 
inhibitory protein and various interleukins such as IL-1, -2, -6, -8 and -12 which results in growth 
inhibition of cancer cell lines (Jurenka, 2009). 
 
Mangiferin is also a natural polyphenol with known anti-inflammatory, anti-oxidant and anti-viral 
properties.  It was shown that mangiferin is capable of blocking TNF induced NF-κB activation 
and NF-κB-dependent genes such as ICAM1 and COX2 in U937 cells through the inhibition of 
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IκB-kinase complex activation and the subsequent inhibition of IκB-α phosphorylation and 
degradation (Sarkar, et al., 2004).  Likewise, an in vivo study by Takeda, et al. (2016) using a 
mouse metastatic melanoma model indicated that mangiferin suppressed NF-κB translocation in 
the same manner as proposed by Sarkar, et al. (2004).  A study by du Plessis-Stoman, et al. 
(2011), showed that mangiferin treatment of HT29 cells increased the amount of NF-κB 
activation suggesting that it does not act as an NF-κB inhibitor.  It was however shown to 
decrease the activation of NF-κB when used in combination with oxaliplatin.  This further 
supports the final aim of this study pertaining to synergism (Chapter 6).       
 
Due to their reported anti-inflammatory activity by means of NF-κB and COX-2 suppression, 
curcumin and mangiferin served as the positive controls for this study.  Of these two, mangiferin 
was the most effective and conformed to its reported activity.  
 
To date, no evidence exists as to how A. nemorosa, A. afra and BC-7 may affect the 
inflammatory response in a cancer cell line.  However, A. afra has previously been studied using 
a RAW 264.7 murine macrophage cell line (Venables, 2013; Young, 2016).  These studies 
reported that A. afra decreased NO production in the presence of LPS (test for anti-
inflammatory effect) and to have no effect on NO production in the absence of LPS (test for pro-
inflammatory effect).  Both studies illustrated a significant increase in NF-κB activation after 18 
hours in the presence of LPS, relative to a control in the absence of LPS.  Young (2016) also 
reported that there was no effect, relative to an LPS treated control.  COX-2 analysis, in the 
presence of LPS, indicated slight significant decreases relative to the LPS control (Venables, 
2013) and no effect (Young, 2016), respectively.  
 
The results of this study indicated that there was no significant stimulatory or inhibitory effect on 
COX-2 expression with any of the treatments of A. nemorosa, A. afra and BC-7 (Figure 5.4).  
However, most of the treatments, with the exception of mangiferin and some of the lower (IC10 
and IC25) concentrations, caused a significant increase in NF-κB activation (Figure 5.3).  This 
contradicts the implication that activation of NF-κB is responsible for the overexpression of 
COX-2 (Tan, et al., 2011; Zeng, et al., 2014).  Thus, suggesting an alternative role of NF-κB in 
cancer cells; that is, one that does not promote an inflammatory response.  Examples of this 
would be the involvement of NF-κB in proliferation and survival (Park & Hong, 2016).   However, 
NF-κB activation can also lead to the activation of iNOS which is responsible for the production 
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of NO (Figure 5.1).  On average, there was a 67% correlation between the effects seen for NF-
κB and NO, following treatment, as opposed to the 39% between NF-κB and COX-2 (Table 5.2).   
Furthermore, with the exception of cisplatin treatment, most of the effects, that indicated a 
significant increase or decrease in NF-κB correlated to a significant increase or decrease in NO 
production (Table 5.1).  This supports the implication that NF-κB activation is ultimately 
responsible for NO production. 
 
Table 5.2: Correlation of NF-κB, COX-2 and NO results.  
Treatment 
NF-κB COX-2 NO 
24H 48H 24H 48H 24H 48H 
Curcumin ↑* ↓ ↑* ↑ ↑* ↑ 
Mangiferin ↑ ↓ ↓ ↓ ↓* ↓* 
Cisplatin 
IC10 ↑* ↑ ↓ ↓ ↓* ↓* 
IC25 ↑* ↑* ↓ ↓ ↓ ↓* 
IC50 ↑* ↑* ↓ ↑ ↑ ↓* 
IC75 ↑* ↑* ↓* ↑ ↑* ↓ 
A. nemorosa 
IC10 ↓ ↓* ↑ ↓ ↓* ↓ 
IC25 ↓ ↓ ↑ ↓ ↑* ↓ 
IC50 ↑* ↓ ↓ ↓ ↑* ↓ 
IC75 ↑* ↑ ↓ ↓ ↓ ↑* 
BC-7 
IC10 ↓* ↑* ↑ ↓ ↓* ↑ 
IC25 ↓ ↑* ↑ ↓ ↓* ↑* 
IC50 ↓ ↑ ↓ ↓ ↑* ↑ 
IC75 ↑* ↑* ↑ ↓ ↑* ↑* 
A. afra 
IC10 ↑* ↓* ↓ ↓ ↓* ↓* 
IC25 ↑* ↓* ↑ ↓ ↑* ↓ 
IC50 ↑ ↑* ↓ ↓ ↑* ↑ 
IC75 ↑* ↑* ↑ ↑ ↑* ↑* 
↑: Increase, ↓: Decrease, *: effect was significant compared to untreated control 
 
Depending on the levels, ROS, as mentioned in section 5.1.4, can function as either a cell death 
or cell survival mediator (Circu & Aw, 2010).   Most treatments, with a few exceptions at the 
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lowest concentrations, led to a significant increase in the levels of ROS (Figure 5.6).   ROS does 
not act through the extrinsic pathway of apoptosis but can influence the intracellular 
environment in order to enhance receptor-ligand engagement or the execution of the 
downstream events leading to apoptosis.  The up-regulation of CD95 and TRAIL death 
receptors has already been observed in response to hydrogen peroxide.  Cisplatin served as 
the positive control as it is known to induce CD95 clustering by increasing intracellular ROS 
(Brodska & Holoubek, 2011) and treatment with antioxidants has shown to counteract this 
effect.  ROS has been shown to sensitize cancer cells to TRAIL-induced apoptosis and caspase 
activation.  Caspases are known to function optimally under reducing conditions therefore 
proteins that can antagonize an increase in cellular ROS levels can protect cancer cells from 
ROS mediated apoptosis (Indran, et al., 2011).  This could possibly explain the low levels of 
cleaved caspase 8 and 3 observed for treatment with A. nemorosa (Tables 4.7 & 4.9) as after 
48 hours, ROS production was significantly decreased.     
 
When combining the results for NF-κB, COX-2, NO and ROS, it can be seen that an increase in 
NF-κB activation seems to favour NO production rather than COX-2 expression.  This, together 
with the increase in ROS levels, following treatment, could be the cell’s way in which to de-toxify 
ROS as it has been shown that NO donors such as sodium nitroprusside are capable of 
scavenging ROS (Beligni & Lamattina, 2002; Hoesel & Schmid, 2013).  However, treatment with 
cisplatin indicated an increase in the levels of ROS and NF-κB but not NO.  Studies have shown 
that an increase in ROS and NF-κB can contribute to the activation of autophagy (Kroemer, et 
al., 2010).  Referring back to section 4.3.8, cisplatin treatment did indeed indicate an increase in 
autophagy induction (Figure 4.18).  Alternatively, the increase in NF-κB activation could also be 
indicative of cisplatin resistance (Oiso, et al., 2012).  An increase in the levels of NO could also 
explain the low levels of cleaved caspase 3 and 8 observed for treatment with BC-7 relative to 
all other treatments (Tables 4.7 & 4.9) as NO can inhibit caspases through the formation of thiol 
adducts (Fulda, et al., 2010).  
 
From this anti-inflammatory study, it can be concluded that a tumour-elicited inflammatory 
response is indeed induced in HeLa cervical cancer cells and that some treatments such as with 
the IC10 of A. nemorosa, BC-7 and A. afra have the potential to significantly inhibit this 
response. 
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Chapter 6: Combination Therapy 
6.1. Introduction 
 
6.1.1. Importance of combination therapy 
 
The low rates of survival for most metastatic cancers, within a 5 year period, coupled with the 
lengthy and sometimes costly process of developing new anti-cancer drugs has led to the 
consideration of new treatment strategies (Mokhtari, et al., 2017).  Such strategies include that 
of combination therapy which can be defined as a treatment modality that combines two or more 
therapeutic agents in order to mainly reduce the dose of treatment which in turn would aid in 
reduced drug resistance as well as toxicity towards normal host cells.  This approach mainly 
involves the repurposing of a known FDA-approved agent, not necessarily always used for 
treatment of cancer per se, and combining it with another drug in order to reduce overall costs 
which would ultimately benefit the “medically underserved” (Mokhtari, et al., 2017).  
6.1.2. Cisplatin 
 
Cisplatin is a platinum derivative that was initially approved by the FDA in 1978 for the treatment 
of testicular cancer (Kelland, 2007).  M. Peyrone was the first to synthesize cisplatin in 1844 and 
Alfred Werner was the first to characterize its chemical structure in 1893.  Scientific 
investigations of cisplatin only started in the 1960’s after it was shown to inhibit the cell division 
of E. coli (Rosenberg, et al., 1965).  Since then, cisplatin was shown to have anti-cancer activity 
against a variety of cancers and remains one of the most widely used chemotherapeutic agents 
to date.  However, increasing evidence associated with cisplatin treatment indicates drug 
resistance by cancer cells and considerable side effects in patients.  These side effects include 
nausea, vomiting, myelosuppression (decreased blood cell and platelet production in bone 
marrow), immunosuppression, nephrotoxicity, hepatotoxicity and cardiotoxicity (Florea & 
Busselberg, 2011; Dasari & Tchounwou, 2014).    All these factors ultimately limit the dose of 
cisplatin that can be administered. 
 
Resistance of cancer cells to chemotherapeutic agents has been said to occur in two forms 
namely acquired and intrinsic resistance.  Acquired resistance refers to a drug that becomes 
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ineffective over time whereas intrinsic resistance refers to a drug that is ineffective from the 
onset of treatment.  Cisplatin resistance is a form of acquired resistance.  Mechanisms involved 
in cisplatin resistance include: 1) decreased intracellular accumulation or increased efflux, 2) 
drug inactivation, 3) alteration of drug target, 4) increased nucleotide excision-repair activity, 5) 
decreased mismatch-repair activity and 6) evasion of apoptosis (Kartalou & Essigmann, 2001; 
Sedletska, et al., 2005; Brabec & Kasparkova, 2005).     Cisplatin resistance due to the evasion 
of apoptosis has been proposed to occur due to the induction of autophagy in ovarian cancer 
cells (Wang & Wu, 2014; Xu, et al., 2015) as well as activation of NF-κB in pancreatic 
carcinoma cells (Mohammad, et al., 2006; Florea & Busselberg, 2011; Niu, et al., 2018).   
 
To overcome resistance, cisplatin is commonly used in combination with drugs such as 
paclitaxel, tegafur-uracil, doxorubicin, gemcitabine, 5-fluorouracil, metformin, vitamin D, 
bleomycin, vinblastine, methotrexate and honey bee venom (Florea & Busselberg, 2011).    
6.1.3. Pitfalls and common errors  
 
The ultimate goal of most drug combination studies is that the two drugs in question yield a 
synergistic rather than an additive or antagonistic effect.  However, as with most other things in 
life, there are some pitfalls associated with combination studies (Chou, 2006).  These pitfalls 
include: 1) synergism versus enhancement or potentiation and 2) most common errors 
associated with pursuing synergism.  For example, if two drugs namely A and B are combined 
but B has no effect on its own then, if the combination of the two has an effect it is described as 
enhancement or potentiation.  However, if the two drugs each has an effect then in combination 
they may produce an additive, synergistic (more than additive) or antagonistic (less than 
additive) effect (Chou, 2006).  Therefore, clearly defining an additive effect is crucial and this 
was the mission of Ting-Chao Chou who spent 10 years deriving and publishing several 
hundreds of equations.  
 
The most common errors associated with pursuing synergism are based on the assumptions 
that an additive effect is a simple arithmetic sum of the two drugs involved.  If this were to be 
true, then if both drugs inhibited 60% growth, the combined additive effect would be 120% which 
is impossible (Chou, 2006).  Webb (1963) tried to solve this problem by using what was later 
referred to as the fractional product method (Chou & Talalay, 1984).  Based on the reasoning by 
Webb (1963), a combination effect will never exceed 100% inhibition therefore (100 - 60)(100 - 
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60) = 16, 100 – 16 = 84%.   This method incorporated the potency of a dose effect curve but not 
the shape.  Thus, assuming that if both drugs inhibited 60% growth then the combined additive 
effect would be 84% is also a gross oversimplification.  The importance of the shape of a dose 
effect curve is explained in Figure 1 of Chou (2006).       
6.1.4. Theoretical basis of the combination index theorem 
 
The term combination index (CI) was introduced as a quantitative method for determining 
synergism or antagonism between two drugs (Chou & Talalay, 1983).  The CI theorem was 
derived by merging the principle of the mass-action law with the mathematical principle of 
induction and deduction.  The derived general theory of dose and effect was also proven to be a 
unified theory of the four basic equations pioneered by Henderson-Hasselbalch, Michaelis-
Menten, Hill and Scatchard.  The equation for the CI theorem is: 
 
CI = [(D)1 / (Dx)1 + (D)2 / (Dx)2] 
 
where (Dx)1 and (Dx)2 denotes the individual dose of each drug required to inhibit a given level 
of cell growth and is determined by Dx = Dm[fa/(1-fa)]
1/m of which Dm refers to the potency (IC50) m 
to the shape and  fa denotes the fraction affected in the dose-effect curves.  (D)1 and (D)2 
denotes the dose of each drug in combination necessary to produce the same effect.  The 
combined effect can then be indicated as CI < 1, synergism; CI = 1, additive effect or CI > 1, 
antagonism, respectively.  The classification of the degree of synergism or antagonism can be 
seen in Table 6.1. 
 
 
 
 
 
 
 
 
 
 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
96 
Table 6.1: Classification of the degree of synergism or antagonism in drug combination 
studies with the combination index method (Chou & Talalay, 1984). 
CI Drug Interaction Description 
< 0.1 Very Strong Synergism 
0.1 – 0.3 Strong Synergism 
0.3 – 0.7 Synergism 
0.7 – 0.85 Moderate Synergism 
0.85 – 0.9 Slight Synergism 
0.90 – 1.10 Additive 
1.10 – 1.20 Slight Antagonism 
1.20 – 1.45 Moderate Antagonism 
1.45 – 3.3 Antagonism 
3.3 – 10 Strong Antagonism 
> 10 Very Strong Antagonism 
 
To complement the algebraic analysis involved in the calculation of the CI, a flexible and widely 
accepted graphical approach can be taken in the form of isobologram analysis (Foucquier & 
Guedj, 2015).  An isobologram is a graph where the x and y axis represent the dose of drugs 1 
and 2, respectively (Figure 6.1).  A line of additivity of negative slope connects the dose of drug 
1 with that of drug 2 (Tallarida, 2001).  An experimental point below the line of additivity is 
indicative of synergism (Figure 6.1: b & c) and corresponds to a CI < 1 whereas a point above 
the line indicates antagonism (Figure 6.1: d & e) and corresponds to a CI > 1.  Any point that 
falls on the line simply indicates an additive effect (Figure 6.1: a) and corresponds to a CI = 1 
(Chou, 2006; Foucquier & Guedj, 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Example of a classic IC50 isobologram (Chou, 2006). 
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6.2. Materials and Methods 
 
6.2.1. Cytotoxicity screening – Combination treatments 
 
HeLa cells were seeded in 96-well plates at a density of 5000 cells/well using 100 µl aliquots 
and left overnight to attach. For treatment, an additional 100 µl of the combination treatments 
were added. Five combination mixtures were made for each of the six plant-plant or plant-
compound combinations using the respective IC50 values of each extract or compound, as 
determined in section 4.3.1, at ratios of 1:3, 1:2, 1:1, 2:1 and 3:1, respectively.  A ratio of 1:1 
refers to IC50:IC50 whereas 1:3 means IC50: 3 x IC50.  These combination mixtures were serially 
diluted until seven concentrations were achieved. Cells were incubated at 37°C in a humidified 
5% CO2 incubator for 48 hours. Treatment medium was removed prior to the addition of the 
Hoechst 33342/PI staining and replaced with 100 µl DPBS with Ca2+ and Mg2+ containing 
Hoechst 33342 at a final concentration of 5 µg/ml. PI was added at a final concentration of 10 
µg/ml using 10 µl per well of a 110 µg/ml stock prior to image acquisition. 
6.2.2. Determination of Combination Index 
 
The CI values for each of the combinations at their respective ratios were calculated using the 
equation in section 6.1.2, for example at the 1:1 ratio of cisplatin:A. afra at inhibition of 50% cell 
growth (IC50): 
 
CI = [0.6936/1.675 + 29.34/70.87] 
CI = 0.83 
 
At inhibition of 75% cell growth (IC75): 
 
CI = [(D)cisplatin / (Dx)cisplatin + (D)A. afra / (Dx)A. afra] where Dx = Dm[fa/(1-fa)]
1/m 
CI = [1.948/(1.675[0.75/(1-0.75)]1/0.692] + [82.39/(70.87[0.75/(1-0.75)]1/1.900] 
CI = 0.238 + 0.652 
CI = 0.89 
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6.2.3. Determination of the Dose Reduction Index 
 
The dose reduction index (DRI) is defined as the level of dose reduction that is possible in a 
combination for a given level of effect as compared to the concentration of the individual drug 
alone.  The equation for the DRI is (DRI)1 = (Dx)1 / (D)1 and (DRI)2 = (Dx)2 / (D)2 and a DRI>1 is 
considered favourable (Li, et al., 2012).  An example of a DRI calculation for the 1:1 ratio of 
cisplatin:A. afra at inhibition of 50% cell growth (IC50) is: 
 
(DRI)cisplatin = (Dx)cisplatin / (D)cisplatin and (DRI)A.afra = (Dx)A. afra / (D)A. afra 
(DRI)cisplatin = 1.675/0.6936 and (DRI)A.afra = 70.87/29.34 
(DRI)cisplatin = 2.42 and (DRI)A.afra = 2.42 
6.2.4. Statistical analysis 
 
At least three experiments were completed for each of the combinations at their respective 
ratios in which three different transfer numbers were used.  Error bars represent the standard 
deviation of the mean (SD, n=3).  IC10, IC25, IC50 and IC75 values were manually calculated from 
Median-effect plots generated from 7-point log-dose response curves for each combination 
ratio.  The IC10, IC25 and IC75 values are summarized in Table A.1 of the Appendices. 
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6.3. Results  
 
The aim of this chapter was to determine whether or not successful synergic combinations could 
be made by combining A. nemorosa, BC-7 and A. afra with cisplatin and each other. 
 
Median-effect plots for cisplatin, A. nemorosa, A. afra and BC-7 were generated from the dose 
response curves in section 4.3.1: Figure 4.7 (Figure 6.2).  These plots were generated by 
plotting the log of the fraction of cells affected (fa) over the fraction of cells unaffected (fu) 
versus the log of the dose, for each of the compounds and extracts.  The shape (m), potency 
(Dm) and conformity (r) of the data to the mass action law for each of the compounds and 
extracts, alone, were determined (Table 6.2).   
 
Classic IC50 isobolograms were constructed (Figure 6.3) by extrapolation through the respective 
IC50 values of each of the extracts or compounds that made up a combination.  The IC50 values 
in combination for each of the ratios were determined and plotted.  Data points on the lower left 
of the hypothenuse are indicative of synergistic combinations and those on the upper right 
indicative of antagonistic mixtures.  Most combination treatments showed to have an 
antagonistic effect except for cisplatin:A. afra (Figure 6.3: a) and cisplatin:BC-7 (Figure 6.3: b) 
combinations that showed synergism.  The 1:2 ratio of cisplatin:BC-7 and the 2:1 ratio of 
cisplatin:A. afra were additive.  
 
The results for the isobolograms (Figure 6.3) are summarized (Table 6.3) and the CI values for 
each of the combinations is displayed along with the m, Dm and r parameters that influence the 
CI value.  This was based on Table 10 of Chou (2006), as can be seen on page 131, in the 
Appendices.  An example of the dose response curves and Median-effect plots, generated for 
each extract or compound, in combination, can be seen in Figure A.1 of the Appendices.  A 
result description, based on the degree of synergism or antagonism (Table 6.1), for each of the 
CI values, indicated that all the mixtures of cisplatin:BC-7, except for the 1:2 ratio, resulted in 
synergism.  Those mixtures of cisplatin:A. afra that were synergistic (Figure 6.3: a) can be 
classified as being moderately (1:2 and 1:1 ratios) and slightly (1:3 and 3:1 ratios) synergistic.     
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Figure 6.2:  Median-effect plots of cisplatin, A. nemorosa, A. afra and BC-7 for HeLa cells.   
After 48 hours of exposure, the cell death percentage was determined with the Hoechst 
33342/PI assay to determine the m value (a measurement of the shape or sigmoidity of the 
dose-effect) and the r value (a linear correlation coefficient of the median-effect plot). 
 
Table 6.2: Median-effect plot parameters of each compound or extract for HeLa cells. 
Treatment 
Parameters 
m   Dm  r 
Compound/Extract  IC10 IC25 IC50 IC75  
Cisplatin (µM) 0.692 0.068 0.336 1.675 8.342 0.979 
A. nemorosa (µg/ml) 1.371 6.435 11.44 20.33 36.14 0.964 
BC-7 (µM) 1.737 27.48 42.45 65.58 101.3 0.957 
A. afra (µg/ml) 1.900 28.03 44.57 70.87 112.7 0.983 
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Figure 6.3: Classic IC50 isobolograms for compounds and extracts with actual doses on 
the x- and y-axis.  Data points that fall on the hypothenuse indicate an additive effect whereas 
data point on the lower left or upper right indicate synergism or antagonism, respectively. 
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Table 6.3: Experimental design and dose-effect relationship of combinations at 50% 
growth inhibition of HeLa cells after 48 hours of exposure. 
 
Combination Parametera   
Ratio Compound/Extract m Dm r CI
b Result Description 
1:3 
Cisplatin + A. nemorosa 2.085 0.9103 + 33.15 0.987 2.17 Antagonism 
Cisplatin + BC-7 0.761 0.2552 + 29.98 0.968 0.61 Synergism 
Cisplatin + A. afra 1.502 0.3664 + 46.50 0.968 0.87 Slight Synergism 
A. nemorosa + A. afra 2.042 6.699 + 70.05 0.993 1.32 Moderate Antagonism 
A. nemorosa + BC-7 0.753 4.966 + 48.05 0.975 0.98 Additive Effect 
A. afra + BC-7 1.475 35.33 + 98.07 0.952 1.99 Antagonism 
       
1:2 
Cisplatin + A. nemorosa 1.670 1.205 + 29.24 0.980 2.16 Antagonism 
Cisplatin + BC-7 0.640 0.5357 + 41.95 0.906 0.96 Additive Effect 
Cisplatin + A. afra 1.222 0.4697 + 39.74 0.990 0.84 Moderate Synergism 
A. nemorosa + A. afra 1.863 9.339 + 65.11 0.988 1.38 Moderate Antagonism 
A. nemorosa + BC-7 0.952 16.58 + 107 0.957 2.45 Antagonism 
A. afra + BC-7 0.631 45.35 + 83.94 0.980 1.92 Antagonism 
       
1:1 
Cisplatin + A. nemorosa 1.536 0.9870 + 11.98  0.969 1.18 Slight Antagonism 
Cisplatin + BC-7 0.898 0.4845 + 18.97 0.967 0.58 Synergism 
Cisplatin + A. afra 0.999 0.6936 + 29.34 0.995 0.83 Moderate Synergism 
A. nemorosa + A. afra 2.480 15.40 + 53.69 0.974 1.52 Antagonism 
A. nemorosa + BC-7 0.894 14.16 + 45.68 0.957 1.39 Moderate Antagonism 
A. afra + BC-7 0.189 69.23 + 64.06 0.964 1.95 Antagonism 
       
2:1 
Cisplatin + A. nemorosa 1.067 1.304 + 7.911 0.972 1.17 Slight Antagonism 
Cisplatin + BC-7 0.743 0.5999 + 11.74 0.961 0.54 Synergism 
Cisplatin + A. afra 1.154 1.110 + 23.49 0.996 0.99 Additive Effect 
A. nemorosa + A. afra 3.323 24.62 + 42.92 0.987 1.82 Antagonism 
A. nemorosa + BC-7 0.863 21.85 + 35.24 0.962 1.61 Antagonism 
A. afra + BC-7 0.488 70.46 + 32.60 0.931 1.49 Antagonism 
       
3:1 
Cisplatin + A. nemorosa 1.054 1.510 + 6.107 0.958 1.20 Moderate Antagonism 
Cisplatin + BC-7 0.858 0.6682 + 8.720 0.998 0.53 Synergism 
Cisplatin + A. afra 0.983 1.115 + 15.72 0.989 0.89 Slight Synergism 
A. nemorosa + A. afra 2.665 31.68 + 36.81 0.983 2.08 Antagonism 
A. nemorosa + BC-7 1.668 34.19 + 36.76 0.762 2.24 Antagonism 
A. afra + BC-7 1.375 63.43 + 19.57 0.717 1.19 Slight Antagonism 
aThe parameters m, Dm and r are the slope, antilog of the x-intercept and the linear correlation 
coefficient of the median-effect plot, which signifies the shape of the dose-effect curve, the 
potency (IC50) and the conformity of the data to the mass-action law, respectively.  Dm and m 
values were used for calculating the CI values. 
bCI values at inhibition of 50%; CI < 1, CI = 1 and CI > 1 indicate synergism, additive effect and 
antagonism, respectively.  As based on the classic isobologram equation: CI = [(D)1/(Dx)1] + 
[(D)2/(Dx)2], where Dx = Dm[fa/(1-fa)]
1/m. 
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DRI values, at 50% inhibition of HeLa cell growth, for each of the compounds and extracts in 
combination were calculated using the equation in section 6.2.3, respectively (Table 6.4).   Most 
of the combinations showed favourable dose reduction (DRI > 1), to varying degrees.  Those 
combinations which showed unfavourable dose reduction in one or both of the compounds 
and/or extracts were highlighted in red.  The greatest dose reduction was seen for cisplatin:BC-
7 and cisplatin:A. afra combinations. 
 
Table 6.4: DRI values for combinations at 50% inhibition of HeLa cell growth. 
 
Combination 
DRIa values at inhibition of 50%  
1:3 1:2 1:1 2:1 3:1 
Cisplatin + A. nemorosa 1.84 : 0.61 1.39 : 0.70 1.70 : 1.70 1.28 : 2.57 1.11 : 3.33 
Cisplatin + BC-7 6.56 : 2.19 3.13 : 1.56 3.46 : 3.46 2.79 : 5.59 2.51 : 7.52 
Cisplatin + A. afra 4.57 : 1.52 3.57 : 1.78 2.42 : 2.42 1.51 : 3.02 1.50 : 4.51 
A. nemorosa + A. afra 3.03 : 1.01 2.18 : 1.09 1.32 : 1.32 0.83 : 1.65 0.64 : 1.93 
A. nemorosa + BC-7 4.09 : 1.36 1.23 : 0.61 1.44 : 1.44 0.93 : 1.86 0.60 : 1.78 
A. afra + BC-7 2.01 : 0.67 1.56 : 0.78 1.02 : 1.02 1.01 : 2.01 1.12 : 3.35 
aBlack: favourable; Red: unfavourable 
 
The CI and DRI values at 10, 25 and 75% inhibition of HeLa cell growth (Table 6.5), for each of 
the combinations, were calculated based on Table 11 of Chou (2006) (Appendices).   
Combinations that showed synergism, based on the CI, was highlighted in blue and those that 
showed an additive effect, in red.  As for the DRI values at inhibition of 50%, those combinations 
which led to unfavourable dose reduction, in one or both, of the compounds and/or extracts 
were highlighted in red.  Most of the combinations for cisplatin:BC-7 resulted in synergism, with 
the exception of the 1:3 and 1:2 ratios for inhibition of 75%.  CI values at the inhibition of 10 and 
25% for cisplatin:A. afra indicated antagonism, except for the 1:2 and 1:1 ratios at 25% which 
showed an additive effect.  At the inhibition of 75%, cisplatin:A. afra resulted in synergism for all 
the ratios.  Combinations for A. nemorosa:BC-7 showed synergism at inhibition of 10 and 25% 
for the 1:3 ratio.  Likewise, synergism was also seen at 10% inhibition for the 1:1 ratio and an 
additive effect at 25% inhibition.  Additive effects were seen for cisplatin:A. nemorosa at 
inhibition of 75% for the 2:1 and 3:1 ratios and synergism for the 1:1 ratio.  Antagonistic effects 
were seen for the 1:3, 1:2, 2:1 and 3:1 ratios of A. afra:BC-7 and A. nemorosa:A. afra 
combinations. However, synergism was seen for the 1:1 ratio of A. afra:BC-7 at inhibition of 10 
and 25% and an additive effect for A. nemorosa:A. afra at inhibition of 75%.   Favourable dose 
reduction was seen in most of the combinations for at least one of the compounds and/or 
extracts, except for cisplatin:A. nemorosa at inhibition of 10 and 25% for the 1:3 and 1:2 ratios.  
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The same was seen for A. nemorosa:A. afra for the 1:1 and 2:1 ratios as well as for A. 
nemorosa:BC-7 for the 3:1 ratio at 10% inhibition and A. afra:BC-7 for the 1:1 ratio at 75% 
inhibition.  
 
Table 6.5: CI and DRI values for combinations at 10, 25 and 75% inhibition of HeLa cell 
growth.  
 
Combination CIa values at inhibition of DRIb values at inhibition of 
Ratio Compound/Extract 10% 25% 75% 10% 25% 75% 
1:3 
Cisplatin + A. nemorosa 7.23 3.67 1.45 0.22 : 0.36 0.64 : 0.47 5.25 : 0.80 
Cisplatin + BC-7 0.21 0.32 1.38 6.90 : 15.7 6.76 : 5.86 6.37 : 0.82 
Cisplatin + A. afra 2.10 1.19 0.77 0.66 : 1.69 1.75 : 1.60 11.9 : 1.45 
A. nemorosa + A. afra 1.82 1.54 1.14 1.60 : 0.83 2.20 : 0.92 4.18 : 1.11 
A. nemorosa + BC-7 0.23 0.48 2.01 13.4 : 6.25 7.40 : 2.92 2.26 : 0.64 
A. afra + BC-7 2.37 2.17 1.83 1.83 : 0.55 1.92 : 0.61 2.10 : 0.74 
        
1:2 
Cisplatin + A. nemorosa 6.27 3.40 1.57 0.22 : 0.55 0.56 : 0.62 3.43 : 0.78 
Cisplatin + BC-7 0.27 0.46 2.45 4.73 : 16.1 3.86 : 5.02 2.53 : 0.49 
Cisplatin + A. afra 1.55 1.01 0.87 0.81 : 3.10 1.71 : 2.35 7.42 : 1.35 
A. nemorosa + A. afra 1.82 1.57 1.22 1.26 : 0.98 1.65 : 1.03 2.87 : 1.15 
A. nemorosa + BC-7 1.42 1.86 3.25 1.71 : 1.20 1.45 : 0.86 1.04 : 0.44 
A. afra + BC-7 1.67 1.78 2.02 2.00 : 0.86 1.81 : 0.82 1.48 : 0.75 
        
1:1 
Cisplatin + A. nemorosa 3.20 1.81 0.89 0.38 : 1.84 0.80 : 1.77 3.58 : 1.63 
Cisplatin + BC-7 0.71 0.58 0.72 1.62 : 11.1 2.38 : 6.20 5.01 : 1.92 
Cisplatin + A. afra 1.44 0.99 0.89 0.78 : 5.99 1.38 : 3.80 4.21 : 1.53 
A. nemorosa + A. afra 3.00 2.12 1.10 0.55 : 0.85 0.85 : 1.06 2.05 : 1.64 
A. nemorosa + BC-7 0.68 0.97 2.01 2.52 : 3.53 1.90 : 2.25 1.08 : 0.92 
A. afra + BC-7 0.18 0.59 6.52 12.1 : 10.8 3.51 : 3.32 0.30 : 0.32 
        
2:1 
Cisplatin + A. nemorosa 2.78 1.71 0.91 0.40 : 3.88 0.72 : 3.16 2.30 : 2.09 
Cisplatin + BC-7 0.54 0.51 0.70 1.97 : 27.0 2.36 : 12.3 3.30 : 2.54 
Cisplatin + A. afra 2.36 1.42 0.87 0.45 : 6.90 0.83 : 4.56 2.74 : 2.00 
A. nemorosa + A. afra 4.20 2.75 1.21 0.31 : 0.98 0.51 : 1.27 1.34 : 2.14 
A. nemorosa + BC-7 1.83 1.71 1.53 0.74 : 2.08 0.83 : 1.97 1.04 : 1.76 
A. afra + BC-7 1.59 1.54 1.44 0.98 : 1.75 0.99 : 1.88 1.02 : 2.16 
        
3:1 
Cisplatin + A. nemorosa 2.73 1.74 0.93 0.39 : 5.73 0.66 : 4.37 1.86 : 2.54 
Cisplatin + BC-7 0.78 0.61 0.55 1.35 : 27.7 1.85 : 14.4 3.39 : 3.92 
Cisplatin + A. afra 1.85 1.21 0.79 0.56 : 12.9 0.93 : 7.64 2.43 : 2.66 
A. nemorosa + A. afra 4.60 3.08 1.42 0.26 : 1.24 0.41 : 1.54 1.00 : 2.40 
A. nemorosa + BC-7 6.29 3.75 1.35 0.20 : 0.83 0.34 : 1.21 1.03 : 2.62 
A. afra + BC-7 1.23 1.21 1.18 1.12 : 3.01 1.12 : 3.18 1.12 : 3.54 
aRed: additive effect; Blue: synergism; Black: antagonism 
bBlack: favourable; Red: unfavourable 
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6.4. Discussion 
 
Combination chemotherapy with cisplatin forms the basis of treatment of cancers such as 
ovarian, biliary tract, lung, gastric, prostate, melanoma, breast, colon, pancreatic and cervical 
cancer.  Although platinum responsiveness is high during the initial stages of treatment 
numerous patients have relapsed with cisplatin-resistant disease (Florea & Busselberg, 2011).  
Therefore, this chapter was an attempt to determine the synergistic potential of combination of 
A. nemorosa, BC-7 and A. afra with cisplatin and each other.   
 
In order to accurately determine synergism or antagonism it is imperative to know both the 
potency and shape of the dose-effect curve for each drug, respectively (Table 6.2).  These 
parameters can easily be determined from the median-effect plot (Figure 6.2) (Chou, 2010). The 
parameters for combinations can also be easily acquired but they are not absolutely necessary. 
This is due to the fact that the CI value can be calculated for even a single combination dose. 
The theoretical minimum of data points, for a two-drug combination, to generate a median-effect 
plot is five (Chou, 2006). For in vitro experiments, each drug and its combination usually 
consists of five to eight points whereas for in vivo experiments it is usually only three points due 
to practicality and costs.  For this study, data points ranged from six to eight, for each of the 
combinations as well as the compounds or extract alone (Figure 6.2). Experiments for a single 
drug and its combinations should generally be carried out simultaneously in order to prevent 
variability due to drug decomposition, personnel changes and cell or animal inconsistency 
(Chou, 2010).    
 
When combining drugs the optimal recommended ratio is to be kept at an equipotency ratio 
(IC50) as the contribution of each drug would be approximately equal (Chou & Talalay, 1983).  
However, this is not required as a drug may be emphasized or de-emphasized in many special 
situations such as: 1) severe toxicity, 2) narrow toxicity dose of one drug or 3) limited 
availability.  The equipotent ratio of 1:1 can also be set at, for example 1:3 and 3:1 ratios in 
order to find out which ratio yields better synergy.  Factors to be aware of would be that the 
dose range is feasible in vivo and that it is therapeutically effective (Chou, 2006).  For this study, 
the equipotency ratio was used and also set at 1:3, 1:2, 2:1 and 3:1, as suggested (Table 6.3).  
The highest dose (3 times the IC50) for each of the compounds and/or extracts used, in 
combination, were 5.025 µM cisplatin, 60.99 µg/ml A. nemorosa, 196.74 µM BC-7 and 212.61 
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µg/ml A. afra, all of which are feasible for in vivo studies.  From the results it could be concluded 
that the equipotency ratio, for all combinations, yielded the best synergism. 
 
Overall, the dose-effect relationships for cisplatin, A. nemorosa, BC-7 and A. afra alone (r = 
0.957-0.983) (Table 6.2) and in combination (0.906-0.998) (Table 6.3) follow the mass-action 
principle excellently.  Exceptions are made for the 3:1 ratios of A. nemorosa:BC-7 and A. 
afra:BC-7 (r = 0.762 and 0.717).  Furthermore, the shape of the dose effect curves for 
treatments alone indicate mostly sigmoidal curves (m>1), except for cisplatin treatment, which 
indicated a flat-sigmoidal curve (m<1) (section 4.3.1: Figure 4.7).  For the combinations, 16 out 
of the 30 indicated sigmoidal and the remaining 14 indicated flat-sigmoidal curves.  Usually in 
vitro studies have an m>1 and in vivo an m>>1 (Chou, 2006).  
 
A frequent question in combination studies, pertaining to synergism, is what the mechanism of 
action for the combination is.  This remains a hard question to answer, as detailed mechanisms 
for even very well-known drugs such as aspirin or ether are not even fully known (Foucquier & 
Guedj, 2015).  The argument for this question depends on what is meant by the word 
mechanism.  Does it refer to the mechanism at a pharmacological, biochemical, cellular, 
molecular or chemical level?  Chou and Talalay (1981) demonstrated that even with a 
combination of the highly purified and crystalized enzyme, horse alcohol dehydrogenase, when 
it is combined with a simple competitive inhibitor, such as ADP, and a simple noncompetitive 
inhibitor, such as o-phenanthrolene, it was difficult to quantitatively predict synergism, 
antagonism or additivity based on the mechanism of action. 
 
Although knowledge of the mechanism of action is not required for combination studies, it is 
sometimes a good thing, such as when combining MDR-substrate drugs with MDR-reversing 
agents, for example vinblastine and adreemin or paclitaxel and ningalin (Chou, et al 1998; Chou 
et al., 2005).  The mechanism does however not allow the prediction of synergism or 
antagonism.  This can only be predicted once the experiment has been performed (Chou, 
2006).   
 
The mechanisms of action of cisplatin, A. nemorosa, BC-7 and A. afra were reported in chapters 
4 and 5 of this study.  When comparing these mechanisms, it can be seen that cisplatin, BC-7 
and A. afra have similar effects on the key components for cell death induction.  Thus, if 
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synergism could be predicted based on mechanism of action, these drugs would be assumed to 
do so.  Interestingly, most of the cisplatin combinations with BC-7 led to synergistic effects being 
observed (CI<0.9) (Tables 6.3 & 6.5).  Likewise, cisplatin combinations with A. afra also 
indicated synergism, especially at the inhibition of 50 and 75% of HeLa cell growth.  However, 
combinations of A. afra and BC-7, did not, except for the 1:1 ratio at the inhibition of 10 and 25% 
of HeLa cell growth (Table 6.5).  This supports the statement that, the mechanism of action 
cannot be used to predict synergism and therefore was not attempted here.        
 
In this study, a greater degree of antagonism was frequently observed at low effect levels, such 
as at 10 and 25% inhibition of HeLa cell growth (Table 6.5), supporting the idea by Chou (2006) 
that high effect levels, such as at 90, 99 and 99.9% inhibition, should be more relevant to 
therapy than low effect levels. 
 
It is generally accepted that, when it is talked about synergism or antagonism, the two drugs in 
combination are mutual.  Even though the dose or effect contributions of each drug in 
combination can be determined, it is simply not possible to quantitatively determine the 
proportions of the mechanistic contributions of each drug that leads to the observed synergism 
or antagonism (Chou, 2006).  Thus, care must be taken when stating the causes and 
consequences in drug combination.  However, when one of the two drugs in combination, on its 
own, has no effect, the enhancement or inhibition of the second drugs activity can be easily 
described by means of percent or fold (Chou, 2010).  The CI can however not be determined as 
the potency and shape of the dose-effect cannot be determined for a drug with no effect.  This 
was however not a problem in this study as both drugs for all combinations showed an effect on 
their own.  Therefore CI values could be determined for all combinations.  If the “how” and “why” 
synergism or antagonism occurs, “wants” to be known, it may take months to years.  However, 
the conclusions may only be tentative, suggestive or implied (Chou, 2006; Chou, 2010).    
 
Perhaps one of the most important objectives of combination therapy, is the ability to reduce the 
dose of a drug used, thus reducing toxicity toward the host while maintaining therapeutic 
efficacy.  As mentioned, the dose contributions of each drug in combination can be determined 
and a DRI can be calculated (section 6.2.3) relative to the dose of each drug alone (Tables 6.4 
& 6.5).  The DRI however, is not necessarily an indicator of synergism as an additive or slight 
antagonistic effect can also yield a DRI greater than 1.  The DRI is therefore most relevant to in 
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vivo experiments and would indicate that the dose of the drug used would reduce the chances 
for toxicity toward the host.  Ideally, a combination of two drugs should yield strong synergism 
with a DRI>1, a CI<1 toward cancer cells and a CI>1 toward host cells (Chou, 2006).   From the 
results of this study, only cisplatin:BC-7 (1:3, 1:1, 2:1, 3:1) and cisplatin:A. afra (1:3, 1:2, 1:1, 
3:1) combinations indicated synergism (CI<1) at inhibition of 50 and 75% (more so at 50 than 
75%) of HeLa cell growth.  This synergism was also accompanied by great dose reduction in 
especially the dose of cisplatin (Tables 6.4 & 6.5).    
 
Thus, it could be concluded that BC-7 and A. afra has the potential to lower the dose of cisplatin 
resulting in reduced drug resistance and could also limit the toxicity of cisplatin on the host (yet 
to be confirmed), essentially decreasing the occurrence of side effects associated with cisplatin, 
as mentioned in section 6.1.2. 
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Chapter 7: Concluding Remarks 
 
This study demonstrated the anti-cancer and anti-inflammatory activity of A. nemorosa, BC-7 
and A. afra upon treatment of cancer cells.   
 
Little research has been done on the cytotoxicity and anti-cancer properties of A. nemorosa 
although it is known to be used to treat various ailments as mentioned in section 1.3.  Other 
species from the Anemone genus have been reported to have anti-cancer activity.  Thus, one of 
the objectives of this study was to determine the anti-cancer potential of A. nemorosa.  This was 
the first in vitro study on the biological activity of A. nemorosa.  It was found and reported that 
the aqueous extract of A. nemorosa was cytotoxic against HeLa and HepG2, but not MeWo, 
cells.  The IC50 value of 20.33 ± 2.480 µg/ml, was low and physiologically relevant.  Analysis of 
the extract against control cell lines such as Vero and MRHF cells showed that there was no 
selectivity toward cancer cells as treatment with the extract yielding similar IC50 values as 
compared to those reported for the cancer cell lines. 
 
A. nemorosa was found to induce apoptosis in HeLa cells, as confirmed by PS translocation, in 
a mitochondrial- and caspase-dependent manner as shown by the decrease in the 
mitochondrial membrane potential and the increase in caspase 8 and 3 levels.  Cell cycle 
analysis in HeLa cells indicated a significant increase in the early M phase, suggesting mitotic 
arrest.  Although staining for Histone H3 phosphorylation did not support the mitotic arrest, it 
was shown that treatment with A. nemorosa led to morphological features of mitotic catastrophe 
being observed, in the form of micronuclei formation.  Therefore, it was suggested that mitotic 
catastrophe plays a role in the onset of apoptosis.  It was also shown that A. nemorosa did not 
induce autophagy which could mean that it favours apoptosis induction.  An article entitled “In 
vitro anti-cancer activity and mechanism of action of Anemone nemorosa” has been prepared 
and is undergoing review by the Romanian collaborators of this study before submission for 
publication. 
 
BC-7 is a pyrazole derivative that was synthesized as a cell cycle kinase inhibitor based on the 
prominent pyrazole ring that is used extensively in the design on compounds targeted to block 
cell cycle progression.  BC-7 has been reported to be cytotoxic against HT29 and THP1 cells 
and the mechanism of action has been outlined using HT29 cells.  HeLa cells were used in this 
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study to further describe the mechanism of action by focusing on additional parameters of cell 
death induction.  It was reported (section 4.4) that the IC50 value of 65.58 ± 8.400 µM (25.58 ± 
3.660 µg/ml) for treatment of HeLa cells with BC-7 was 1.4 times lower than that reported on 
HT29 cells.  The cytotoxic effect of BC-7 on control cell lines such as Vero and MRHF cells has 
never been reported.  This study was therefore the first to report that BC-7 yielded IC50 values of  
169.5 ± 27.45 μM (73.86 ± 11.96 μg/ml) and 111.4 μM ± 9.300 μM (48.54 ± 4.052 μg/ml) on 
Vero and MRHF cells, respectively.  BC-7 treatment also showed to have no effect on HepG2 
and MeWo cells, supporting the statement (section 3.2) that cancer cells accumulate multiple 
mutations which affect their sensitivity toward anti-cancer treatment.   
 
The same in vitro assays used for A. nemorosa were performed to determine the mechanism of 
action for BC-7. This was the first time that BC-7 was investigated for Histone H3 
phosphorylation, micronuclei formation, mitochondrial membrane depolarization and autophagy 
induction. It was shown that BC-7 also induces apoptosis in a mitochondrial- and caspase-
dependent manner possibly preceded by the onset of mitotic catastrophe as supported by the 
formation of micronuclei.  Treatment with BC-7 was also shown to induce autophagy.  Cell cycle 
arrest occurred in the early M after 24 and 48 hours with a noticeable increase in G2 arrest after 
48 hours.   
 
As mentioned in section 4.4, an extensive study on the anti-cancer activity of an ethanolic 
extract of A. afra has been done by Spies, et al. (2013).   The mechanism of action in HeLa cells 
has also been detailed, using different assays and detection methods, and the results of this 
study correlated well to that reported.  Results for the micronuclei formation assay as well as the 
caspase protein levels and activation will be combined with some of the work done by Spies 
(now Venables – co-supervisor to this study) in an article entitled “The anti-mitotic potential of 
Artemisia afra and isoalantolactone”. 
 
It has long since been proposed that inflammation and cancer are linked by the NF-κB pathway.  
NF-κB is a transcription factor that regulates the transcription of numerous genes involved in the 
immune response leading to inflammation.  Therefore the activation of NF-κB and its 
downstream and upstream mediators such as COX-2, NO and ROS were used to investigate, 
for the first time, the anti-inflammatory potential of A. nemorosa, BC-7 and A. afra using a 
cancer cells line (HeLa) rather than a macrophage cell line (RAW 264.7).  This was mainly done 
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to see whether a tumour-elicited inflammatory response is induced in cancer cells.  It was 
shown that most treatments significantly induced the activation of NF-κB, but there was no 
significant increase in the expression of COX-2 for any of the treatments.   However, there was 
a significant increase in the production of NO which suggested that NF-κB activation favoured 
NO production rather than COX-2 expression.  A dose dependent increase in the production of 
ROS was also evident with most treatments and supported the idea of ROS-mediated 
apoptosis.  Altogether, the results for this study indicated that a tumour-elicited response is 
indeed induced and can be significantly inhibited by some treatments. 
 
An overview of the mechanisms of action for cisplatin, A. nemorosa, BC-7 and A. afra, after 48 
hours of exposure at their IC50 values, are summarized in Table 7.1 in order to gain a better 
understanding of the overall effects of each of the extracts and compounds.  
 
Table 7.1: Overview of the mechanisms of action after 48 hours for cisplatin, A. 
nemorosa, BC-7 and A. afra. 
 Cisplatin A. nemorosa BC-7 A. afra 
Cell Cycle Arrest G2 Early M (EM) G2/EM S/EM 
Histone H3 analysis ↑* ↑* ↑ ↑* 
Micronuclei formation ↑* ↑* ↑* ↑* 
PS translocation ↑ ↑* ↑* ↑* 
MMP ↓* ↓* ↓* ↓* 
Caspase 8 activation ↑* ↑* ↑* ↑* 
Caspase 3 activation ↑* ↑* ↑* ↑* 
Autophagy induction ↑* ↓* ↑* ↑* 
NF-κB activation ↑* ↓ ↑ ↑* 
COX-2 expression ↑ ↓ ↓ ↓ 
NO production ↓* ↓ ↑ ↑ 
ROS production ↑* ↓* ↑* ↑* 
↑: Increase, ↓: Decrease, *: effect was significant compared to control 
 
The final aim of this study was to investigate combinations of A. nemorosa, BC-7 and A. afra 
with cisplatin and each other, for their synergistic cytotoxic activity.  It was found that most of the 
combinations indicated antagonism.  However, this study showed that, for the first time, 
combinations of A. afra and BC-7 with cisplatin induced synergistic cytotoxic effects, 
respectively.  This was evident by CI values less than 1.  Furthermore, favourable dose 
reduction, for all ratios, at inhibition of 10, 25, 50 and 75% of HeLa cell growth, was seen for 
both BC-7 and cisplatin in combination.  Exceptions could be made for the 1:3 and 1:2 ratios at 
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inhibition of 75% of HeLa cell growth as there was an unfavourable dose reduction in the dose 
of BC-7.  This could possibly indicate that BC-7, when in excess, with cisplatin at higher effect 
levels (such as 75%) interact in an unfavourable manner possibly leading to antagonism as 
supported by the CI values for the 1:3 and 1:2 ratios of 1.38 and 2.45, respectively. 
 
Combinations of cisplatin:A. afra was found to become more synergistic at higher effect levels 
as opposed to cisplatin:BC-7 which caused a greater degree of synergism to be observed at 
lower effect levels.  Favourable dose reduction was also observed for both A. afra and cisplatin 
for most of the ratios at all effect levels.  Greater dose reduction was seen at inhibition of 75% of 
HeLa cell growth. This suggests that A. afra and cisplatin interact in a more favourable manner 
at higher effect levels leading to synergism as supported by the CI values ranging from 0.77  - 
0.89.        
 
It was therefore concluded that A. afra and BC-7 has the potential to lower the dose of cisplatin 
which could result in decreased drug resistance and a reduced onset of side effects associated 
with cisplatin monotherapy.   An article entitled “Synergistic in vitro anti-cancer activity of N-[[3-
(4-bromophenyl)-1H-pyrazol-5-yl]-carbamothioyl]-4-chloro-benzamide with cisplatin against 
cervical cancer” is in preparation for publication. A second article entitled “Synergistic anti-
cancer activity of A. afra and cisplatin against HeLa human cervical cancer cells” will also be 
prepared for publication. 
 
In conclusion, future prospects for this study could include the isolation of active compounds 
from A. nemorosa, which was shown, for the first time, to have anti-cancer potential in vitro.  
Similarly, a more extensive study can be undertaken to further characterize the role of tumour-
elicited inflammatory responses and the inhibition thereof.   
 
With regards to the combination therapy, a study can be done on the cytotoxic effects of 
cisplatin:BC-7 and cisplatin:A. afra combinations on normal cell lines which could, depending on 
the outcome, further support the use of these new biomaterials for anti-cancer therapy in vivo.    
 
 
 
Thank You 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
113 
REFERENCES 
 
Abbas, A. K., Lichtman, A. H. & Pillai, S. (2012). Cellular and Molecular Immunology (Seventh 
ed.). Philadelphia, United States of America: Saunders, an imprint of Elsevier Inc. 
 
Adams, J. M. & Cory, S. (1998). The Bcl-2 protein family: arbiters of cell survival. Science, 281: 
1322-1326. 
 
Algra, A. M. & Rothwell, P. M. (2012). Effects of regular aspirin on long-term cancer incidence 
and metastasis: a systematic comparison of evidence from observational studies versus 
randomised trials. Lancet Oncology, 13: 518-527. 
 
Amado, N. (2011). Flavanoids: Potential Wnt/beta-catenin signalling modulators in cancer. Life 
Sciences, 89: 545-554. 
 
Aubry, J. P., Blaecke, A., Lecoanet-Henchoz, S., Jeannin, P., Herbault, N., Caron, G., Moine, V. 
& Bonnefoy, J. Y. (1999). Annexin V used for measuring apoptosis in the early events of 
cellular cytotoxicity. Cytometry, 37: 197-204. 
 
Beligni, M. V. & Lamattina, L. (2002). Nitric oxide interferes with plant photo-oxidative stress by 
detoxifying reactive oxygen species. Plant, Cell and Environment, 25: 737-748. 
 
Bildirici, I., Longtine, M. S., Chen, B. & Nelson, D. M. (2012). Survival by self-destruction: A role 
for autophagy in the placenta? Placenta, 33: 591-598. 
 
BioLegend, I. (2018). Annexin V Reagents and Moxi Flow. Retrieved November 20, 2018, from 
http://www.biolegend.com/bio-bits/2326 
 
Blanc, C., Deveraux, Q. L., Krajewski, S., Janicke, R. U., Porter, A. G., Reed, J. C., Jaggi, R. & 
Marti, A. (2000). Caspase-3 is essential for procaspase-9 processing and cisplatin-
induced apoptosis of MCF-7 breast cancer cells. Cancer Research, 60: 4386-4390. 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
114 
Boukes, G. J. (2010). The in vitro biological activities of three Hypoxis species and their active 
compounds. Port Elizabeth: Nelson Mandela Metropolitan University. 
 
Boukes, G. J. & van de Venter, M. (2016). The apoptotic and autophagic properties of two 
natural occuring prodrugs, hyperoside and hypoxoside, against pancreatic cancer cell 
lines. Biomedicine & Pharmacotherapy, 83: 617-626. 
 
Brabec, V. & Kasparkova, J. (2005). Modifications of DNA by platinum complexes. Relation to 
resistance of tumours to platinum antitumor drugs. Drug Resistance Updates, 8: 131-
146. 
 
Brenner, C., Cadiou, H., Vieira, H. L., Zamzami, N., Marzo, I., Xie, Z., Leber, B., Andrews, D., 
Duclohier, H., Reed, J. C. & Kroemer, G. (2000). Bcl-2 and Bax regulate the channel 
activity of the mitochondrial adenine nucleotide translocator . Oncogene, 19: 329-336. 
 
Brodska, B. & Holoubek, A. (2011). Generation of Reactive Oxygen Species during Apoptosis 
Induced by DNA-Damaging Agents and/or Histone Deacetylase Inhibitors. Oxidative 
Medicine and Cellular Longevity, doi:10.115/2011/253529, 1-7. 
 
Busino, L., Chiesa, M., Draetta, G. F. & Donzelli, M. (2004). Cdc25A phosphatase: 
Combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene, 23: 2050-
2056. 
 
Byun, J., Sohn, J., Leem, D., Park, B., Nam, J., Shin, D., Shin, J., Kim, H., Lee, K. & Lee, J. 
(2016). In vitro synergistic anticancer activity of the combination of T-type calcium 
channel blocker and chemotherapeutic agent in A549 cells. Bioorganic & Medicinal 
Chemistry Letters, 26: 1073-1079. 
 
CANSA. (2014). CANSA. Retrieved January 3, 2017, from www.cansa.org.za/south-african-
cancer-statistics/ 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
115 
Cartron, P.-F., Bellot, G., Oliver, L., Grandier-Vazeille, X., Manon, S. & Vallette, F. M. (2008). 
Bax inserts into the mitochondrial outer membrane by different mechanisms. FEBS 
Letters, 582: 3045-3051. 
 
Cell Signaling Technology. (2017). Cell Signaling. Retrieved January 4, 2017, from 
www.cellsignal.com 
 
Chazotte, B. (2011). Labeling nuclear DNA with hoechst 33342. Cold Spring Harbor Protocols, 
1: 83-85. 
 
Chou, T. C. & Talalay, P. (1981). Generalized equations for the analysis of inhibitions of 
Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive 
and nonexclusive inhibitors. European Journal of Biochemistry 115: 207-216. 
 
Chou, T. C. & Talalay, P. (1983). Analysis of combined drug effects: a new look at a very old 
problem. Trends Pharmacological Sciences, 4: 450-454. 
 
Chou, T. C. & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: the 
combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme 
Regulation, 22: 27-55. 
 
Chou, T. C., Depew, K. M., Zheng, Y. H., Safer, M. L., Chan, D., Helfrich, B., Zatorska, D. A., 
Bornmann, W. & Danishefsky, S. J. (1998). Reversal of anticancer multidrug resistance 
by the adreemins. Proceedings of the National Academy of Sciences, USA, 95: 8369-
8374. 
 
Chou, T. C., Dong, H. J., Zhang, X. G., Tong, W. P. & Danishefsky, S. J. (2005). Therapeutic 
cure against human tumor xenografts in nude mice by a microtubule stabilization agent, 
fludelone, via parenteral or oral route. Cancer Research, 65: 9445-9454. 
 
Chou, T. C. (2006). Theoretical Basis, Experimental Design, and Computerized Simulation of 
Synergism and Antagonism in Drug Combination Studies. Pharmacological Reviews, 58: 
621-681. 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
116 
Chou, T. C. (2010). Drug Combination Studies and Their Synergy Quantification Using the 
Chou-Talalay Method. Cancer Research, 70(2): 440-446. 
 
Choudhury, D. (2013). Apigenin shows synergistic anticancer activity with curcumin by binding 
at different sites of tubulin. Biochemie, 13(6): 1297-1309. 
 
Ciancio, G., Pollack, A., Taypier, M. A., Block, N. L. & Irvin, G. L. (1998). Measurement of cell-
cycle phase-specific cell death using Hoechst 33342 and propidium iodide: preservation 
by ethanol fixation. Journal of Histochemistry and Cytochemistry, 36(9): 1147-1152. 
 
Circu, M. L. & Aw, T. K. (2010). Reactive Oxygen Species, Cellular Redox Systems and 
Apoptosis. Free Radical Biology and Medicine, 48(6): 749-762. 
 
Cohen, G. M. (1997). Caspases: the executioners of apoptosis. Biochemical Journal, 326: 1-16. 
 
Colotta, F., Allavena, P., Sica, A., Garlanda, C. & Mantovani, A. (2009). Cancer-related 
inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 
30(7): 1073-1081. 
 
Cragg, G. M. & Newman, D. J. (2005). Plants as a source of anti-cancer agents. Journal of 
Ethnopharmacology, 100: 72-79. 
 
Crusz, S. & Balkwill, F. (2015). Inflammation and cancer: advances and new agents. Nature 
Reviews Clinical Oncology, doi:10.1038/nrclinonc.2015.105: 1-13. 
 
Cryns, V. & Yuan, J. (1999). Proteases to die for. Genes & Development, 12: 1551-1570. 
 
Dasari, S. & Tchounwou, P. B. (2014). Cisplatin in cancer therapy: molecular mechanisms of 
action. European Journal of Pharmacology, 0: 364-378. 
 
 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
117 
Del Bello, B., Valentini, M. A., Mangiavacchi, P., Comporti, M. & Maellaro, E. (2004). Role of 
caspase-3 and -7 in Apaf-1 proteolytic cleavage and degradation events during cisplatin-
induced apoptosis in melanoma cells. Journal of Experimental and Clinical Cancer 
Research, 293: 302-310. 
 
du Plessis-Stoman, D., du Preez, J. G. & van de Venter, M. (2011). Combination treatment with 
oxaliplatin and mangiferin causes increased apoptosis and downregulation of NFkB in 
cancer cell lines. African Journal of Traditional Complementaty and Alternative Medicine, 
8(2): 177-184. 
 
Duprez, L., Wirawam, E., Vanden Berghe, T. & Vandenabeele, P. (2009). Major cell death 
pathways at a glance. Microbes and Infection, 11: 1050-1062. 
 
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C. & Flavell, R. A. (2013). Inflammation-
induced cancer: crosstalk between tumours, immune cells and microorganisms. Nature 
Reviews, 13: 759-771. 
 
Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicology Pathology, 35(4), 
495-516. 
 
Fadeel, B. & Orrenius, S. (2005). Apoptosis: a basic biological phenomenon with wide-ranging 
implications in human disease. Journal of International Medicine, 258: 479-517. 
 
Florea, A. & Busselberg, D. (2011). Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of 
Activity, Drug Resistance and Induced Side Efects. Cancers, 3: 1351-1371. 
 
Foucquier, J. & Guedj, M. (2015). Analysis of drug combinations: current methodological 
landscape. Pharmacology Research & Perspectives, 3(3): e00149 (Page 1-11). 
 
Fragkos, M. & Beard, P. (2011). Mitotic Catastrophe Occurs in the Absence of Apoptosis in p53-
Null Cells with a Defective G1 Checkpoint. PLoS ONE, 6(8): 1-12. 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
118 
Fulda, S. & Debatin, K. A. (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer 
chemotherapy. Oncogene, 25: 4798-4811. 
 
Fulda, S., Gorman, A. M., Hori, O. & Samali, A. (2010). Cellular Stress Responses: Cell Survival 
and Cell Death. International Journal of Cell Biology, 2010: 1-23. 
 
G-Biosciences. (2016). TMRE Mitochondrial Membrane Potential Assay. Retrieved November 
20, 2018, from http://www.gbiosciences.com/Bioassays/Cell_Health_Assay/Apoptosis-
Assays-Accessories/TMRE_Mitochondrial_Membrane_Potential_Assay 
 
Grivennikov, S. I., Greten, F. R. & Karin, M. (2010). Immunity, Inflammation and Cancer. Cell, 
140: 883-899. 
 
Guan, J., Simon, A. K., Prescott, M., Menendez, J. A., Liu, F., Wang, F., Wang, C., Wolvetang, 
E., Vazquez-Martin, A. & Zhang, J. (2013). Autophagy in stem cells. Autophagy, 9(6): 
830-849. 
 
Gutierrez-Venegas, G. (2014). Flavanoids inhibit iNOS production via mitogen activated 
proteins in lipoteichoic acid stimulated cardiomyoblasts. International 
Immunopharmacology, 21(2): 320-327. 
 
Hagenbuchner, J., Lungkofler, L., Kiechl-Kohlendorfer, U., Viola, G., Ferlin, M. G., 
Ausserlechner, M. J. & Obexer, P. (2017). The tubulin inhibitor MG-2477 induces 
autophagy-regulated cell death, ROS accumulation and activation of FOXO3 in 
neuroblastoma. Oncotarget, 8(19): 32009-32026. 
 
Han, L., Fang, Y., Li, M., Yang, H. & Huang, F. (2013). The Antitumor Effects of Triterpenoid 
Saponins from Anemone flaccida and the Underlying Mechanism. Evidence-Based 
Complementary and Alternative Medicine, 1-8. 
 
Hanahan, D. & Weinberg, R. A. (2000). The hallmarks of cancer . Cell, 100: 57-70. 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
119 
Hanahan, D. & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. Cell, 144: 
646-674. 
 
Hans, F. & Dimitrov, S. (2001). Histone H3 phosphorylation and cell division. Oncogene, 20: 
3021-3027. 
 
Hao, D., Gu, X. & Xiao, P. (2017). Anemone medicinal plants: ethnopharmacology, 
phytochemistry and biology. Acta Pharmaceutica Sinica B, 7(2): 146-158. 
 
Hearst, M., Nelson, D., McCollum, G., Ballard, L. M., Millar, B. C., Moore, S., McClean, S., 
Moore, J. E. & Rao, J. R. (2010). Antimicrobial properties of protein extracts from wild 
mushroom fungi and native plant species against hospital pathogens. Journal of 
Pharmacognosy and Phytotherapy, 2(8): 103-107. 
 
Hers, I., Vincent, E. & Tavare, J. (2011). Akt signalling in health and disease. Cellular Signalling, 
23: 1515-1527. 
 
Hingorani, R., Deng, J. J. E., McIntyre, C. & Mittar, D. (2011). Detection of Apoptosis Using the 
BD Annexin V FITC Assay. BD Biosciences, 2. 
 
Hoesel, B. & Schmid, A. (2013). The complexity of NF-κB signalling in inflammation and cancer. 
Molecular Cancer, 12(86): 1-15. 
 
Indran, I., Tufo, G., Pervaiz, S. & Brenner, C. (2011). Recent advances in apoptosis, 
mitochondria and drug resistance in cancer cells. Biochimica et Biophysica Acta, 1807: 
735-745. 
 
Jurenka, J. S. (2009). Anti-inflammatory Properties of Curcumin, a Major Constituent of 
Curcuma longa: A Review of Preclinical and Clinical Research. Alternative Medicine 
Review, 14(2): 141-153. 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
120 
Kalsbeek, D. & Golsteyn, R. M. (2017). G2/M-Phase Checkpoint Adaptation and Micronuclei 
Formation as Mechanisms That Contribute to Genomic Instability in Human Cells.  
International Journal of Molecular Sciences, 18: 1-16.    
 
Kartalou, M. & Essigmann, J. M. (2001). Mechanisms of resistance to cisplatin. Mutation 
Research, 478: 23-43. 
 
Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews 
Cancer, 7: 573-584. 
 
Kerr, J. F., Wylie, A. H. & Currie, A. R. (1972). Apoptosis: a basic phenomenon with wide-
ranging implications in tissue kinetics. British Journal of Cancer, 26: 239-257. 
 
Koczurkiewicz, P., Czyz, J., Podolak, I., Wojcik, K., Galanty, A., Janeczko, Z. & Michalik, M. 
(2015). Multidirectional effects of triterpine saponins on cancer cells - mini review of in 
vitro studies. Acta Biochimica Polonica, 62(3): 383-393. 
 
Krauss, G. (2008). Biochemistry of Signal Transduction and Regulation (4th ed.). Weinheim: 
Wiley-VCH Verlag. 
 
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E.S., Baehrecke, E.H., 
Blagosklonny, M.V., El-Deiry, W.S., Golstein, P., Green, D.R., Hengartner, M., Knight, 
R.A., Kumar, S., Lipton, S.A., Malorni, W., Nunez, G., Peter, M.E., Tschopp, J., Yuan, J., 
Piacentini, M., Zhivotovsky, B. & Melino, G. (2009). Classification of cell death: 
recommendations of the Nomeclature Comittee on Cell Death. Cell Death and 
Differentiation, 16: 3-11. 
 
Kroemer, G., Marino, G. & Levine, B. (2010). Autophagy and the Integrated Stress Response. 
Molecular Cell, 40: 280-293. 
 
Krohn, A. J., Wahlbrink, T. & Prehn, J. H. (1999). Mitochondrial Depolarization Is Not Required 
for Neuronal Apoptosis. The Journal of Neuroscience, 19(17): 7394-7404. 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
121 
Kung, G., Konstantinidis, K. & Kitsis, R. N. (2011). Programmed Necrosis, Not Apoptosis, in the 
Heart. Circulation Research, 108: 1017-1036. 
 
Kurokawa, M. & Kornbluth, S. (2009). Caspases and Kinases in a Death Grip. Cell, 138(5): 838-
854. 
 
Lewis, C. W. & Golsteyn, R. M. (2016). Cancer cells that survive checkpoint adaptation contain 
micronuclei that harbor damaged DNA. Cell Cycle, 15: 3131-3145. 
 
Li, C. J., Chu, C. Y., Huang, L. H., Wang, M. H., Sheu, L. F., Yeh, J. I. & Hsu, H. Y. (2012). 
Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in 
gastric cancer in vitro and in vivo. Cancer Letters, 319: 203-213. 
 
Liu, N. Q., van der Kooy, F. & Verpoorte, R. (2009). Artemisia afra: A potential flagship for 
African medicinal plants? South African Journal of Botany, 75: 185-195. 
 
Lodish, H., Berk, A., Matsudaira, P., Kaiser, C. A., Krieger, M., Scott, M. P., Zipursky, L. & 
Darnell, J. (2000). Molecular Cell Biology (5th ed.). New York: W. H. Freeman. Pp. 894-
895 
 
Lu, H., Ouyang, W. & Huang, C. (2006). Inflammation, a Key Event in Cancer Development. 
Molecular Cancer Research, 4(4): 221-233. 
 
Lukianchuk, A., Khropot, O., Konechnyi, Y., Konechna, R. & Novikov, V. (2017). WOOD 
ANEMONE. ANEMONE NEMOROSA L. ANALYTICAL REVIEW. ScienceRise: 
Pharmaceutical Science, 7(3): 38-42. 
 
Luo, J., Manning, B. D. & Cantley, L. (2003). Targeting the PI3K-Akt pathway in human cancer: 
Rationale and promise. Cancer Cell, 4: 257-262. 
 
Mativandlela, S. P., Meyer, J. J., Hussein, A. A., Houghton, P. J., Hamilton, C. J. & Lall, N. 
(2008). Activity against Mycobacterium smegmatis and M. tuberculosis by extract of 
South African medicinal plants. Phytotherapy Research, 22: 841-845. 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
122 
McGee, M. M. (2015). Targeting the Mitotic Catastrophe Signaling Pathway in Cancer. 
Mediators of Inflammation, 1-13. 
 
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P. & Malik, A. B. (2014). Reactive Oxygen 
Species in Inflammation and Tissue Injury. Antioxidants and Redox Signaling, 20(7): 
1126-1167. 
 
Mizushima, N. & Komatsu, M. (2011). Autophagy: Renovation of cells and Tissues. Cell, 147: 
728-74. 
 
Mohammad, R. M., Banerjee, S., Li, Y., Aboukameel, A., Kucuk, O. & Sarkar, F. H. (2006). 
Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in 
BxPC-3 pancreatic tumor xenografts. Cancer, 106: 1260-1268. 
 
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B. & Yeger, H. 
(2017). Combination therapy in combating cancer. Oncotarget, 8(23): 38022-38043. 
 
Molecular Probes. (2001). Nitric Oxide Indicators: DAF-FM and DAF-FM Diacetate. Retrieved 
November 20, 2018, from https://assets.thermofisher.com>manuals 
 
Nathan, C. (2002). Points of control in inflammation. Nature, 420: 846-852. 
 
Nitulescu, G. M., Draghici, C. & Missir, A. V. (2010). Synthesis of new pyrazole derivatives and 
their anticancer evaluation. European Journal of Medicinal Chemistry, 45: 4914-4919. 
 
Nitulescu, G. M., Matei, L., Aldea, I. M., Draghici, C., Olaru, O. T. & Bleotu, C. (2015). 
Ultrasound-assisted synthesis and anticancer evaluation of new pyrazole derivatives as 
cell cycle inhibitors. Arabian Journal of Chemistry, 1-9. 
 
Niu, P., Shi, D., Zhang, S., Zhu, Y. & Zhou, J. (2018). Cardamonin enhances the anti-
proliferative effect of cisplatin on ovarian cancer. Oncology Letters, 15: 3991-3997. 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
123 
Oiso, S., Ikeda, R., Nakamura, K., Takeda, Y., Akiyama, S. & Kariyazono, H. (2012). 
Involvement of NF-κB activation in cisplatin resistance of human epidermoid carcinoma 
KCP-4 cells. Oncology Reports, 28: 27-32. 
 
Olaru, O., Venables, L., van de Venter, M., Nitulescu, G., Margina, D., Spandidos, D. & 
Tsatsakis, A. (2015). Anticancer potential of selected Fallopia Adans species. Oncology 
Letters, 10: 1323-1332. 
 
Park, M. H., & Hong, J. T. (2016). Roles of NF-κB in Cancer and Inflammatory Diseases and 
Their Therapeutic Approaches. Cells, 5(15): 1-13. 
 
Parsai, S. (2013). Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-
phenoxyphenol derivatives . Oncology Letters, 7(1): 17-22. 
 
Perry, S. W., Norman, J. P., Barbieri, J., Brown, E. B. & Gelbard, H. A. (2011). Mitochondrial 
membrane potential probes and the proton gradient: a practical usage guide. 
Biotechniques, 50: 98-115. 
 
Pietenpol, J. A. & Stewart, Z. A. (2002). Cell cycle checkpoint signalling: Cell cycle arrest versus 
apoptosis. Toxicology , 181-182: 475-481. 
 
Pollard, T. D., & Earnshaw, W. C. (2008). Cell Biology (2nd ed.). Philidelphia: Elsevier. 
 
Proskuryakov, S. Y., Konopylannikov, A. G. & Gabai, V. L. (2003). Necrosis: a specific form of 
programmed cell death? Experimental Cell Research, 283: 1-16. 
 
Rayburn, E. R., Ezell, S. J. & Zhang, R. (2009). Anti-Inflammatory Agents for Cancer Therapy. 
Molecular and Cellular Pharmacology, 1(1): 29-43. 
 
Regulski, M., Regulska, K., Prukala, W., Piotrowska, H., Stanisz, B., & Murias, M. (2016). COX-
2 inhibitors: a novel strategy in the management of breast cancer. Drug Discovery 
Today, 21(4): 598-615. 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
124 
Riss, T. L., Moravec, R. A., & Niles, A. L. (2013). Cell Viability Assays. In G. S. Sittampalam, N. 
P. Coussens & K. Brimacombe (Eds.), Assay Guidance Manual (pp. 2004-). Bethesda 
(MD): Eli Lily & Company and the National Center for Advancing Translational Sciences. 
 
Roederer, M. (2001). Spectral Compensation for Flow Cytometry: Visualization Artifacts, 
Limitations, and Caveats . Cytometry, 45: 194-205. 
 
Rosenberg, B., Vancamp, L. & Krigas, T. (1965). Inhibition of cell division in Escherichia coli by 
electrolysis products from a platinum electrode. Nature, 205: 698-699. 
 
Sarkar, A., Screenivasan, Y., Ramesh, G. T. & Manna, S. K. (2004). β-D-Glucoside Suppresses 
Tumor Necrosis Factor-induced Activation of Nuclear Transcription Factor κB but 
Potentiates Apoptosis. Journal of Biological Chemistry, 279: 33768-33781. 
 
Schink, M., Garcia-Kaufer, M., Bertrams, J., Duckstein, S. M., Muller, M. B., Huber, R., 
Stintzing, F. C. & Grundemann, C. (2015). Differential cytotoxic properties of Helleborus 
niger L. on tumour and immunocompetent cells. Journal of Ethnopharmacology, 159: 
129-136. 
 
Sedletska, Y., Giraud-Panis, M. J. & Malinge, J. M. (2005). Cisplatin is a DNA-damaging 
antitumour compound triggering multifactorial biochemical responses in cancer cells: 
importance of apoptotic pathways. Current Medicinal Chemistry - Anticancer Agents, 5: 
251-265. 
 
Shalapour, S. & Karin, M. (2015). Immunity, inflammation, and cancer: an eternal fight between 
good and evil. Journal of Clinical Investigation, 125(9): 3347-3355. 
 
Simstein, R., Burow, M., Parker, A., Weldon, C. & Beckman, B. (2003). Apoptosis, 
chemoresistance, and breast cancer: insights from the MCF-7 cell model system. 
Experimental Biology and Medicine., 228: 995-1003. 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
125 
Sobolewski, C., Cerella, C., Dicato, M., Ghibelli, L., & Diederich, M. (2010). The Role of 
Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies. 
International Journal of Cell Biology, 2010: 1-21. 
 
Speidel, D. (2009). Transcription-independent p53 apoptosis: an alternative route to death. 
Trends in Cell Biology, 20(1): 14-24. 
 
Spies, L., Koekemoer, T. C., Sowewimo, A. A., Goosen, E. D. & van de Venter, M. (2013). 
Caspase-dependent apoptosis is induced by Artemisia afra Jacq. ex Willd in a 
mitochondria-dependent manner after G2/M arrest. South African Journal of Botany, 84: 
104-109. 
 
Starr, C., Taggart, R., Evers, C. & Starr, L. (2009). Biology The Unity and Diversity of Life. 
Belmont: Brooks/Cole Cengage Learning. 
 
Strocchi, E., Fornari, F., Minguzzi, M., Gramantieri, L., Milazzo, M., Rebuttini, V., Rebuttini, V., 
Breviglieri, S., Camaggi, C., Locatelli, E., Bolondi, L. & Comes-Franchini, M. (2012). 
Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-
kinase inhibitors in hepatocellular carcinoma. European Journal of Medicinal Chemistry, 
48: 391-401. 
 
Takeda, T., Tsubaki, M., Sakamoto, K., Ichimura, E., Enomoto, A., Suzuki, Y., Itoh, T., Imano, 
M., Tanabe, G., Muraoka, O., Matsuda, H., Satou, T. & Nishida, S. (2016). Mangiferin, a 
novel nuclear factor kappa B-inducing kinase inhibitor, suppresses metastasis and tumor 
hrowth in a mouse metastatic melanoma model. Toxicology and Applied Pharmacology, 
306: 105-112. 
 
Tallarida, R. J. (2001). Drug Synergism: Its Detection and Applications. Pharmacology and 
Experimental Therapeutics, 298(3): 865-872. 
 
Tan, A. C., Konczak, I., Sze, D. M. & Ramzan, I. (2011). Molecular Pathways for Cancer 
Chemoprevention by Dietary Phytochemicals. Nutrition and Cancer, 63(4): 495-505. 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
126 
Trinchieri, G. (2012). Cancer and Inflammation: An Old Intuition with Rapidly Evolving New 
Concepts. Annual Review of Immunology, 30: 677-706. 
 
Turker, H. & Yildirim, A. B. (2015). Screening for antibacterial activity activity of some Turkish 
plants agaisnt fish pathogens: a possible alternative in the treatment of bacterial 
infections. Biotechnology & Biotechnological Equipment, 29(2): 281-288. 
 
van Engeland, M., Nieland, L. J., Ramaeker, F. C., Schutte, B., & Reutelingsperger, C. P. 
(1998). Annexin V-affinity assay: a review on an apoptosis detection system based on 
phosphatidylserine exposure. Cytometry, 31: 1-9. 
 
van Hooser, A., Goodrich, D. W., Allis, C. D., Brinkley, B. R. & Mancini, M. A. (1998). Histone 
H3 phosphorylation is required for the initiation, but not maintenance, of mammalian 
chromosome condensation. Journal of Cell Science, 111: 3497-3506. 
 
van Wyk, B-E., van Oudsthoorn, B., & Gerike, N. (1997). Medicinal Plants of South Africa. 
Pretoria: Briza Publications. 
 
vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H. & Vandenabeele, P. 
(2014). Regulated necrosis: the expanding network of non-apoptotic cell death. Nature 
Reviews , 15: 135-147. 
 
Vara, J., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C. & Gonzalez-Baron, M. (2004). 
PI3K/Akt signalling pathway and cancer. Cancer Treatment Reviews, 30: 193-204. 
 
Vega-Avila, E., & Pugsley, M. K. (2011). An Overview of Colorimetric Assay Methods Used to 
Assess Survival or Proliferation of Mammalian Cells. Proceedings of the Western 
Pharmacology Society, 10-14. 
 
Venables, L. (2013). In vitro induction of cell death pathways by Artemisia afra extract and 
isolation of an active compound, isoalantolactone. Port Elizabeth: Nelson Mandela 
Metropolitan University. 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
127 
Vyssokikh, M. Y., Zorova, L., Zorov, D., Heimlich, G., Jurgensmeier, J. J. & Brdiczka, D. (2002). 
Bax releases cytochrome c preferentially from a complex between porin and adenine 
nucleotide translocator Hexokinase activity suppresses this effect . Molecular Biology 
Reports, 29: 93-96. 
 
Wang, J. & Wu, G. S. (2014). Role of autophagy in cisplatin resistance in ovarian cancer cells. 
Journal of Biological Chemistry, 289(24): 17163-17173. 
 
Webb, J. L. (1963). Effect of more than one inhibitor. in Enzyme and Metabolic Inhibitors, vol 1, 
(66-79, 488-512), Academic Press, New York. 
 
Wong, M., & Chiu, G. (2010). Simultaneous liposomal delivery of quercetin and vincristine for 
enhanced estrogen-receptor-negative breast cancer treatment . Anticancer Drugs, 21(4): 
401-410. 
 
Wong, R. S. Y. (2011). Apoptosis in cancer: from pathogenesis to treatment. Journal of 
experimental & Clinical Cancer Research, 30(87): 1-14. 
 
World Health Organization. (2014). World Cancer Report. Lyon: International Agency of 
Research on Cancer. 
 
Xu, S., Fu, G. B., Tao, Z., OuYang, J., Kong, F., Jiang, B. H., Wan, X. & Chen, K. (2015). MiR-
497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. 
Oncotarget, 6: 26457-26471. 
 
Xu, Y. (2011). Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PloS 
One, 6(12). 
 
Yang, Z., Chee, C., Huang, S. & Sinicrope, F. (2011). The Role of Autophagy in Cancer: 
Therapeutic Implications. Molecular Cancer Therapy, 10(9): 1533-1541. 
 
Young, C. (2016). Establishment of a high content innate immune modulatory screening 
platform. Port Elizabeth: Nelson Mandela Metropolitan University. 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
128 
Zeng, L., Zhen, Y., Chen, Y., Zou, L., Zhang, Y., Hu, F., Feng, J., Shen, J. & Wei, B. (2014). 
Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced 
activation of NF-κB/COX-2-caspase-1 pathway in HeLa cervical cancer cells. 
International Journal of Oncology, 45: 1929-1936. 
 
Online sources used: 
(http://www.pixnio.com/flora-plants/flowers/anemone-nemorosa-flower/wood 
anemone-anemone-nemorosa-flower) 
 
(http://pza.sanbi.org/artemisia-afra)   
 
(https://commons.m.wikimedia.org/wiki/File:Pyrazole_2D_numbered.svg)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nelson Mandela University                                                                         
Department of Biochemistry and Microbiology  
 
 
129 
APPENDICES 
 
 
 
 
 
 
 
Figure A. 1: Example of dose response curves and Median-effect plots generated for 
combinations.   This specific examples are for the 1:3 ratio of cisplatin:A. afra combination. 
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Table A.1: Summary of IC10, IC25 and IC75 values for each of the compounds and/or 
extracts in combination as determined from dose response curves. 
 
Combination   
Ratio Compound/Extract IC10 IC25 IC75 IC10 IC25 IC75 
1:3 
Cisplatin + A. nemorosa 0.3091 0.5304 1.562 11.25 19.32 56.89 
Cisplatin + BC-7 0.01 0.0506 1.287 1.179 5.946 151.2 
Cisplatin + A. afra 0.1041 0.1953 0.6874 13.21 24.78 87.24 
A. nemorosa + A. afra 2.555 4.138 10.85 26.72 43.27 113.4 
A. nemorosa + BC-7 0.3057 1.232 20.01 2.958 11.92 193.7 
A. afra + BC-7 12.17 20.73 60.21 33.77 57.55 167.1 
        
1:2 
Cisplatin + A. nemorosa 0.3068 0.608 2.388 7.444 14.75 57.95 
Cisplatin + BC-7 0.0146 0.0886 3.238 1.148 6.94 253.6 
Cisplatin + A. afra 0.085 0.2 1.104 7.188 16.9 93.44 
A. nemorosa + A. afra 3.261 5.518 15.81 22.73 38.47 110.2 
A. nemorosa + BC-7 2.392 6.298 43.65 15.44 40.65 281.7 
A. afra + BC-7 11.17 22 85.41 21.62 42.6 165.4 
        
1:1 
Cisplatin + A. nemorosa 0.183 0.425 2.292 2.222 5.159 27.82 
Cisplatin + BC-7 0.0425 0.1435 1.635 1.665 5.62 64.03 
Cisplatin + A. afra 0.088 0.247 1.948 3.721 10.45 82.39 
A. nemorosa + A. afra 7.484 10.74 22.09 26.09 37.43 77.02 
A. nemorosa + BC-7 1.625 4.797 41.8 5.243 15.48 134.8 
A. afra + BC-7 1.851 11.32 423.4 1.713 10.48 391.7 
        
2:1 
Cisplatin + A. nemorosa 0.174 0.4764 3.569 1.056 2.89 21.65 
Cisplatin + BC-7 0.035 0.145 2.483 0.6855 2.837 48.59 
Cisplatin + A. afra 0.1528 0.4118 2.992 3.233 8.715 63.31 
A. nemorosa + A. afra 13.03 17.91 33.84 22.71 31.22 58.99 
A. nemorosa + BC-7 5.51 10.97 43.51 8.887 17.7 70.17 
A. afra + BC-7 22.82 40.1 123.8 10.56 18.55 57.28 
        
3:1 
Cisplatin + A. nemorosa 0.1766 0.5165 4.415 0.7144 2.089 17.86 
Cisplatin + BC-7 0.0511 0.1848 2.416 0.6671 2.412 31.53 
Cisplatin + A. afra 0.1223 0.3692 3.367 1.724 5.205 47.47 
A. nemorosa + A. afra 15.51 22.17 45.28 18.02 25.75 52.61 
A. nemorosa + BC-7 20.79 26.66 43.84 22.35 28.67 47.14 
A. afra + BC-7 19.94 35.57 113.1 6.153 10.97 34.9 
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